Post on 28-Feb-2021
i
α-conotoxins targeting neuronal nAChRs:
Understanding molecular pharmacology and potential therapeutics
This thesis is submitted in fulfilment of the requirements for the degree of Doctor of Philosophy
Shiva Nag Kompella B.Sc., MS (The University of Queensland)
School of Medical Sciences, Health Innovations Research Institute
RMIT University October 2013
ii
Declaration by the Candidate
I, Shiva Nag Kompella, declare that:
a) except where due acknowledgement has been made, this work is that of myself alone;
b) this work has not been submitted previously, in whole or part, to qualify for any other
academic award;
c) the content of the thesis is the result of work that has been carried out since the official
commencement date of the approved research program;
d) any editorial work, paid or unpaid, carried out by a third party is acknowledged.
Signed: Date:
iii
Statement of contributions by others to the thesis as a whole The collaborators for the work in this thesis include Dr. Richard Clark (School of
Biomedical Sciences, The University of Queensland ) for peptide synthesis and Dr. Norelle
Daly (Institute for Molecular Biosciences, The University of Queensland) for NMR
structural analysis in Chapter 3. Dr. Andrew Hung (RMIT University) for molecular
modelling and docking simulations.
Statement of parts of the thesis submitted to qualify for the award of another degree None Published works by the candidate incorporated into the thesis
1. Chapter 3 Section 3.3.1:
Franco A, Kompella SN, Akondi KB, Melaun C, Daly NL, Luetje CW, Alewood PF, Craik DJ, Adams DJ, Marí F. (2012) RegIIA: an α4/7-conotoxin from the venom of Conus regius that potently blocks α3β4 nAChRs. Biochem Pharmacol. 83(3):419-26
2. Chapter 4
Inserra MC †, Kompella SN †, Vetter I, Brust A, Daly NL, Cuny H, Craik DJ, Alewood PF, Adams DJ, Lewis RJ. (2013) Isolation and characterisation of α-conotoxin LsIA with potent activity at nicotinic acetylcholine receptors. Biochem Pharmacol. 86(6):791-9. (†co-first author).
3. Chapter 6
van Lierop BJ †, Robinson SD †, Kompella SN †, McArthur JR, Hung A, MacRaild C, Adams DJ, Norton RS, Robinson AJ. (2013) Dicarba α-conotoxin Vc1.1 analogues with differential selectivity for nicotinic acetylcholine and GABAB receptors. ACS Chem Biol. 8(8):1815-21. (†co-first author).
Additional published works by the candidate during PhD but not incorporated into the thesis
1. Yu R, Kompella SN, Adams DJ, Craik D, Kaas Q. (2013) Determination of the α-conotoxin Vc1.1 binding site on the α9α10 nicotinic acetylcholine receptor. J Med Chem. 56(9):3557-67.
2. Safavi-Hemami H, Siero WA, Kuang Z, Williamson NA, Karas JA, Page LR, MacMillan D, Callaghan B, Kompella SN, Adams DJ, Norton RS, Purcell AW. (2011) Embryonic toxin expression in the cone snail Conus victoriae: primed to kill or divergent function? J Biol Chem. 286(25):22546-57.
iv
Talks at Conferences/Meetings:
1. Kompella SN, Hung A, Clark RJ, Adams DJ. (2012) α-Conotoxins targeting nAChRs: mutagenesis studies improving selectivity and potency. Biomed Link Conference, St. Vincent’s Hospital, University of Melbourne.
2. Kompella SN, Marco Inserra, Irina Vetter, Andreas Brust, Paul Alewood, Richard Lewis, David J. Adams. (2012) α-Conotoxin LsIA targeting nAChRs: structure – function relationship studies for future design and development of selective ligands. Higher Degree Research Student Conference – ‘From Inception to Excellence’, RMIT University.
3. Kompella SN, Nevin S, Hung A, Adams DJ. (2010) α-conotoxins targeting neuronal nicotinic acetylcholine receptors (nAChRs) – potential therapeutic drug development. Higher Degree Research Student Conference– ‘Presenting Tomorrow's Knowledge’, RMIT University.
Poster presentation at Conferences/Meetings:
1. Kompella SN, Shaoqiong Xu, Tianlong Zhang, Mengdi Yan, Xiaoxia Shao, Chengwu Chi, Jianping Ding, and Chunguang Wang, David J. Adams (2013) Novel Strategy of Blocking nAChR Revealed by Dissecting a Dimeric Conotoxin αD-GeXXA. ‘Nicotinic Acetylcholine Receptors as Therapeutic Targets: Emerging Frontiers in Basic Research & Clinical Science, Society for neuroscience satellite symposium, San Diego, CA.
2. Kompella SN, Hung A, Clark RJ, Adams DJ. (2013) α-Conotoxins targeting nAChRs: mutagenesis studies improving selectivity and potency. Gage Ion Channels and Transporters Conference, Canberra Boys Grammar School, ACT, Australia.
3. Kompella SN, Hung A, Clark RJ, Adams DJ. (2013) α-Conotoxins targeting nAChRs: mutagenesis studies improving selectivity and potency. Biophysical Society 57th Annual Meeting, Philadelphia, Pennsylvania, USA.
4. Kompella SN, Nevin S, Hung A, Adams DJ. (2010) α-conotoxins targeting neuronal nicotinic acetylcholine receptors (nAChRs) – potential therapeutic drug development. Higher Degree Research Student Conference– ‘Presenting Tomorrow's Knowledge’, RMIT University.
v
Acknowledgements I am deeply thankful to my supervisor Prof. David J. Adams for the opportunity to do this
PhD and his constant support towards experimental designs and publications. I would also
like to thank my supervisor for the opportunity to attend various national and international
conferences to understand the scope of my research work and network with other leading
scientists. I like to thank my co-supervisor Dr. Brett A. Cromer and all my lab members
during the period of my PhD for their support and feedback for publications, conference
talks and poster presentations. I am thankful for Dr. Richard Clark and Dr. Norelle Daly for
providing the opportunity to visit their labs to learn peptide synthesis and NMR structural
analysis respectively. I wish to thank all the members and groups of my publications (listed
above) with whom I have collaborated, for the opportunity to be part of their various
projects. Thanks to our collaborator Dr. Frank Marí (Department of Chemistry &
Biochemistry, Florida Atlantic University, USA) for providing the α-conotoxin RegIIA for
structural and functional characterisation (Chapter 3). My thanks to Chunguang Wang
(Institute of Protein Research, Tongji University, China), Jianping Ding (State Key
Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai
Institutes for Biological Sciences, China) and their lab members for providing the
opportunity to collaborate with respective to the αD-GeXXA project (Chapter 5).
Last, but not the least I would like to thank my family for their phenomenal support in
undertaking and completion of my PhD.
vi
Table of Contents
List of Figures…………………………………………………………………………………..….ix
List of Tables…………………………………………………………………………………..…...xi
Abbreviations…………………………………………………………………………………..…..xii
Abstract…………………………………………………………………………………………..….1
Chapter 1: General Introduction……………………………………………………………..…5
1.1 Nicotinic acetylcholine receptors
1.1.1 Discovery…………………………………………………………………………......6
1.1.2 Subunit diversity……………………………………………………………………...8
1.1.3 Receptor structure………………………………………………………………………8
1.3.1 Extracellular domain (ECD) or Ligand-binding domain (LBD)………….......9
1.3.2 Transmembrane domain (TMD) and Intracellular domain…………………….12
1.1.4 Subunit stoichiometry of nAChRs: structural and functional implications…………...14
1.1.5 Function and Biophysical properties……………………………………………15
1.1.6 Calcium signaling and modulation of neuronal growth……………………………….18
1.1.7 Nicotinic acetylcholine receptors and diseases.…………………………………....23
1.1.7.1 nAChRs and pain……………………………………………………………..23
1.1.7.2 nAChR signalling and lung cancer……….…………………………………..25
1.1.8.1.1 Role of α3 nAChR subunit………………………………………...25
1.1.8.1.2 Physiological to biochemical translation: cellular difference mediated by α7 and α3 subunits………………………………….28
1.1.8.1.3 Targeting α3β4 nAChR…………………………………………....29
1.2. Conotoxins……………………………………………………………………………..31
1.2.1 Venom apparatus and biosynthesis……………………………………………………...31
1.2.2 Classification and nomenclature……………………………………………………...33
1.2.3 Conotoxin structural diversity…………………………………………………………….35
1.2.4 Conotoxin structure–activity relationship……………………………………………36
1.2.4.1 Use of alanine scanning mutagenesis…………………………….. . . . . .38
1.2.5 Conotoxin re-engineering………………………………………………………...39
1.2.5.1 Dicarba modification…………………………………………………….....39
1.2.6 Conotoxins: potential therapeutics…………………………………………………40
1.3 References……………………………………………………………………………..41
Chapter 2: Materials and Methods……………………………………………………………..67
2.1 Materials………………………………………………………………………………..68
2.2 Peptide Synthesis……………………………………………………………………….68
2.2.1 Solid Phase Peptide Synthesis (SPPS) ……………………………………………68
vii
2.2.2 Fmoc SPPS…………………………….……………………...……………….69
2.2.2.1 Peptide assembly…………………………….……………………...69
2.2.2.2 Peptide cleavage…………………………….…………….………...71
2.2.2.3 Directed disulphide bond formation………………………………..72 2.2.3 NMR Spectroscopy…………………………….……………………………..74
2.3 Electrophysiological recordings in Xenopus oocyctes……………………………….74
2.4 Data analysis…………………………….…………………………….………………76
2.5 References…………………………….…………………………….…………………77 Chapter 3: α-RegIIA targeting α3β4 nAChR: unlocking novel therapeutics towards lung
cancer 3.1 Introduction………………………………………………………………………..80
3.1.1 Nicotinic acetylcholine receptors (nAChRs)……………………………......80
3.1.2 Pathophysiological role of α3β4 nAChR subtype…………………………...80
3.1.3 α-Conotoxins targeting neuronal nAChRs……………………………….....81
3.2 Aims………………………………………………………………………………..83
3.3 Results
3.3.1 Selective α-conotoxin RegIIA inhibition of recombinant nAChR subtypes…84
3.3.2 Directed Peptide Synthesis of α-conotoxin RegIIA analogues and NMR……86
3.3.3 Inhibition of nAChR subtypes by α-conotoxin RegIIA analogues……………87
3.3.4 Double mutant [N11A,N12A]RegIIA selectively inhibits α3β4 nAChR
subtype……………………………………………………………………….91
3.4 Discussion
3.4.1 Conus regius: characterization of novel α-conotoxin RegIIA………………..92
3.4.2 Alanine mutagenesis reveals pharmacological role of –NNP– motif in RegIIA………………………………………………………………………..93
3.4.3 Molecular modelling and MD reveal structural topology of α3β2 and α3β4
subtypes and residues interacting with RegIIA………………………………93
3.5 Summary and conclusion ……………………………………………………………….95
3.6 References…………………………………………………………………………….…97
Chapter 4: Isolation and characterisation of α-conotoxin LsIA
4.1 Introduction………………………………………………………………………….…106
4.2 Aims……………………………………………………………………………………107
4.3 Results…………………………………………………………………………….……108
4.3.1 LsIA inhibition of recombinant nAChR subtypes…………………….……..108
4.3.2 Influence of C-terminal carboxylation and N-terminal truncation of LsIA….113
4.4 Discussion……………………………………………………………………..….……115
4.5 Summary and Conclusion …………………………………………………….….……118
viii
4.6 References……………………………………………………………………..….……119
Chapter 5: Characterization of Dimeric αD-Conotoxin GeXXA Reveals a Novel Strategy of Blocking nAChRs
5.1 Introduction………………………………………………………………………….…125
5.2 Aims ……………………………………………………………………………………127
5.3 Results…………………………………………………………………………….……128
5.3.1 Concentration-dependent inhibition of α3-containing receptors by α-D
conotoxin GeXXA……………………………………………..……............128
5.3.2 Monomeric α-D conotoxin GeXXA selectively inhibits the α9α10 nAChR……………………………………………………………..….…….130
5.3.3 α9α10 hybrid nAChR studies reveal the site of monomeric α-D conotoxin
GeXXA binding……………………………………………………………..131
5.4 Discussion and conclusion…………………………………………………..….……...132
5.5 References……………………………………………………………………..….……136
Chapter 6: Dicarba modification of α-conotoxins exhibits differential selectivity for nAChRs and GABAB receptors
6.1 Introduction………………………………………………………………………….…139
6.1.1 Conotoxins - Conus victoriae and Conus regius………………………….…139
6.1.2 The molecular mechanism of analgesia………………………….…………..139
6.1.3 The α9α10 nAChR subtype: expression and function…………………….…140
6.1.4 α-Conotoxin drug development: limitations and strategies……………….…141
6.2 Aims ……………………………………………………………………………………143
6.3 Results…………………………………………………………………………….……144
6.3.1 Regioselective dicarba Vc1.1 analogues exhibit differential activity at α9α10
nAChR subtypes……………………………………………………….……144
6.3.2 Dicarba modification of RgIA confers similar pharmacological effects to those of Vc1.1……………………………………………………….………….…145
6.4 Discussion ……………………………………………………………………..….……148
6.5 Summary and conclusion …………………………………………………….…..……150
6.6 References……………………………………………………………………..….……151
Chapter 7: Conclusion & future directions……………………………………………………...156
References………………………………………………………………………….…...160
ix
List of Figures
Figure 1.1: Structural features of Torpedo nAChR……………………………………………………7
Figure 1.2: nAChR subunits forming (A) homomeric and (B) heteromeric receptors………………..9
Figure 1.3: Cartoon representation of the ligand binding domain between α and δ subunit of Torpedo
nAChR……………………………………………………………………………………..11
Figure 1.4: Surface overlayed-cartoon representation of transmembrane domains of Torpedo
nAChR……………………………………………………………………………………..13
Figure 1.5: Various stoichiometric combinations of a heteromeric receptor………………………….14
Figure 1.6: nAChR-mediated Ca2+ signalling and modulation of neuronal growth…………………...20
Figure 1.7: nAChR mediated signalling pathway involved in lung cancer and their cells of origin….27
Figure 1.8: Predatory marine cone snails (A) Conus regius and (B) Conus victoriae………………...31
Figure 1.9: Schematic representation of cone snail’s venom apparatus representing the main
parts………………………………………………………………………………………...32
Figure 1.10: Classification of conotoxins……………………………………………………………...34
Figure 1.11: Structural diversity among conotoxins…………………………………………………...36
Figure 1.12: AChBP and [A10L,D14K]PnIA co-crystal structures…………………………………...38
Figure 2.1: The basic apparatus setup required for solid phase peptide synthesis…………………….69
Figure 2.2: Directed disulphide formation of α-conotoxins using orthogonal cysteine protecting
groups.……………………………………………………………………………………73
Figure 2.3: Schematic representation of the various steps involved in two-electrode voltage clamp
studies using Xenopus laevis oocytes. …………………………………………………….75
Figure 3.1: Concentration-dependent RegIIA inhibition of ACh-evoked current amplitude mediated by
(A) α3β2, (B) α3β4 and (C) α7 nAChRs expressed in oocytes……………………………84
Figure 3.2: Selectivity of α-conotoxin RegIIA inhibition of nAChR subtypes………………………..85
Figure 3.3: RegIIA and alanine analogues secondary αH shifts……………………………………….87
Figure 3.4: RegIIA and alanine analogue (300 nM) inhibition of various nAChR subtypes expressed in
Xenopus oocytes…………………………………………………………………………...88
x
Figure 3.5: [N11A]RegIIA and [N12A]RegIIA exhibiting improved selectivity at α3β4 nAChR
subtypes……………………………………………………………………………………89
Figure 3.6: [N11A, N12A]RegIIA inhibition of α3β2 and α3β4 nAChR compared with that of wild-
type RegIIA………………………………………………………………………………..91
Figure 4.1: α-Conotoxin LsIA selectivity for various nAChR subunit combinations expressed in
Xenopus oocytes………………………………………………………………………….108
Figure 4.2: Kinetics of LsIA inhibition of peak ACh-evoked current amplitude as a function of
time……………………………………………………………………………………….110
Figure 4.3: Kinetics of α-conotoxin LsIA block and recovery at the α7 nAChR subtype…………...111
Figure 4.4: Influence of N-terminus truncation and C-terminus carboxylation of LsIA on ACh-evoked
current inhibition at the α7 (A) and α3β2 (B) nAChR subtypes………………………….113
Figure 5.1: Dimeric αD-conotoxin GeXXA inhibition of various nAChR subtypes………………...129
Figure 5.2: α9α10 hybrid nAChR inhibition by monomeric αD-conotoxin GeXXA………………...130
Figure 5.3: The sequence and disulphide linkage of αD-conotoxin GeXXA………………………...132
Figure 5.4: The crystal structure of αD-conotoxin GeXXA………………………………………….133
Figure 5.5: Pairwise sequence alignment of the ACh-binding site of the mature α10 subunit
peptide.……………………………………..……………………………………………..135
Figure 6.1: Dicarba Vc1.1 analogues (3 µM) percentage inhibition of ACh-evoked currents at (A)
α9α10 and (B) α3β4 nAChR subtypes……………………………………………………144
Figure 6.2: Dicarba Vc1.1 analogues concentration-dependent inhibition of ACh-evoked currents at
the α9α10 nAChR subtype………………………………………………………………..145
Figure 6.3: [3,12]-Dicarba RgIA analogue inhibition of ACh-evoked currents at rat α9α10 and human
α7 nAChRs expressed in Xenopus oocytes……………………………………………….147
xi
List of Tables
Table 1.1: Sequence alignment of α-conotoxins targeting neuronal nAChR subtypes………………..37
Table 3.1: α-Conotoxin RegIIA inhibition of recombinant nAChR subunits expressed in Xenopus
oocytes……………………………………………………………………………………..85
Table 3.2: RegIIA and analogues inhibition of nAChR subtypes……………………………………..90
Table 3.3: Sequence alignment of α-conotoxins targeting various nAChR subtypes…………………96
Table 4.1: α-Conotoxin LsIA’s kinetic constants for blocking nAChR subtypes……………………112
Table 4.2: Half-maximal inhibitory concentrations (IC50) and Hill slope (nH) values from
concentration–response curves for LsIA and its analogues at the α3β2 and α7 nAChR
subtypes…………………………………………………………………………………..114
Table 4.3: Sequence alignment of LsIA and α-conotoxins…………………………………………...115
Table 5.1: Sequence alignment of αD-conotoxin GeXXA with other, previously discovered αD-
conotoxins………………………………………………………………………………...126
Table 5.2: Pharmacological profile of dimeric αD-conotoxin GeXXA inhibition of various
nAChRs…………………………………………………………………………………...128
xii
Abbreviations
ACh Acetylcholine AChBP Acetylcholine binding protein ACN Acetonitrile Acm Acetamidomethyl Ala Alanine Arg Arginine Asn Asparagine Asp Aspartic acid BiP Immunoglobulin-binding protein Boc tert-butyloxycarbonyl BSA Bovine serum albumin Ca2+ Channel Voltage gated calcium channel CaMPK Ca2+ -calmodulin-dependent protein kinase
CCI Chronic constriction nerve injury CI Confidence interval CICR calcium induced calcium release Cys Cysteine CNS Central nervous system CTD C-terminal domain
CREB cAMP response element-binding protein DCM Dichloromethane DIPEA N,N-diisopropylethylamine DMF Dimethylformamide DNA Deoxyribonucleic acid DRG Dorsal root ganglion ECD Extracellular domain
ERK/MARK Extracellular signal-regulated mitogen-activated protein kinase ES-MS Electrospray mass spectrometer Fmoc 9-Fluorenylmethyloxycarbonyl g Grams Gln Glutamine Glu Glutamic acid Gly Glycine GWAS Genome-wide association studies HBTU O-Benzotriazole-N,N,N’,N’-tetramethyl-uronium- hexafluoro-phosphate HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid HF Hydrogen fluoride His Histidine HPLC High performance liquid chromatography HVA High voltage-activated Hyp Hydroxyproline IAP Inhibitors of Apoptosis ICD Intracellular domain Ile Isoleucine IC50 Half-maximal inhibitory concentration ICK Inhibitory cysteine knot IP3R inositol (1,4,5)-triphosphate receptors KCN Potassium cyanide Leu Leucine Lys Lysine MBHA 4-Methylbenzhydrylamine MD Molecular dynamics
xiii
Mec Mecamylamine Met Methionine mg milligrams min minutes ml milliliters MS Mass spectroscopy MS-222 Tricaine methanesulphonate nAChR Nicotinic acetylcholine receptor NFκB Nuclear factor kappa beta nH Hill slope NHBE normal human airway epithelial cells
NNK 4-(methylnitrosamino)-1-(3-pyridyl)-butanone NNN N-nitrosonornicotine
NMR Nuclear magnetic resonance NOE Nuclear Overhauser Effect NOESY Nuclear Overhauser Effect Spectroscopy NSCLC Non-small cell lung carcinoma NTD N-terminal domain P13K phosphatidyl-inositol 3-kinase PAC Peripheral adenocarcinoma PCR Polymerase chain reaction PDI Protein disulfide bond isomerase Phe Phenylalanine PKC Protein kinase C PNEC Pulmonary neuroendocrine cells PNS Peripheral nervous system PPI Peptidyl-prolyl cis-trans isomerase Pro Proline PSNL Partial sciatic nerve ligation RP-HPLC Reversed-phase high performance liquid chromatography RNA Ribonucleic acid RyR Ryanodine receptors
RT-PCR Reverse transcription polymerase chain reaction s Seconds SCLC Small cell lung carcinoma SEM Standard error of the mean Ser Serine SNP Single nucleotide polymorphisms SPPS Solid phase peptide synthesis TFA Trifluoroacetic acid TH Tyrosine hydroxylase TIPS Triisopropylsilane TOCSY Total Correlated Spectroscopy Thr Threonine Trp Tryptophan Trt Trityl or triphenylmethyl Tyr Tyrosine Val Valine VDCC voltage-dependent calcium channels XIAP X-liked inhibitor of apoptosis
1
ABSTRACT:
INTRODUCTION: Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion
channels expressed in both central nervous system (CNS) and peripheral nervous system
(PNS) and are involved in fast ACh-mediated synaptic transmission. Neuronal nAChRs are
pentamers composed of a combination of alpha subunits (α2-10) and beta subunits (β2-4)
exhibiting diverse structural and functional heterogeneity. nAChRs are shown to contribute to
the physiological roles of nAChRs in neurotransmitter release and synaptic plasticity. Further,
they are also implicated in various pathophysiological conditions including Alzheimer’s
disease, schizophrenia, tobacco addiction and lung cancer.
α-Conotoxins, a new class of peptides that act as nAChR antagonists have been identified
from the venom of predatory marine cone snails. α-Conotoxins are a class of short di-sulphide
rich peptides which specifically target various nAChRs subtypes and are excellent molecular
probes for identifying the physiological role of nAChR subtypes in both normal and disease
states. They are defined by their characteristic cysteine framework, CCXmCXnC (Xm and Xn
represent the number of non-cysteine residues), classifying them into various subclasses.
CHAPTER 3: The α3β4 subtype is shown to be involved in lung cancer, nicotine addiction
and drug-abusive behaviour. Despite this, the knowledge of the pathophysiological role of
α3β4 subtypes is limited by the lack of adequate subtype specific probes. To-date only five α-
conotoxins inhibiting α3β4 nAChR subtype are known. Of these, α-conotoxin AuIB
belonging to a unique 4/6 subclass is the only peptide shown to selectively inhibit α3β4
nAChR subtype with an IC50 of 2.5µM.
We report the discovery of new α4/7-conotoxin RegIIA which was isolated from Conus
regius. RegIIA has a classical ω-shaped globular structure with balanced distribution of
shape, charges and polarity. RegIIA specifically inhibits ACh-evoked currents of α3β2, α3β4,
and α7 nAChRs isoforms. The implication of α3β4 nAChRs in various diseases such as lung
2
cancer and nicotine addiction along with RegIIA being the most-potent α3β4 nAChR
antagonist to date led us to investigate and improve RegIIA’s selectivity profile at the α3β4
nAChR subtype. Using alanine scanning mutagenesis and modelling studies, we identified
critical residues of α-conotoxin RegIIA that interact with the ACh-binding site of α3β2, α3β4
and α7 nAChRs.
CHAPTER 4: α3β2 and α7 nAChR subtypes play vital roles in various functions, such as
neuronal plasticity, angiogenesis and gene regulation. α-Conotoxins targeting these receptors
form excellent probes to understand their physiological roles in normal and diseases
conditions. Here I describe the pharmacological properties of the novel α-conotoxin LsIA, the
first peptide isolated from Conus limpusi, a species of worm-hunting cone snail commonly
found on the south east coast of Queensland, Australia. LsIA is an α4/7-conotoxin with the
characteristic I–III and II–IV disulfide connectivity. LsIA exhibited selective and potent α7
and α3β2 nAChR subtype antagonism. In this report, I also examined the structure–function
relationship of the presence of a unique N-terminal serine at position 2 and C-terminal
carboxylation. Furthermore, I also investigated the pharmacological implications, involving
incorporation of the α5 subunit towards the inhibition of LsIA at α3β2 nAChR subtypes.
CHAPTER 5: Novel α-conotoxins of the D-superfamily have only recently been discovered
and functionally characterized. These were found to be non-competitive nAChR antagonist
and are naturally dimeric, which makes their blocking mechanism more intriguing. From the
venom of Conus generalis, we identified a novel αD-conotoxin GeXXA. This toxin is a
disulfide-linked homodimer of a 10-Cys-containing peptide with each peptide chain made of
50 amino acid residues. Each polypeptide chain is composed of an N-terminal domain (NTD,
residues 1-20) involved in dimerization and a C-terminal domain (CTD, residues 21-50). αD-
GeXXA is a non-selective inhibitor of nAChR subtypes exhibiting most potency at the α7
3
subtype with an IC50 of 210 nM. However, for rat and human α9α10 nAChRs, the inhibition
by αD-GeXXA is irreversible, indicating the tight binding of αD-GeXXA to α9α10 nAChR.
To get further insight about its inhibition mechanism, the CTD of each chain was isolated and
tested against various nAChR subtypes. Contrary to native peptide, GeXXA-CTD showed
selective and reversible inhibition of α9α10 nAChR subtype. This specificity was further
investigated using hybrid receptors of rat and human α9 and α10 subunits. GeXXA-CTD was
10-fold less potent on human α9α10 than on rat α9α10 nAChR while similar potency was
observed with hα9rα10 hybrid receptor indicating significant role of α10 subunit in inhibition.
These results provide more insight into the novel blocking mechanism of α-D conotoxins.
CHAPTER 6: Conotoxins have emerged as useful leads for the development of novel
therapeutic analgesics. However, the disulfide connectivity of α-conotoxins can change under
oxidative and reduced conditions leading to changes in structural conformation. Exploitation
of these and other peptides in research and clinical settings has been hampered by the lability
of the disulfide bridges that are essential for toxin structure and activity. One solution to this
problem is replacement of cysteine bridges with nonreducible dicarba linkages. We explore
this approach by determining the functional characteristics of dicarba analogues of a novel
analgesic α-conotoxin Vc1.1 and RgIA which is known to inhibit high voltage-activated
(HVA) calcium channel currents via GABAB receptors and α9α10 nAChR subtypes. When
tested, dicarba Vc1.1 and dicarba RgIA analogues showed differential activity wherein the
[2,8]-dicarba analogues of both Vc1.1 and RgIA were active at HVA calcium channel current
via GABAB receptors whereas the [3,16]-dicarba analogues retained its activity at α9α10
nAChR subtypes. These results provide new leads towards the elucidation of the biological
target responsible for the peptide’s potent analgesic activity.
4
SUMMARY: In the past-decade, nAChRs have been identified as potential drug targets for
various diseases. However, knowledge about the role of various nAChR subtypes in both
physiological and pathophysiological conditions is scarce. My research describes the
discovery, characterization and development of a novel α3β4 antagonist as potential tool
towards understanding its role in lung cancer. Further, dicarba modification of peptides and
characterization of new class of α- and αD-conotoxins provide future insights towards drug
development.
5
CHAPTER 1
INTRODUCTION
6
1.1 Nicotinic acetylcholine receptors
1.1.1 The discovery
After the initial discovery of nicotinic acetylcholine receptors (nAChR) in 1914 by Henry H
Dale [1] and Otto Loewi [2], substantial progress has been made to improving our
understanding of the nicotinic mechanisms brought us a step closer to ever growing
knowledge hill. Numerous reviews documenting this progress have been published and
focused on nAChR structure, function, physiology, pharmacological tools and potential
therapeutic use [3-8]. Ironically, these advances only raised more questions about the
complexity of the nervous system and neurotransmission, and the contribution of these
receptors in various diseases, such as Parkinson’s disease, Alzheimer’s disease,
schizophrenia, epilepsy, dementia and cancer [9, 10]. Today, the major breakthroughs in
understanding nAChRs seem but a fascinating history tale that starts with the initial discovery
of the chemical nature of neurotransmission by Claude Bernard, a French physiologist, in
1857. The complexity of the cholinergic transmission or role of acetylcholine (ACh) was as
yet unanticipated.
In the mid-1980s, advancements in molecular biology enabled the identification and cloning
of the genes that encoded the first nAChR from Torpedo marmorata [11]. Since then, more
nAChR family members have been identified, with 16 genes encoding structurally
homologous yet distinct nAChR subunits now known [12]. The muscle nAChR was primarily
isolated, purified and sequenced by Jean-Pierre Changeux from the Torpedo electric organ
[13]. Consequently, the neuromuscular junction (endplate) for the analysis of nAChR-
mediated neurotransmission became widely used. This enabled physiologists to conduct
various experiments to improve our understanding of the biochemical nature and physiology
of neurotransmission.
7
nAChRs are ionotropic channels belonging to the cys-loop superfamily of the ligand-gated
ion channels [3]. Other ion channels belonging to this superfamily include GABAA, glycine
(GlyR), 5-HT3 serotonin and zinc-activated receptors, which have similar structural features
to nAChRs [12]. These features include an extracellular NH2-terminal domain (ECD), four
transmembrane domains (M1-M4), and a intracellular COOH-terminal sequence (ICD)
[Figure 1.1] [14]. Structural homology of human nAChRs was found to be evolutionarily
linked to the ionotropic channels, dating back as far as nematodes and molluscs and to simple
life forms, such as prokaryotes. [15, 16]. Along with these features, various nAChR subunits
have high sequence homology with each other.
Figure 1.1: Structural features of Torpedo nAChR (PDB 2BG9 [14]). Schematic
representation of (A) the pentameric structure of a Torpedo nAChR (B) a nAChR subunit
showing various structural features (C) Cartoon representation of the three dimensional of the
α-subunit of Torpedo nAChR generated using PyMol Molecular Graphics System (DeLano
Scientific LLC.).
8
1.1.2 Subunit diversity
The nAChR is one of the most well-studied ligand-gated ion channel family members. This is
due to various multidisciplinary studies, including genetic, protein, microscopic and structural
studies, that stemmed from earlier studies on the Torpedo electric organ nAChR structure.
Original studies made two major significant findings: 1) nAChRs from Torpedo have
remarkable density, enabling the pseudo-crystalline studies of the receptor at 4Ǻ resolution
[14]; and 2) studies of the crystal structure of a water soluble protein, ACh binding-protein
(AChBP) [17].
The 16 subunits that have been discovered are broadly classified as muscle or neuronal
subtypes, based on their tissue expression. Muscle subtypes include α1, β1, δ, γ and ε
subunits, and neuronal subtypes include α2–α10 and β2–β4 subunits. However, although this
nomenclature is widely used and provides a simple way to class receptor subtypes, it is being
discouraged by the International Union of Pharmacology [12]. This is because various studies
have indicated that more than one neuronal subtype receptor is expressed in various non-
neuronal tissues [18-20].
1.1.3 Receptor structure
nAChRs are pentameric structures made from various transmembrane subunit combinations.
The above-mentioned subunits assemble in numerous combinations to form two distinct
receptors classes, namely homomeric receptors (composed of only α subunits, such as α7) and
heteromeric receptors (composed of α and β subunits, such as α4β2) [Figure 1.2]. Up until
recently, only α7, α9 and α10 subunits were believed to form only homomeric receptors [21].
However, recent studies have provided evidence of the formation of α7-containing
heteromeric receptors [22, 23]. The pentameric structure of these receptors was initially
identified during earlier studies into the muscle nAChRs isolated from the Torpedo electric
9
organ. Only two known muscle nAChR combinations have been characterised, α1β1δγ and
α1β1δε. These were identified as fetal and adult muscle subtypes, respectively, based on their
expression levels during the developmental stages [24, 25].
Figure 1.2: nAChR subunits forming (A) homomeric and (B) heteromeric receptors. The
ACh binding site in each receptor is indicated in red triangles [26].
1.1.3.1 Extracellular domain/Ligand-binding domain
As mentioned earlier, nAChRs are ligand-gated ion channels and activated or opened in the
presence of an endogenous agonist or ligand ACh. The ligand- or agonist-binding site exists
on the extracellular domain, within the interface of two α subunits (in homomeric receptors)
or between an α and β subunit (in heteromeric receptors) in the receptor. A nomenclature of
‘agonist-binding subunit’ for α subunits and ‘structural subunits’ for non-α subunits (β1–β4,
δ, γ and ε subunits), was used to indicate the presence of the cysteine loop in α subunits. The
cysteine loop is needed to aid the formation of the functional ligand-binding domain [12].
However, this nomenclature was discontinued after it was discovered how vital the non-α
subunits are in the binding pocket. Today, the α-subunit interface is called the ‘principal’ or
‘+’ face and the β-subunit interface is called the ‘complementary’ or ‘-’ face [Figure 1.3] [27,
28].
Our knowledge of the N-terminal domain has developed through various binding and
functional assays in combination with chemical modification and mutagenesis experiments
[29-31]. Initial studies of photo affinity labelling (photolysis of covalently bound chemical
10
tags to the active sites of protein molecules) on muscle nAChRs using the Torpedo receptor
identified key amino acid residues, such as α-Tyr 93, which constitute the agonist-binding site
[32]. These studies provided an early indication of the hydrophobic nature of the agonist-
binding pocket. In muscle nAChRs, this site was located between the interface of α1-δ and
α1-γ subunits in fetal form, and α1-δ and α1-ε subunits in adult form [33].
More recently, major improvements in understanding the three-dimensional structure of these
receptors came through X-ray crystallographic and high-resolution electron microscopy
studies of the ACh binding protein (AChBP) and Torpedo receptor [17, 34]. AChBP, isolated
from glial cells of molluscs (Lymnaea), is a small, water-soluble protein. Its features are
structurally similar to those of the N-terminal extracellular domain of nAChRs, but it lacks
any of the other characteristics of the cys-loop receptor superfamily. The binding interaction
of ACh to AChBP is similar to nAChR receptor activation. As such, it has received significant
attention as it may help improve our understanding of the ligand-binding domain of these
proteins [35].
AChBP crystal structures revealed that the α subunit plays a major role in the agonist-binding
site. The Cys-Cys pair present only within the α subunits that form the ‘principal’ face of the
binding site is essential for ligand binding [Figure 1.3]. Mutation of these residues, Cys191–
Cys192 (Torpedo α subunit numbering), significantly affected receptor function and assembly
[36]. Furthermore, structural and simulation models revealed conformational changes in the
Cys-Cys pair of up to ~ 11Ǻ, interlocking the agonist/ligand deep within the binding pocket
[37].
Along with the mobility of the Cys-Cys pair, a series of conserved aromatic amino acid
residues in the ‘principal’ face contribute to the agonist-binding site. These residues are
11
labelled and grouped into various loops (indicated in parenthesis): Tyr93 (loop A), Trp149
and Tyr 151 (loop B), Tyr190 and Tyr198 (loop C). As the numbering indicates, the Cys-Cys
pair belongs to the C-loop of the ‘positive’ interface [Figure 1.3] [38-40]. It is worth noting at
this stage that among all of the identified α subunits, α5 and α10 subunits do not form the
‘principal’ face of the agonist-binding site within the receptor complex. Therefore, despite the
presence of the Cys-Cys pair, these subunits do not form homomeric or heteromeric
functional receptors. This may be due to the lack of conservation within the key residues. For
example, substitution of Asp for Tyr at position 198 of the α5 subunit makes it inactive to the
nicotinic agonist [41, 42].
Figure 1.3: Cartoon representation of the ligand binding domain between α and δ
subunit of Torpedo nAChR (PDB 2BG9 [14]). Amino acids contributing by the α-subunit
to the ‘principal’ or ‘+’ interface of the ACh-binding pocket (Y93, W149, Y151, Y190 and
Y198) and those contributed by the β-subunit interface to the ‘complementary’ or ‘-’ interface
(W54 and L108) are represented in stick, overlayed with sphere representation. The Cys191–
Cys192 of α-subunit is coloured yellow. Image generated using PyMol Molecular Graphics
System (DeLano Scientific LLC.).
12
1.1.3.2 The transmembrane domain and intracellular domain
Agonist-bound AChBP crystals significantly contributed to our understanding of the various
conformational changes within the N-terminal extracellular domain and are a very valuable
scientific tool [43, 44]. However, the lack of other components, such as a transmembrane
domain and channel gating, hindered the extrapolation of the information to complete
nAChRs.
The transmembrane domain of each nAChR subunit is made of four segments, M1–M4
[Figure 1.1]. These segments are important for channel gating and anchoring the receptor in
the lipid bilayer. The four transmembrane segments are arranged inside the pentameric
structure of the receptor with the M2 of all of the five subunits lining the channel pore and the
M4 of all of the five subunits forming the outer surface of the receptor [Figure 1.4]. This
arrangement, originally hypothesised after the initial bilayer membrane experiments with
isolated M2 segments of the Torpedo nAChR, was authenticated only after the electron
microscopic study of Torpedo nAChR by the Unwin group [14]. While the M2 segment is
primarily involved with channel gating, M1 and M4 segments modulate receptor assembly,
function and localisation. Early studies using chimeric M1 and M2 constructs reveal that M1–
M2 coupling is involved in the pentameric assembly of α7 nAChR [45]. This was evaluated
through simultaneous studies on muscle nAChR, and indicated that the M1 contributes to the
heterodimer structure of the receptor [46].
The orientation of the M4 to the outer surface of the receptors [Figure 1.4] suggests it has a
role in receptor localisation through its interactions with lipids and cholesterol in the
membrane bilayer [47, 48]. Furthermore, scanning mutagenesis studies within this Torpedo
nAChR segment altered its function and assembly [49, 50].
13
Figure 1.4: Surface overlayed-cartoon representation of transmembrane domains of
Torpedo nAChR (PDB 2BG9) [14]. The M2 segment (red) of all five subunits forms the ion
pore of the channel. The M1, M2 and M4 segments are represented in cyan, blue and green
colour respectively. α-V255 and α-L251 residues involved in channel gating are represented
in yellow spheres. Image generated using PyMol Molecular Graphics System (DeLano
Scientific LLC.).
Although the ligand-binding domain and transmembrane domain are vital for nAChR function
and assembly, the intracellular domain also significantly contributes to it. However, the
cytoplasmic loops of M1–M2 and M3–M4 have the distinct role of signal transduction to
these receptors via phosphorylation. While further validation of this function is required,
recent studies suggested that potential intracellular proteins, such as Rapsyn, interact with the
α9 nAChR and modulate its surface distribution [51, 52]. Mutations within the large M3–M4
intracellular loop of the α7 nAChR significantly reduced receptor function and assembly, and
mutations in the α3 subunit disrupted the distribution of α3-containing receptors in the
interneuronal synapse [53, 54].
1.1.4 Subunit stoichiometry of nAChRs: structural and functional implications
14
Sixteen nAChR subunits that assemble into homomeric or heteromeric pentamers have been
identified. Heteromeric receptors exhibit a huge diversity in structure, function and receptor
localisation, which can be attributed to the various possible subunit stoichiometric
combinations. To date, about 30 known subunit combinations arranged in various
stoichiometries have been identified. Thus, homomeric structure of a receptor provides a key
advantage in structural and functional understanding of the receptor. [55].
Stoichiometry of a heteromeric receptor is defined by the identity of the 5th subunit. For
example, for the α3β2 receptor, the pentameric structure can assemble the 5th subunit with α3
or β2, producing a simple stoichiometry of this receptor of either (α4)3(β2)2 or (α4)2(β2)3
[Figure 1.5]. Complex stoichiometries evolve when other subunits such as α5, α6 and β3 are
introduced as the 5th subunit, to form (α4)2(β2)2α5, (α4)2(β2)2α6 and α4α6(β2)2β3 receptor
combinations [Figure 1.5]. In the case of muscle nAChRs, only one subunit stoichiometry
exist: (α1)2β1δε/γ [14]. While recent studies have highlighted some of the roles played by
different stoichiometric combinations [5], much is to be learned about their contribution to
receptor function, pharmacology and physiology.
Figure 1.5: Various stoichiometric combinations of a heteromeric receptor [26].
While the pure mathematical combinations of different subunits represent a complex issue,
native nAChRs assemble predominantly with specific subunit stoichiometry. For example,
15
single-channel recording and direct biochemical studies of α4β2 nAChR, a major subtype
expressed throughout central nervous system (CNS), showed assembly primarily in the
(α4)2(β2)3 stoichiometry [56, 57]. However, this composition can be changed in model
expression systems, such as Xenopus oocytes, via RNA injection of different subunit ratios.
Recent studies on recombinant receptors using this technique showed differential agonist
sensitivity based on the subunit ratio of α4 and β2 subunits used (1:10 or 10:1), along with
changes in calcium permeability [58, 59]. Similar differences in affinity for both agonist
(ACh) and antagonist (α-conotoxin AuIB) were observed with α3β4 nAChR stoichiometry
[60]. Furthermore, recent electrophysiological studies with α5, α6 and β3 subunits revealed
complex subunit stoichiometries with a unique functional role in the receptors such as
receptor desensitization and gating (these concepts will be discussed in the next section). The
β3 subunit was reported to extensively co-localise with the α6 subunit, while forming
complex stoichiometric combinations [61].
Different α6-containing receptor stoichiometries have been implicated in the pathophysiology
of neurological disorders, such as Parkinson’s disease [62]. In addition, when the α5 subunit
is co-assembled with the α3β4 nAChR, calcium permeability increases [63] and nicotine-
evoked dopamine release in synaptosomal preparations containing α4β2 nAChRs is affected
[64]. Therefore, subunit stoichiometry plays a vital role in the pharmacological and
physiological role of various nAChR subtypes.
1.1.5 Receptor function, biophysical properties and gating
Mammalian nAChRs are activated by the natural endogenous agonist ACh binding to the N-
terminal extracellular domain. Upon ligand binding, the receptor undergoes rapid
conformational changes which transition into channel opening. These receptors are cation
16
selective and modulate mono- and divalent cation influx, depolarising cell membranes and
creating neuronal excitability.
Various residues within the extracellular, transmembrane and intracellular domains of the
receptor contribute to the microsecond conformation changes from ligand binding to channel
gating [3]. M1 and M2 are involved in the gating process, and help determine the ionic
selectivity of these receptors. Mutagenesis study has shown the presence of charged glutamate
and valine within M2 and a lack of proline in the intracellular domain of M1–M2 correspond
with the cation permeability of nAChRs [65].
While there is no direct experimental proof that the receptor changes, the various transitions
within the protein structure of the receptor are based on computational simulations from
various mutational and structural studies. The current model [34] describes a rotation or
torque produced by significant C-loop movement (~ 11Ǻ) when the ligand interacts with the
agonist-binding site. This torque is transitioned through the receptor, influencing the
orientation of the M2 that lines the channel pore. These transitions place the receptor in three
structural states: closed, open and desensitised, which determine the receptor’s functional and
pharmacological properties and influence various intracellular signalling cascades.
The channel-gating process involves switching from a closed or non-ligand-bound receptor
state to an open state, with a change in channel pore size from ~ 4Ǻ to ~ 8Ǻ respectively [66].
This is accomplished via the transitional torque produced by the extracellular domain and
transitory shift of hydrophobic residues within the M2 helices. It leads to concurrent influx of
Na+, K+ and Ca2+ ions, which activates an array of signalling pathways.
17
The pore’s ion-gating function is attributed to two special properties: the near perfect
arrangement of M2 helices in a radially inward tilt towards the pore axis, and symmetric
orientation of hydrophobic residues α-Leu 251 and α-Val 255 that constrict to form a narrow
energetic barrier during the closed state of the receptor [Figure 1.4] [67, 68]. This model was
evaluated when mutational studies of these residues led to increased channel conductivity
[69].
The above-mentioned studies provided the first rationale linking the physiological function of
the nAChR with its biophysical properties. There are two major nAChR biophysical
properties that modulate its physiological functions. Firstly, the rapid transition of the receptor
between the closed and open state governs its primary role of fast synaptic transmission. The
release of ACh and subsequent activation of the nAChR in presynaptic junctions modulates
the release of other neurotransmitters, such as dopamine and GABA [70, 71]. Secondly, the
ionic permeability of nAChRs to Ca2+ mediates various downstream signalling cascades [72].
The relative permeability ratio (Ca2+/Na+) of the nAChR is calculated by two methods:
measuring the shift in reversal potential of nAChR-mediated current under varying calcium
concentrations [73]; and calcium fluorescence imaging [74]. These techniques indicate the
highest calcium permeability for homomeric α7 and heteromeric α9/α10 with a ratio of ≥10.
This ratio was the least for muscle nAChRs at ~ 0.1, while all of the other heteromeric
receptors exhibited a ratio of ~ 2.0 [75, 76]. While the residues that contribute to the barrier
within the pore are highly conserved in various nAChR subunits, the relative permeability of
calcium to sodium ions is affected by the arrangement of residues within the ion conduction
path of the pore. These residues include α-Glu 262, α-Ser 266 (top end of the pore) and α-Glu
241 (at the intracellular mouth of the pore), and were identified through mutational and
electrophysiological studies [77, 78]. This variance in calcium permeability changes the
18
physiological roles played by different nAChR subtypes [79]. The physiological implication
of nAChR-mediated Ca2+ signalling will be discussed in detail in Section 1.6.
While nAChRs were initially identified in neuromuscular and synaptic junctions, and their
primary role in fast cholinergic transmission is long established, recent discoveries showing
non-synaptic nAChR expression significantly expanded the functional scope of these
receptors [80]. Unlike synaptic junctions, where neurotransmitter levels are highly regulated
via release and active reuptake producing the instantaneous open and closed transition of
nAChR, non-neuronal nAChRs are prone to prolonged agonist application. This sustained
exposure led to the identification of a third state of the receptor: desensitised.
Desensitisation is a process in which the receptor transitions from an open state to an agonist-
bound non-conducting state. The transition rates between these states depend directly on the
dissociation rates of the agonist. Therefore, this is dependent on the nature of the agonist
bound and the subunit composition of that receptor. As α and β subunits contribute
differentially to the pharmacological properties of the receptor, the same is applicable to the
rate of receptor desensitisation. For example, α7 nAChRs desensitise more quickly than other
subtypes. Also, incorporating the α5 subunit has been shown to change the biophysical
properties of all three functional states of a receptor [63, 81].
1.1.6 nAChR-mediated Ca2+ signalling and modulation of neuronal growth
nAChRs exhibit strong calcium permeability, which is dependent on the receptor composition
and stoichiometry [59, 76]. Subtypes such as the α7 nAChR can directly raise the cytoplasmic
calcium levels due to their high permeability; however, indirect calcium influx has also been
shown to occur due to nAChR-mediated depolarisation. Indirect calcium influx occurs in two
19
ways: through voltage-dependent calcium channels (VDCC), and being released from calcium
intracellular stores, such as the endoplasmic reticulum [Figure 1.6] [82, 83].
VDCC-mediated calcium influx occurs at depolarising potentials of > –40 mV, which are
generated by nAChR activation. Under these conditions, the initial Ca2+ entry via nAChRs is
augmented and may be functionally complementary, an association that is also observed with
NMDA receptors [84].
The third process contributing to increased cytoplasmic Ca2+ signal is through calcium
induced calcium release (CICR) from intracellular stores [83]. While calcium signalling via
VDCCs is significantly mediated by α7-, α3- and/or β2-containing receptors in neuronal
ganglia, α7 also increases transient Ca2+ levels independently of VDCCs via CICR. Calcium-
quenching experiments in neurons of substantia nigra pars compacta showed reduced
cytoplasmic calcium levels when α7 nAChR was activated with choline [85]. Receptor
antagonists were later used to show that CICR involved ryanodine (RyR) receptors and
inositol (1,4,5)-triphosphate receptors (IP3Rs) expressed in the endoplasmic reticulum
[Figure 1.6] [82, 86]. Although the molecular mechanism behind nAChR-activated IP3R-
calcium release is still unclear, secondary signalling molecules, such as Ca2+-dependent
phospholipase C and Ca2+ -sensor proteins, have been implicated [87, 88]. The various
mechanisms of cytoplasmic calcium influx reflect a complex and intricate functional coupling
of nAChRs with RyR and IP3 receptors, which leads to a sustained calcium signal. These
calcium signals play a vital role in the activation of various downstream signalling processes.
20
Figure 1.6: nAChR-mediated Ca2+ signalling and modulation of neuronal growth.
Downstream signalling events upon nAChR activation are classed as immediate, interim and
long-term effects. The calcium ion influx occurs through three ways: nAChR activation,
VDCC activation and CICR mechanism from calcium internal stores (mediated by RyR and
IP3 receptors). The Ca2+ influx leads to immediate cell depolarisation and activation of
various kinases and proteins such as PKC, PKA and Calmodulin. This is followed by
subsequent activation of downstream signalling molecules, leading to various physiological
responses such as neuronal plasticity, memory, neuroprotection.
The above-discussed calcium influx is a sequential process occurring in the following order:
nAChR > VDCCs > ryanodine receptor > IP3 receptors. Therefore, it is only logical for the
various downstream signalling events upon nAChR activation to be sequential and classed as
immediate, interim and long-term effects based on their duration and timing.
21
1.1.6.1 Immediate effects
nAChRs expressed in presynaptic junctions of the peripheral nervous system (PNS) and CNS
mediate their primary role in fast synaptic transmission. This process not only depolarises
cells, but also initiates exocytosis either directly or via VDCC activation [Figure 1.6] [89]. In
addition, nAChRs and VDCCs play physiologically complimentary roles in the regulation of
neurotransmitter release. In striatal synaptosomes, VDCC mediates nAChR-evoked dopamine
release [90]. However [3H]noradrenaline release from hippocampal synaptosomes, triggered
by α3β4 nAChR activation, is VDCC-independent [91].
1.1.6.2 Interim effects
The two major short-term implications of nAChR activation include regulation of gene
expression and nAChR desensitisation. CICR-mediated calcium influx activates the IP3
second messenger system involving various Ca2+-sensor proteins and kinases, such as protein
kinase C (PKC), is classed as an immediate effect [Figure 1.6]. However, concurrent
activation of downstream molecules, such as extracellular signal-regulated mitogen-activated
protein kinase (ERK/MAPK) [Figure 1.6], that has been shown to modulate the gene
expression of the tyrosine hydroxylase (TH), is defined as a short-term Ca2+-signalling effect.
TH is a known modulator of neurotransmitter release in catecholamine-containing neurons.
Prolonged nicotine exposure has been shown to promote TH mRNA expression [92]. In
addition, the role of nAChRs in the regulation of c-Fos and c-Jun gene expression has long
been apparent [Figure 1.6] [93].
In synaptic and non-synaptic regions, prolonged exposure of agonist leads to nAChR
desensitisation. Furthermore, high intracellular calcium levels have been shown to affect
various desensitisation properties, such as recovery of α7-containing nAChRs in chromaffin
cells and rat hippocampal neurons [94, 95]. These changes to the nAChR’s biophysical
22
properties are implicated in synaptic efficacy, and corresponding changes in pathological
conditions suggest a complex reciprocal relationship [81].
1.1.6.3 Long-term effects
In a complex scenario, nAChR activation and intracellular calcium influx translates into vital
physiological functions, such as neuronal plasticity, memory mechanisms, neuroprotection
and regulation of cell death [79]. Recent studies showed activation of other kinases, such as
Ca2+ -calmodulin-dependent protein kinase (CaMPK) and cAMP response element-binding
protein (CREB), was mediated via nAChR and CICR calcium influx [Figure 1.6] [96].
ERK/MAPK is an important molecule, central to various signalling cascades. Activation of
the ERK/MAPK signalling cascade via nAChR activation is critical for regulating gene
expression. Disrupting these kinase signalling cascades and consequent modulation of α7
nAChR expression and function has been implicated in Alzheimer’s disease [97]. Today, α7-
evoked activation of phosphatidyl-inositol 3-kinase (PI3K) and ERK/MAPK is a known
pathway for mediating neuroprotection and stimulating angiogenesis [Figure 1.6]. This anti-
apoptotic property of nAChR signalling is implicated in various cancers and is currently a
major target for novel therapeutics [98]. The nAChRs role in cancer is detailed in section
1.7.3.
The many signalling pathways mediated by direct and indirect calcium influx via nAChR-
activation reflect the complexity, yet specificity, of intracellular mechanisms. While recent
studies have shed light on these dynamic processes, much is yet to be proven and learnt about
the exact cellular pathways mediated by various specific nAChR subtypes, to improve our
understanding of their pathological implications.
23
1.1.8 nAChRs and diseases
Since their discovery, nAChRs have been extensively researched to build knowledge about
their structure and function. However, it was only in the past few decades that their true
nature and complexity has been understood. nAChR subunits have various different
compositions and stoichiometries, which correspond with specific biophysical and functional
properties, including tissue distribution. This suggests nAChRs may be involved in a huge
range of identified and as yet unidentified health conditions. nAChRs are known to be
implicated in numerous pathophysiological conditions, such as epilepsy, schizophrenia,
Alzheimer’s disease, Parkinson’s disease, pain, auto-immune disease, lung cancer and
nicotinic dependence, with other conditions being investigated and identified [3, 7, 99]. Each
of these conditions involves dynamic cellular interactions with a specific receptor subtype.
However, only three conditions will be discussed within the scope of this thesis: pain, nicotine
dependence and lung cancer.
1.1.8.1 nAChRs and pain
Pain is one of the most common health conditions and affects millions of people throughout
the world. It is a sensory response to nociception (a neuronal process involving noxious
stimuli), can be classified as either acute (sudden onset) or chronic (prolonged persistent
pain), and involves various pain pathways.
Nicotinic acetylcholine receptors have long been implicated in pain mediation, and various
nicotinic compounds that produce analgesic effects have been identified [100]. The initial
breakthrough came with the discovery of epibatidine which is a potent analgesic and a
nAChR agonist, although this drug was discontinued due to its severe side effects [101]. This
knowledge highlighted an alternative pain target to opioid receptors, which were targeted by
conventional analgesics. Epibatidine is a potent agonist of α4β2 nAChRs, one of the most
24
abundant subtypes in the CNS, and inhibits the nociceptive signals transmitted through the
dorsal horn of spinal cord [102]. The α4β2 nAChR’s role as a target for analgesics was further
established with the discovery of the promising therapeutic candidate ABT-594, a potent α4β2
nAChR inhibitor that lacks the side effects of opioid-targeting drugs [103, 104]. In
conjunction with α4 and β2 knockout mice studies, this paved the way for nAChRs to be
novel therapeutic target in pharmaceutical industry [105] and various compounds that target
α4β2 nAChRs are currently in clinical trials [5].
While, α4β2 nAChR subtype is a prominent candidate, recent study showed various other
nAChR subtypes with α7, α3, α9, α10, β2 and β4 subunits, to be involved in pain pathways
[106]. This study re-established the role of the α4β2 nAChR subtype in the analgesic efficacy
of various compounds. However, it also suggested that the α3β2 and α3β4 subtypes have a
significant role in the analgesia by these compounds. While this study excludes the role of the
α7 nAChR subtype in pain alleviation, other studies contradict this idea [107, 108]. These
other studies showed that α7 nAChR subtype activation induces anti-nociceptive in acute pain
model and anti-inflammatory effects in peritoneal macrophages. This was collaborated by
further studies in which α7 knockout mice exhibited increased hyperalgesia (an exaggerated
response to pain stimulus) and pain inflammation [109].
A new mechanism of nAChR-mediated pain modulation via receptor desensitisation has also
been proposed, and involves direct activation of these receptors. Incorporating auxiliary α5
subunits in α4β2 and α3β4, increases receptor desensitisation [110].
25
Finally, α9-containing receptor inhibition by a novel class of conotoxins showed significant
analgesic effects in peripheral neuropathy pain models [111, 112], and as a result, α9 has also
been proposed as novel target for analgesic drugs. Conotoxins and their analgesic properties
will be discussed in detail in the Chapters 6.
1.1.8.2 nAChR signalling and lung cancer
The pathophysiology of lung cancer has studied for almost half a century. Divided into two
major types: small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC),
it is the second most frequent and leading cause of cancer-related deaths worldwide. NSCLC
accounts for 80% of all lung cancer cases [113] and smoking, specifically tobacco intake, has
been a documented risk factor for lung cancer since the 1950s [114, 115]. Nicotine, polycyclic
aromatic hydrocarbons and nicotine-derived metabolites, such as 4-(methylnitrosamino)-1-(3-
pyridyl)-butanone (NNK) and N-nitrosonornicotine (NNN), are among the carcinogens in
tobacco smoke that are primary agents that initiate cancer [116]. Tobacco-related
tumorigenesis is caused either via the genocentric model, in which genomic interaction of
nicotine and carcinogenic nitrosamines leads to DNA adduct formation and mutation [117], or
the biochemical model, in which tobacco-derived nicotine and nitrosamines act as potent
nAChR agonists [118] and mediate the cell signalling pathways of growth, proliferation [119]
and apoptosis [120]. The biochemical model also leads to various biological effects, including
nicotine addiction and dependence [121].
1.1.8.2.1 Role of α3 subunit
Following the Schuller group’s first report in 1989, which implicated nAChRs in the
regulation of cancer cell growth [119], many studies started exploring the role of nAChRs in
cancer development and progression. In 1998, Schuller’s group conducted radiolabelled
binding assay studies using [125I]α-BTX and [3H]EB. These studies conclusively showed that
26
NNK and NNN, tobacco-specific carcinogenic nitrosamines, were potent nAChR agonists
[118]. At this point, concentrations of these nitrosamines were known to be 5000–10,000
times greater than nicotine in tobacco smoke, with the NNN concentration two–three times
that of NNK [117].
The binding assay experiments in this study also revealed the selective binding profile of
these nitrosamines. NNK was found to be a high-affinity ligand of the α-BTX-sensitive α7
nAChR subtype, while NNN is selective to the α4/α3 nAChR subtype, classified as an EB-
sensitive neuronal nAChR [Figure 1.7]. Also, the proliferation assay, which used the
incorporation of [3H]thymidine, identified that NNK’s binding to the α7 nAChR subtype is a
potent mitogenic stimulus. However, NNN and nicotine showed no effect in the proliferation
assay. These results, along with previous studies showing apoptotic inhibition of lung cancer
cells by nicotine, provided strong evidence that nAChRs are involved in tumour progression
[120].
Consecutively, NNK and nicotine were also shown to have a direct biochemical effect on
rapid Akt activation in normal human airway epithelial cells (NHBE) [122]. Serine/Threonine
kinase Akt is a key regulator of cell cycle process. Its activation leads to various signalling
cascades involved in cell proliferation and apoptosis [123]. This was confirmed by Dennis’
group, which demonstrated constitutive activation of Akt/protein kinase B in 90% of NSCLC
cell lines [124] and increased phosphorylation of downstream Akt substrates, such as MDM2,
mTOR and NFκB [Figure 1.7] [125]. This is known to promote cellular survival, resistance
to chemotherapy and radiation, and NFκB-dependent apoptotic inhibition.
27
Figure 1.7: nAChR mediated signalling pathway involved in lung cancer and their cells
of origin. A summarised model of the various cellular signalling molecules involved in SCLC
and NSCLC, mediated by the activation of α7 and heteromeric α3-containing receptor such as
αβ34 nAChRs. Activation of α7 nAChR by NNK or nicotine has shown to enhance cell
proliferation via β-Arrestin-SRC pathways involving the activation of Raf1 and ERK family
of kinases. Whereas, α7 and α3-containing receptor mediated activation of Akt, contribute to
the anti-apoptotic properties of NNK, NNN and Nicotine.
- kinases; - transcription factors; - IAP proteins
In 2003, Dennis’ group provided the first evidence that nAChR stimulation causes Akt
overexpression in NSCLCs [122]. It also conclusively provided the first indication that α3
antagonists are potential therapeutic drugs towards NSCLC. Treatment with NNK and
nicotine, led to rapid activation of Akt in NHBEs. This action was attenuated in the presence
28
of the α3/α4 antagonist DHβE, but not the α7 nAChR antagonists α-BTX and MLA, which
showed no effect. Further, Akt phosphorylation increases in NHBEs were observed in the
presence of an α3-specific agonist, α-ATX [126]. This supports the idea that nicotine causes
α3-mediated Akt activation. This was later confirmed by Arredondo’s study, in which
mecamylamine (Mec), a nAChR antagonist effectively abolished NNN’s pathobiologic
effects in BEP2D cells [127].
1.1.8.2.2 Physiological to biochemical translation: cellular difference mediated by α7 and
α3 subunits
SCLC and NSCLC exhibit different physiological profiles as well as different major
histological types. NSCLCs show constitutive Akt activation, increased NFκB-dependent
cellular survival and inhibition of apoptosis, mediated by α3/α4 nAChR subunits and due
primarily to the agonist effects of tobacco carcinogens NNN and nicotine. Concurrent studies
show that NNK’s tumorigenic effects are mediated by the α7 nAChR subtype predominantly
in SCLC, but also in NSCLC [128, 129]. Molecular studies show that α7 nAChR expression
in SCLC and pulmonary neuroendocrine cells (PNEC) is high [128], which is consistent with
α7 nAChR expression being upregulated as a result of chronic NNK exposure [130]. These
results, in conjunction with previous binding studies, show tumorigenesis in SCLC and
PNECs is mediated via the α7 nAChR subtype, while both α7 and heteromeric α3 nAChR
subtypes are involved in NSCLC and peripheral adenocarcinoma (PAC) [118, 129].
An in vitro proliferation assay of PNECs or SCLC in the presence of nicotine or NNK
induced a serotonergic autocrine loop, which was abolished when an α7 nAChR antagonist or
serotonin uptake inhibitor was added [131, 132]. This autocrine response involved the
activation of cellular regulators the serine/threonine kinase RAF1, protein kinase C (PKC),
mitogen-activated kinases ERK1 and ERK2, and transcription factors FOS, JUN and MYC
29
[Figure 1.7] [129, 131, 132]. Along with studies that show pharmacological inhibition of
these regulators block the proliferation and apoptosis response identified α7 as the key
regulator of cell proliferation [133, 134]. However in NSCLC, NNK-induced cell
proliferation activated signal transducers, transcription 1 (STAT1), NFκB, GATA3, β-
arrestin-SRC, and ERK1 and ERK2 [Figure 1.7] [127, 135]. While, NNK’s anti-apoptotic
activity in SCLC was modulated by activating Bcl-2, in NSCLC, E2F1-mediated upregulation
of survivin and X-liked inhibitor of apoptosis (XIAP) contributed to nicotine-induced
apoptotic inhibition [Figure 1.7] [134, 136]. However, these results are yet to identify the role
of IAP (Inhibitors of Apoptosis) proteins (survivin and XIAP) as characteristic signalling
proteins underlying the anti-apoptotic effect in NSCLC.
1.1.8.2.3 Targeting the α3β4 nAChR: unlocking novel therapeutics for NSCLC
Previous studies have identified nicotine and its derivatives as potent nAChR agonists and
highlighted their regulatory role in cancer cell apoptosis [118, 120]. Recent candidate–gene
analysis and genome-wide association studies (GWAS) have also identified gene clusters and
single nucleotide polymorphisms (SNP) encoding α3, α5 and β4 nAChR subunits associated
with lung cancer [118, 137]. These studies showed the existence of CHRNA5/A3/B4 gene
cluster overexpression and other specific nAChR subunits in lung cancer tissue [138, 139]. An
important transcription factor, ASCL1, was shown to play a key regulatory role in the
initiation and development of SCLC, and the overexpression of the CHRNA5/A3/B4 gene
cluster [140, 141]. These studies suggest a strong correlation between the overexpression α3,
α5 and β4 subunits and lung cancer.
NNK and NNN are leading carcinogens involved in the development of lung cancer in
smokers. Along with nicotine, these nitrosamines have also been shown to be strong nAChR
agonists and easily displace the endogenous nAChR agonist, ACh [118]. Binding studies have
30
shown that NNK is a selective α7 nAChR agonist, and NNN is a selective agonist of α3/α4-
containing nAChRs [118]. Subsequent studies also showed that expression and activation of
signalling molecules involved in cell proliferation and the apoptotic inhibition of NSCLC
increased in the presence of NNN and NNK. This response was abolished when an α7 or α3
nAChR antagonist was added [124, 136]. More recent GWAS also suggest α3β4 nAChRs are
key modulators of cell proliferation and apoptotic inhibition of NSCLC [137]. However, a
lack of adequate molecular α3β4-specific probes has limited the study of the physiological
role of this receptor subtype in disease progression.
31
1.2. Conotoxins
The venom of various animals, such as snakes, spiders and molluscs, has long attracted the
attention of scientists for their ability to kill or paralyse their prey, almost instantly. Most
venomous animals target invertebrates, with few targeting vertebrates. The venom of animals
that do target vertebrates has been found to be dangerous – even fatal – to humans. Various
bioactive peptides, called conotoxins, in the venom bind selectively and potently to different
ion channel receptors. This makes them biomedically and pharmacologically significant
[142].
Figure 1.8: Predatory marine cone snails (A) Conus regius [143] and (B) Conus victoriae.
Predatory marine snails of the genus Conus from the Conoidae superfamily, is one of the
largest and most diverse genera, with around 500 snail species [Figure 1.8]. Few snails in this
genus prey on vertebrates like fish. Their venom, which includes thousands of conotoxins,
also targets different ion channels in humans. α-Conotoxins, a conotoxin subclass found in
this venom, are short, disulphide-rich peptides that selectively target different nAChR subtype
isoforms [144].
1.2.1 Venom apparatus and biosynthesis
The vast diversity in conotoxin structure and sequence corresponds to the complex venom
apparatus and biosynthesis process in cone snails. The cone snails’ general venom apparatus
32
includes a long, convoluted tubular gland that synthesises venom, a muscular bulb that moves
the venom, and the proboscis, which helps deliver the venom and consists of various hallow,
harpoon-shaped radula teeth [Figure 1.9] [143, 145].
Figure 1.9: Schematic representation of cone snail’s venom apparatus representing the
main parts [146].
The conotoxin diversity in venom extends from cone snail gene and proteome level to post-
translational modifications. Interestingly, thousands of peptides in the venom are generated
from a relatively small number of gene families [147]. The genes encoding conotoxins
translate into a precursor protein molecule consisting of three distinct segments: N-terminal
signal sequence, a pro-peptide region and the mature toxin sequence. The N-terminal signal
sequence and pro-peptide region are highly conserved, however, hypermutation is observed in
the mature toxin sequence [147, 148].
After the gene is translated, various enzymes are responsible for the production of the mature
toxin. These include protein disulphide isomerase (PDI), peptidyl-prolyl cis-trans isomerase
(PPI), cysteine-rich protease Tex31 and immunoglobulin-binding protein (BiP). Recent
studies have identified various PDI isoforms that contribute to the conotoxins diversity at
proteomic level [149]. In addition to this variability in the mature toxin sequence, mature
peptides can undergo post-translational modifications, such as C-terminal amidation and
33
proline hydroxylation, which confers a unique functional activity compared with unmodified
sequences [150, 151].
Due to their potential pharmacological significance, it is vital to find a way to effectively and
accurately synthesise conotoxins in vitro and characterise their structure and function.
Understanding the diverse post-transcriptional and post-translational regulation of cone snail
venom biosynthesis will provide important information that will help to improve in vitro
synthesis of complex conotoxins.
1.2.2 Classification and nomenclature
The venom repertoire of cone snails is mainly constituted of disulphide-rich conopeptides and
are categorised into various superfamilies and classified by their structural and functional
features, such as cysteine pattern and pharmacology. Figure 1.10 illustrates some of these
superfamilies. This classification is also used to name conotoxins.
The first nomenclature guidelines were introduced in 1985 and updated several years later
[152]. They outline that conotoxins that have been functionally characterised should be
labelled with (in the order listed below):
• a Greek letter indicating their pharmacological target
• one (uppercase) or two letters (second letter is lowercase) from the Conus species from
which the peptide was isolated
• a Roman numeral indicating the cysteine framework pattern
• an uppercase letter representing the peptide variant discovered in respective cone species.
For example, α-RgIA represents a conotoxin isolated from Conus regius with cysteine
framework I that targets ACh receptors.
34
Figure 1.10: Classification of conotoxins. The classification of conotoxins into various
superfamilies is based on their cysteine pattern and pharmacology. Subclass α- and αD-
conotoxins discussed in the following chapter of the thesis are boxed in red. Na+ – voltage
gated sodium channel; K+ – voltage gated potassium channel; Ca+2 – voltage gated calcium
channel; nAChR – nicotinic acetyl choline receptors [153].
There has been a significant increase in the number of conotoxins discovered from complex
venom repertoire due to recent advances in protein and molecular techniques such as high-
performance liquid chromatography (HPLC) and reverse transcription polymerase chain
reaction (RT-PCR) [154]. The pharmacology of some of these peptides is unknown, so they
are labelled differently from those that have been functionally characterised. They are labelled
with:
35
• one or two letters (both lowercase) from the Conus species from which the peptide was
isolated
• an Arabic numeral representing the cysteine framework
• a lowercase letter representing the peptide variant.
For example, before its pharmacological characterisation, α-RgIA was represented as rg1a.
1.2.3 Conotoxin structural diversity
Along with high sequence hypervariability, conotoxins show structural diversity. The
disulphide framework of different conotoxin classes translates these peptides into specific,
rigid, three-dimensional structures [155]. These structures play an important role in
determining pharmacological properties of a peptide, including its potency and selectivity
[156]. In the past decade, nuclear magnetic resonance (NMR) has enabled to determine the
three-dimensional structures of many conotoxins with characteristic cysteine frameworks
[157]. For example, α-conotoxins of the A superfamily of conopeptides, fold into a ω-shaped
structure with a characteristic α-helix secondary structure [Figure 1.11(A)], whereas, χ-
conotoxin MrIA of the T superfamily is dominated by β-helix secondary structures [Figure
1.11(B)] [157, 158]. Conotoxins with three or more disulphide bonds, such as ω-conotoxin
MVIIA, have complex cysteine knot structures [Figure 1.11(C)] [159]. α-Conotoxins of the
D superfamily are composed of five disulphide bonds and exhibit dimerization that yields
complex three-dimensional structures [160]. These characteristic folds reveal critical residues
that interact with the ion channel and determine the pharmacological activity of conotoxins.
36
Figure 1.11: Structural diversity among conotoxins. Cartoon representation of the three
dimensional structures of conotoxins (A) α-Vc1.1 (PDB 2H8S) [161] (B) χ-MrIA (PDB
2EW4) [162] (C) ω-MVIIA (PDB 1MVI) [163]. α-helics are shown in blue, β-sheets in red
and disulphide bonds are shown in yellow. Images generated using PyMol Molecular
Graphics System (DeLano Scientific LLC.).
Though rich in cysteines, these residues are buried within the conotoxin’s three-dimensional
structure, exposing a hydrophobic patch at the surface [164]. The surface-exposed residues
contribute to overall net charge of the conotoxin. This charge distribution influences the
peptide’s selectivity and potency for its pharmacological target. For example, α-conotoxins
with net positive charge target muscle nAChR subtypes, and those with neutral or negative net
charge target neuronal nAChR subtypes [165].
1.2.4 Conotoxin structure–activity relationship
Conotoxin diversity enables them to identify various isoforms of ion channels, making them
excellent probes to study different receptors. α-Conotoxins are excellent examples of this,
because they specifically and potently target nAChR subtypes [166]. This has increased our
understanding of the physiological role each receptor subtype plays in normal and disease
states. In this thesis, I will limit my discussion to α- and αD-conotoxins.
α-Conotoxins range from 12–25 amino acids in length and belong to the A superfamily of
conopeptides. They are characterised with the CCXnCXmC cysteine framework, where n and
37
m represent the number of amino acids and indicate the subclass of a peptide. Most native α-
conotoxins exhibit I–III and II–IV disulphide connectivity, yielding a ω-shaped, three-
dimensional globular conformation [155]. Although, α-conotoxins exhibit sequence
hypervariability, conserved residues are observed among various α-conotoxins. Table 1.1 lists
some of the α-conotoxins that target neuronal nAChR subtypes. Residues in loop1 (residues
between Cys II and III) are highly conserved, with most peptides showing a –SXPA– motif.
Table 1.1: Sequence alignment of α-conotoxins targeting neuronal nAChR subtypes.
α-Conotoxin Sequence nAChR selectivity Reference
Ls1a SGCCSNPACRVNNPNIC* α3β2≈α7>α3α5β2 [167] GID IRDγCCSNPACRVNNOHVC# α7≈α3β2>α4β2 [164] ArIB DECCSNPACRVNNPHVCRRR# α7≈α6β2^>α3β2 [168] RegIIA GCCSHPACNVNNPHIC* α3β2>α3β4> α7 [169] OmIA GCCSHPACNVNNPHICG* α3β2>α7>α6β2^ [170] GIC GCCSHPACAGNNQHIC* α3β2≈α6β2*>α7 [171] AuIB GCCSYPPCFATNPD-C* α3β4 [172] RgIA GCCSDPRCRYR----CR# α9α10>>α7 [173] * amidated C-terminus; # carboxylated C-terminus; ^ receptors containing the subunits; conserved cysteine framework is indicated in yellow.
Significant interaction between these loop1 residues and the principal face of the receptor was
identified using X-ray studies of AChBP, ImI, [A10L,D14K]PnIA [Figure 1.12] and
[A10L]TxIA co-crystal structures [174, 175]. These studies identified that loop1 has a role in
the peptide’s secondary structure and affinity, and loop2 residues interact with the
complementary side of the receptor, contributing to the α-conotoxin’s subtype selectivity
[Figure 1.12] [156].
38
Figure 1.12: AChBP and [A10L,D14K]PnIA co-crystal structures (PDB 2BR8) [176]
shown in (A) surface representation and (B) cartoon representation. Mutated residues
Leu10 and Lys14 of loop2 (green) interact with the (-) interface (orange) while Leu5, Pro6
and Pro7 residue side chains of loop1 (cyan) have shown to interact with the ‘principal’/(+)
interface (blue) of the ACh binding pocket. Disulphide bonds of the conotoxin and Cys-Cys
pair of (+) interface are indicated in yellow. Images generated using PyMol Molecular
Graphics System (DeLano Scientific LLC.).
1.2.4.1 Use of alanine scanning mutagenesis
To date, most mutational studies have involved replacing various non-cysteine residues with
the inert residue alanine. These experiments provided vital information about the various α-
conotoxin residues that interact with receptors, and in combination with modelling simulation
studies, they have helped to determine α-conotoxin pharmacological selectivity [166]. For
example, loop2 residues (11–15) in Vc1.1 have been shown to be important for its activity at
α9α10 nAChR subtypes. Alanine mutation of these residues causes significant loss in activity
at this subtype [177]. In RgIA, similar experiments showed an approximate 1500-fold loss in
activity for [R9A]RgIA at the α9α10 subtype. Surprisingly, the opposite effect was seen at the
39
α7 subtype, with an approximate 5-fold increase in activity [178]. This mutation was
homologous with that of α4/3-conotoxin ImI, which selectively inhibits α7 and α3β2 nAChR
subtypes [179].
Alanine scanning mutagenesis not only contributed to the molecular basis for various
conotoxins’ antagonism of their respective nAChR subtypes, but also significantly improved
our understanding of these peptides’ subtype selectivity. Furthermore, alanine mutation
improved α-conotoxin potency and selectivity. For example, E11A mutation in α-conotoxin
MII improved its selectivity and potency towards α6-containing nAChRs [180]. In Vc1.1,
N9A mutation increased potency at α9α10 nAChR subtypes about 10-fold [177].
1.2.5 Conotoxin re-engineering
α-Conotoxin use in research and clinical settings has been hampered because of their peptidic
nature, which makes them susceptible to natural degradation, such as proteolytic attack, or
disruptions of their disulphide connectivity. These problems drastically affect their
bioavailability and half-life. In vitro chemical synthesis of conotoxins allows them to be
chemically modified to improve their structure and ability to be used in research and clinical
settings.
1.2.5.1 Dicarba modification
Various strategies to improve α-conotoxin stability have been implemented, such as
cyclisation and selenocysteine modification [181, 182]. Recent studies have shown that
replacing the cysteine bridges (S–S motif) with non-reducible dicarba links (CH2–CH2,
CH=CH groups) [183] is a novel way to improve stability and resistance to peptide
degradation and scrambling [184]. In addition, this modification maintains the
pharmacological activity of α-conotoxins [185, 186].
40
1.2.6 Conotoxins: potential therapeutics
That conotoxins selectively and potently inhibit various ion channels has put them at the
forefront of novel drug development. Several conotoxins are, and have been, tested clinically
to treat a range of health conditions, including neuropathic pain and benign prostatic
hyperplasia [187]. For example, ω-Conotoxin MVIIA, isolated from Conus magus, inhibits N-
type calcium channels [188] and is an FDA-approved drug for pain relief. Peptides
undergoing clinical trials include χ-MrIA (a non-competitive neuronal noradrenaline receptor
inhibitor) to treat benign prostatic hyperplasia symptoms [189], and conantokin-G (a selective
NMDA receptor inhibitor) to manage epilepsy [190].
Recent studies have also identified nAChR subtypes that are involved in various health
conditions, such as schizophrenia (α7 and α4β2), Parkinson’s disease (α6-containing
receptors), Alzheimer’s disease (α7 and α4β2), lung cancer (α3β4) and pain (α4β2). These
discoveries have provided new therapeutic applications for α-conotoxins that target neuronal
nAChRs [40, 99, 144, 191].
41
1.3. References
1. Dale, H. H. (1914) The action of certain esters and ethers of choline, and their relation
to muscarine, Journal of Pharmacology and Experimental Therapeutics 6, 147-190.
2. Loewi, O. (1921) Humoral transferability of the heart nerve effect. I. Announcement.,
Pflug Arch Ges Phys 189, 239-242.
3. Albuquerque, E. X., Pereira, E. F., Alkondon, M., and Rogers, S. W. (2009)
Mammalian nicotinic acetylcholine receptors: from structure to function,
Physiological reviews 89, 73-120.
4. Dani, J. A., and Bertrand, D. (2007) Nicotinic acetylcholine receptors and nicotinic
cholinergic mechanisms of the central nervous system, Annual review of
pharmacology and toxicology 47, 699-729.
5. Hurst, R., Rollema, H., and Bertrand, D. (2013) Nicotinic acetylcholine receptors:
from basic science to therapeutics, Pharmacology & therapeutics 137, 22-54.
6. Gotti, C., and Clementi, F. (2004) Neuronal nicotinic receptors: from structure to
pathology, Progress in neurobiology 74, 363-396.
7. Bencherif, M., Hauser, T. A., Jordan, K. G., and Gatto, G. J. (2006) Therapeutic
potential of novel selective drugs targeting nicotinic acetylcholine receptors, Journal
of molecular neuroscience : MN 30, 17-18.
8. Cassels, B. K., Bermudez, I., Dajas, F., Abin-Carriquiry, J. A., and Wonnacott, S.
(2005) From ligand design to therapeutic efficacy: the challenge for nicotinic receptor
research, Drug discovery today 10, 1657-1665.
9. Picciotto, M. R., and Zoli, M. (2002) Nicotinic receptors in aging and dementia,
Journal of neurobiology 53, 641-655.
10. Perry, E., Martin-Ruiz, C., Lee, M., Griffiths, M., Johnson, M., Piggott, M.,
Haroutunian, V., Buxbaum, J. D., Nasland, J., Davis, K., Gotti, C., Clementi, F.,
Tzartos, S., Cohen, O., Soreq, H., Jaros, E., Perry, R., Ballard, C., McKeith, I., and
42
Court, J. (2000) Nicotinic receptor subtypes in human brain ageing, Alzheimer and
Lewy body diseases, European journal of pharmacology 393, 215-222.
11. Noda, M., Furutani, Y., Takahashi, H., Toyosato, M., Tanabe, T., Shimizu, S.,
Kikyotani, S., Kayano, T., Hirose, T., Inayama, S., and et al. (1983) Cloning and
sequence analysis of calf cDNA and human genomic DNA encoding alpha-subunit
precursor of muscle acetylcholine receptor, Nature 305, 818-823.
12. Lukas, R. J., Changeux, J. P., Le Novere, N., Albuquerque, E. X., Balfour, D. J., Berg,
D. K., Bertrand, D., Chiappinelli, V. A., Clarke, P. B., Collins, A. C., Dani, J. A.,
Grady, S. R., Kellar, K. J., Lindstrom, J. M., Marks, M. J., Quik, M., Taylor, P. W.,
and Wonnacott, S. (1999) International Union of Pharmacology. XX. Current status of
the nomenclature for nicotinic acetylcholine receptors and their subunits,
Pharmacological reviews 51, 397-401.
13. Changeux, J. P., Kasai, M., Huchet, M., and Meunier, J. C. (1970) [Extraction from
electric tissue of gymnotus of a protein presenting several typical properties
characteristic of the physiological receptor of acetylcholine], Comptes rendus
hebdomadaires des seances de l'Academie des sciences. Serie D: Sciences naturelles
270, 2864-2867.
14. Unwin, N. (2005) Refined structure of the nicotinic acetylcholine receptor at 4A
resolution, Journal of molecular biology 346, 967-989.
15. Hibbs, R. E., and Gouaux, E. (2011) Principles of activation and permeation in an
anion-selective Cys-loop receptor, Nature 474, 54-60.
16. van Nierop, P., Keramidas, A., Bertrand, S., van Minnen, J., Gouwenberg, Y.,
Bertrand, D., and Smit, A. B. (2005) Identification of molluscan nicotinic
acetylcholine receptor (nAChR) subunits involved in formation of cation- and anion-
selective nAChRs, The Journal of neuroscience : the official journal of the Society for
Neuroscience 25, 10617-10626.
43
17. Brejc, K., van Dijk, W. J., Klaassen, R. V., Schuurmans, M., van Der Oost, J., Smit,
A. B., and Sixma, T. K. (2001) Crystal structure of an ACh-binding protein reveals the
ligand-binding domain of nicotinic receptors, Nature 411, 269-276.
18. Conti-Fine, B. M., Navaneetham, D., Lei, S., and Maus, A. D. (2000) Neuronal
nicotinic receptors in non-neuronal cells: new mediators of tobacco toxicity?,
European journal of pharmacology 393, 279-294.
19. Kawashima, K., and Fujii, T. (2003) The lymphocytic cholinergic system and its
contribution to the regulation of immune activity, Life sciences 74, 675-696.
20. Kurzen, H., Wessler, I., Kirkpatrick, C. J., Kawashima, K., and Grando, S. A. (2007)
The non-neuronal cholinergic system of human skin, Hormone and metabolic
research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 39, 125-
135.
21. Couturier, S., Bertrand, D., Matter, J. M., Hernandez, M. C., Bertrand, S., Millar, N.,
Valera, S., Barkas, T., and Ballivet, M. (1990) A neuronal nicotinic acetylcholine
receptor subunit (alpha 7) is developmentally regulated and forms a homo-oligomeric
channel blocked by alpha-BTX, Neuron 5, 847-856.
22. Murray, T. A., Bertrand, D., Papke, R. L., George, A. A., Pantoja, R., Srinivasan, R.,
Liu, Q., Wu, J., Whiteaker, P., Lester, H. A., and Lukas, R. J. (2012) alpha7beta2
nicotinic acetylcholine receptors assemble, function, and are activated primarily via
their alpha7-alpha7 interfaces, Molecular pharmacology 81, 175-188.
23. Criado, M., Valor, L. M., Mulet, J., Gerber, S., Sala, S., and Sala, F. (2012)
Expression and functional properties of alpha7 acetylcholine nicotinic receptors are
modified in the presence of other receptor subunits, Journal of neurochemistry 123,
504-514.
44
24. Witzemann, V., Barg, B., Nishikawa, Y., Sakmann, B., and Numa, S. (1987)
Differential regulation of muscle acetylcholine receptor gamma- and epsilon-subunit
mRNAs, FEBS letters 223, 104-112.
25. Mishina, M., Takai, T., Imoto, K., Noda, M., Takahashi, T., Numa, S., Methfessel, C.,
and Sakmann, B. (1986) Molecular distinction between fetal and adult forms of
muscle acetylcholine receptor, Nature 321, 406-411.
26. Hendrickson, L. M., Guildford, M. J., and Tapper, A. R. (2013) Neuronal nicotinic
acetylcholine receptors: common molecular substrates of nicotine and alcohol
dependence, Frontiers in psychiatry 4, 29.
27. Corringer, P. J., Galzi, J. L., Eisele, J. L., Bertrand, S., Changeux, J. P., and Bertrand,
D. (1995) Identification of a new component of the agonist binding site of the
nicotinic alpha 7 homooligomeric receptor, The Journal of biological chemistry 270,
11749-11752.
28. Bertrand, D., and Changeux, J. P. (1995) Nicotinic Receptor - an Allosteric Protein
Specialized for Intercellular Communication, Semin Neurosci 7, 75-90.
29. Changeux, J. P., Galzi, J. L., Devillers-Thiery, A., and Bertrand, D. (1992) The
functional architecture of the acetylcholine nicotinic receptor explored by affinity
labelling and site-directed mutagenesis, Quarterly reviews of biophysics 25, 395-432.
30. Karlin, A., Cox, R. N., Dipaola, M., Holtzman, E., Kao, P. N., Lobel, P., Wang, L.,
and Yodh, N. (1986) Functional domains of the nicotinic acetylcholine receptor,
Annals of the New York Academy of Sciences 463, 53-69.
31. Blount, P., and Merlie, J. P. (1990) Mutational analysis of muscle nicotinic
acetylcholine receptor subunit assembly, The Journal of cell biology 111, 2613-2622.
32. Galzi, J. L., Revah, F., Black, D., Goeldner, M., Hirth, C., and Changeux, J. P. (1990)
Identification of a novel amino acid alpha-tyrosine 93 within the cholinergic ligands-
binding sites of the acetylcholine receptor by photoaffinity labeling. Additional
45
evidence for a three-loop model of the cholinergic ligands-binding sites, The Journal
of biological chemistry 265, 10430-10437.
33. Sine, S. M. (2002) The nicotinic receptor ligand binding domain, Journal of
neurobiology 53, 431-446.
34. Miyazawa, A., Fujiyoshi, Y., and Unwin, N. (2003) Structure and gating mechanism
of the acetylcholine receptor pore, Nature 423, 949-955.
35. Smit, A. B., Syed, N. I., Schaap, D., van Minnen, J., Klumperman, J., Kits, K. S.,
Lodder, H., van der Schors, R. C., van Elk, R., Sorgedrager, B., Brejc, K., Sixma, T.
K., and Geraerts, W. P. (2001) A glia-derived acetylcholine-binding protein that
modulates synaptic transmission, Nature 411, 261-268.
36. Green, W. N., and Wanamaker, C. P. (1997) The role of the cystine loop in
acetylcholine receptor assembly, The Journal of biological chemistry 272, 20945-
20953.
37. Gao, F., Bren, N., Burghardt, T. P., Hansen, S., Henchman, R. H., Taylor, P.,
McCammon, J. A., and Sine, S. M. (2005) Agonist-mediated conformational changes
in acetylcholine-binding protein revealed by simulation and intrinsic tryptophan
fluorescence, The Journal of biological chemistry 280, 8443-8451.
38. Sine, S. M., and Engel, A. G. (2006) Recent advances in Cys-loop receptor structure
and function, Nature 440, 448-455.
39. Corringer, P. J., Le Novere, N., and Changeux, J. P. (2000) Nicotinic receptors at the
amino acid level, Annual review of pharmacology and toxicology 40, 431-458.
40. Taly, A., Corringer, P. J., Guedin, D., Lestage, P., and Changeux, J. P. (2009)
Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system,
Nature reviews. Drug discovery 8, 733-750.
41. Boulter, J., O'Shea-Greenfield, A., Duvoisin, R. M., Connolly, J. G., Wada, E., Jensen,
A., Gardner, P. D., Ballivet, M., Deneris, E. S., McKinnon, D., and et al. (1990) Alpha
46
3, alpha 5, and beta 4: three members of the rat neuronal nicotinic acetylcholine
receptor-related gene family form a gene cluster, The Journal of biological chemistry
265, 4472-4482.
42. Couturier, S., Erkman, L., Valera, S., Rungger, D., Bertrand, S., Boulter, J., Ballivet,
M., and Bertrand, D. (1990) Alpha 5, alpha 3, and non-alpha 3. Three clustered avian
genes encoding neuronal nicotinic acetylcholine receptor-related subunits, The Journal
of biological chemistry 265, 17560-17567.
43. Celie, P. H., van Rossum-Fikkert, S. E., van Dijk, W. J., Brejc, K., Smit, A. B., and
Sixma, T. K. (2004) Nicotine and carbamylcholine binding to nicotinic acetylcholine
receptors as studied in AChBP crystal structures, Neuron 41, 907-914.
44. Talley, T. T., Harel, M., Hibbs, R. E., Radic, Z., Tomizawa, M., Casida, J. E., and
Taylor, P. (2008) Atomic interactions of neonicotinoid agonists with AChBP:
molecular recognition of the distinctive electronegative pharmacophore, Proceedings
of the National Academy of Sciences of the United States of America 105, 7606-7611.
45. Vicente-Agullo, F., Rovira, J. C., Campos-Caro, A., Rodriguez-Ferrer, C., Ballesta, J.
J., Sala, S., Sala, F., and Criado, M. (1996) Acetylcholine receptor subunit homomer
formation requires compatibility between amino acid residues of the M1 and M2
transmembrane segments, FEBS letters 399, 83-86.
46. Wang, Z. Z., Hardy, S. F., and Hall, Z. W. (1996) Assembly of the nicotinic
acetylcholine receptor. The first transmembrane domains of truncated alpha and delta
subunits are required for heterodimer formation in vivo, The Journal of biological
chemistry 271, 27575-27584.
47. Pato, C., Stetzkowski-Marden, F., Gaus, K., Recouvreur, M., Cartaud, A., and
Cartaud, J. (2008) Role of lipid rafts in agrin-elicited acetylcholine receptor clustering,
Chemico-biological interactions 175, 64-67.
47
48. Baier, C. J., Gallegos, C. E., Levi, V., and Barrantes, F. J. (2010) Cholesterol
modulation of nicotinic acetylcholine receptor surface mobility, European biophysics
journal : EBJ 39, 213-227.
49. Diaz-De Leon, R., Otero-Cruz, J. D., Torres-Nunez, D. A., Casiano, A., and Lasalde-
Dominicci, J. A. (2008) Tryptophan scanning of the acetylcholine receptor's betaM4
transmembrane domain: decoding allosteric linkage at the lipid-protein interface with
ion-channel gating, Channels 2, 439-448.
50. Roccamo, A. M., and Barrantes, F. J. (2007) Charged amino acid motifs flanking each
extreme of the alphaM4 transmembrane domain are involved in assembly and cell-
surface targeting of the muscle nicotinic acetylcholine receptor, Journal of
neuroscience research 85, 285-293.
51. Kabbani, N., Woll, M. P., Levenson, R., Lindstrom, J. M., and Changeux, J. P. (2007)
Intracellular complexes of the beta2 subunit of the nicotinic acetylcholine receptor in
brain identified by proteomics, Proceedings of the National Academy of Sciences of
the United States of America 104, 20570-20575.
52. Osman, A. A., Schrader, A. D., Hawkes, A. J., Akil, O., Bergeron, A., Lustig, L. R.,
and Simmons, D. D. (2008) Muscle-like nicotinic receptor accessory molecules in
sensory hair cells of the inner ear, Molecular and cellular neurosciences 38, 153-169.
53. Williams, B. M., Temburni, M. K., Levey, M. S., Bertrand, S., Bertrand, D., and
Jacob, M. H. (1998) The long internal loop of the alpha 3 subunit targets nAChRs to
subdomains within individual synapses on neurons in vivo, Nature neuroscience 1,
557-562.
54. Mukherjee, J., Kuryatov, A., Moss, S. J., Lindstrom, J. M., and Anand, R. (2009)
Mutations of cytosolic loop residues impair assembly and maturation of alpha7
nicotinic acetylcholine receptors, Journal of neurochemistry 110, 1885-1894.
48
55. Millar, N. S., and Gotti, C. (2009) Diversity of vertebrate nicotinic acetylcholine
receptors, Neuropharmacology 56, 237-246.
56. Cooper, E., Couturier, S., and Ballivet, M. (1991) Pentameric structure and subunit
stoichiometry of a neuronal nicotinic acetylcholine receptor, Nature 350, 235-238.
57. Anand, R., Conroy, W. G., Schoepfer, R., Whiting, P., and Lindstrom, J. (1991)
Neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes have a
pentameric quaternary structure, The Journal of biological chemistry 266, 11192-
11198.
58. Zwart, R., and Vijverberg, H. P. (1998) Four pharmacologically distinct subtypes of
alpha4beta2 nicotinic acetylcholine receptor expressed in Xenopus laevis oocytes,
Molecular pharmacology 54, 1124-1131.
59. Tapia, L., Kuryatov, A., and Lindstrom, J. (2007) Ca2+ permeability of the
(alpha4)3(beta2)2 stoichiometry greatly exceeds that of (alpha4)2(beta2)3 human
acetylcholine receptors, Molecular pharmacology 71, 769-776.
60. Grishin, A. A., Wang, C. I., Muttenthaler, M., Alewood, P. F., Lewis, R. J., and
Adams, D. J. (2010) Alpha-conotoxin AuIB isomers exhibit distinct inhibitory
mechanisms and differential sensitivity to stoichiometry of alpha3beta4 nicotinic
acetylcholine receptors, The Journal of biological chemistry 285, 22254-22263.
61. Le Novere, N., Zoli, M., and Changeux, J. P. (1996) Neuronal nicotinic receptor alpha
6 subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat
brain, The European journal of neuroscience 8, 2428-2439.
62. Yang, K. C., Jin, G. Z., and Wu, J. (2009) Mysterious alpha6-containing nAChRs:
function, pharmacology, and pathophysiology, Acta pharmacologica Sinica 30, 740-
751.
63. Gerzanich, V., Wang, F., Kuryatov, A., and Lindstrom, J. (1998) alpha 5 Subunit
alters desensitization, pharmacology, Ca++ permeability and Ca++ modulation of
49
human neuronal alpha 3 nicotinic receptors, The Journal of pharmacology and
experimental therapeutics 286, 311-320.
64. Grady, S. R., Salminen, O., McIntosh, J. M., Marks, M. J., and Collins, A. C. (2010)
Mouse striatal dopamine nerve terminals express alpha4alpha5beta2 and two
stoichiometric forms of alpha4beta2*-nicotinic acetylcholine receptors, Journal of
molecular neuroscience : MN 40, 91-95.
65. Galzi, J. L., Devillers-Thiery, A., Hussy, N., Bertrand, S., Changeux, J. P., and
Bertrand, D. (1992) Mutations in the channel domain of a neuronal nicotinic receptor
convert ion selectivity from cationic to anionic, Nature 359, 500-505.
66. Kuryatov, A., Gerzanich, V., Nelson, M., Olale, F., and Lindstrom, J. (1997) Mutation
causing autosomal dominant nocturnal frontal lobe epilepsy alters Ca2+ permeability,
conductance, and gating of human alpha4beta2 nicotinic acetylcholine receptors, The
Journal of neuroscience : the official journal of the Society for Neuroscience 17,
9035-9047.
67. Beckstein, O., Biggin, P. C., and Sansom, M. S. P. (2001) A hydrophobic gating
mechanism for nanopores, J Phys Chem B 105, 12902-12905.
68. Blanton, M. P., Dangott, L. J., Raja, S. K., Lala, A. K., and Cohen, J. B. (1998)
Probing the structure of the nicotinic acetylcholine receptor ion channel with the
uncharged photoactivable compound -3H-diazofluorene, The Journal of biological
chemistry 273, 8659-8668.
69. Filatov, G. N., and White, M. M. (1995) The role of conserved leucines in the M2
domain of the acetylcholine receptor in channel gating, Molecular pharmacology 48,
379-384.
70. Dani, J. A. (2001) Overview of nicotinic receptors and their roles in the central
nervous system, Biological psychiatry 49, 166-174.
50
71. Mameli-Engvall, M., Evrard, A., Pons, S., Maskos, U., Svensson, T. H., Changeux, J.
P., and Faure, P. (2006) Hierarchical control of dopamine neuron-firing patterns by
nicotinic receptors, Neuron 50, 911-921.
72. Shen, J. X., and Yakel, J. L. (2009) Nicotinic acetylcholine receptor-mediated calcium
signaling in the nervous system, Acta pharmacologica Sinica 30, 673-680.
73. Lewis, C. A. (1979) Ion-concentration dependence of the reversal potential and the
single channel conductance of ion channels at the frog neuromuscular junction, The
Journal of physiology 286, 417-445.
74. Zhou, Z., and Neher, E. (1993) Calcium permeability of nicotinic acetylcholine
receptor channels in bovine adrenal chromaffin cells, Pflugers Archiv : European
journal of physiology 425, 511-517.
75. Fayuk, D., and Yakel, J. L. (2005) Ca2+ permeability of nicotinic acetylcholine
receptors in rat hippocampal CA1 interneurones, The Journal of physiology 566, 759-
768.
76. Fucile, S. (2004) Ca2+ permeability of nicotinic acetylcholine receptors, Cell calcium
35, 1-8.
77. Bertrand, D., Galzi, J. L., Devillers-Thiery, A., Bertrand, S., and Changeux, J. P.
(1993) Mutations at two distinct sites within the channel domain M2 alter calcium
permeability of neuronal alpha 7 nicotinic receptor, Proceedings of the National
Academy of Sciences of the United States of America 90, 6971-6975.
78. Imoto, K., Busch, C., Sakmann, B., Mishina, M., Konno, T., Nakai, J., Bujo, H., Mori,
Y., Fukuda, K., and Numa, S. (1988) Rings of negatively charged amino acids
determine the acetylcholine receptor channel conductance, Nature 335, 645-648.
79. Dajas-Bailador, F., and Wonnacott, S. (2004) Nicotinic acetylcholine receptors and the
regulation of neuronal signalling, Trends in pharmacological sciences 25, 317-324.
51
80. de Almeida, J. P., and Saldanha, C. (2010) Nonneuronal cholinergic system in human
erythrocytes: biological role and clinical relevance, The Journal of membrane biology
234, 227-234.
81. Giniatullin, R., Nistri, A., and Yakel, J. L. (2005) Desensitization of nicotinic ACh
receptors: shaping cholinergic signaling, Trends in neurosciences 28, 371-378.
82. Dajas-Bailador, F. A., Mogg, A. J., and Wonnacott, S. (2002) Intracellular Ca2+
signals evoked by stimulation of nicotinic acetylcholine receptors in SH-SY5Y cells:
contribution of voltage-operated Ca2+ channels and Ca2+ stores, Journal of
neurochemistry 81, 606-614.
83. Berridge, M. J., Bootman, M. D., and Roderick, H. L. (2003) Calcium signalling:
dynamics, homeostasis and remodelling, Nature reviews. Molecular cell biology 4,
517-529.
84. Mulle, C., Choquet, D., Korn, H., and Changeux, J. P. (1992) Calcium influx through
nicotinic receptor in rat central neurons: its relevance to cellular regulation, Neuron 8,
135-143.
85. Tsuneki, H., Klink, R., Lena, C., Korn, H., and Changeux, J. P. (2000) Calcium
mobilization elicited by two types of nicotinic acetylcholine receptors in mouse
substantia nigra pars compacta, The European journal of neuroscience 12, 2475-2485.
86. Sharma, G., and Vijayaraghavan, S. (2001) Nicotinic cholinergic signaling in
hippocampal astrocytes involves calcium-induced calcium release from intracellular
stores, Proceedings of the National Academy of Sciences of the United States of
America 98, 4148-4153.
87. Eberhard, D. A., and Holz, R. W. (1987) Cholinergic stimulation of inositol phosphate
formation in bovine adrenal chromaffin cells: distinct nicotinic and muscarinic
mechanisms, Journal of neurochemistry 49, 1634-1643.
52
88. Yang, J., McBride, S., Mak, D. O., Vardi, N., Palczewski, K., Haeseleer, F., and
Foskett, J. K. (2002) Identification of a family of calcium sensors as protein ligands of
inositol trisphosphate receptor Ca(2+) release channels, Proceedings of the National
Academy of Sciences of the United States of America 99, 7711-7716.
89. Wonnacott, S. (1997) Presynaptic nicotinic ACh receptors, Trends in neurosciences
20, 92-98.
90. Soliakov, L., and Wonnacott, S. (1996) Voltage-sensitive Ca2+ channels involved in
nicotinic receptor-mediated [3H]dopamine release from rat striatal synaptosomes,
Journal of neurochemistry 67, 163-170.
91. Kulak, J. M., McIntosh, J. M., Yoshikami, D., and Olivera, B. M. (2001) Nicotine-
evoked transmitter release from synaptosomes: functional association of specific
presynaptic acetylcholine receptors and voltage-gated calcium channels, Journal of
neurochemistry 77, 1581-1589.
92. Kumer, S. C., and Vrana, K. E. (1996) Intricate regulation of tyrosine hydroxylase
activity and gene expression, Journal of neurochemistry 67, 443-462.
93. Greenberg, M. E., Ziff, E. B., and Greene, L. A. (1986) Stimulation of neuronal
acetylcholine receptors induces rapid gene transcription, Science 234, 80-83.
94. Khiroug, L., Giniatullin, R., Klein, R. C., Fayuk, D., and Yakel, J. L. (2003)
Functional mapping and Ca2+ regulation of nicotinic acetylcholine receptor channels
in rat hippocampal CA1 neurons, The Journal of neuroscience : the official journal of
the Society for Neuroscience 23, 9024-9031.
95. Khiroug, L., Giniatullin, R., Sokolova, E., Talantova, M., and Nistri, A. (1997)
Imaging of intracellular calcium during desensitization of nicotinic acetylcholine
receptors of rat chromaffin cells, British journal of pharmacology 122, 1323-1332.
53
96. Hu, M., Liu, Q. S., Chang, K. T., and Berg, D. K. (2002) Nicotinic regulation of
CREB activation in hippocampal neurons by glutamatergic and nonglutamatergic
pathways, Molecular and cellular neurosciences 21, 616-625.
97. Dineley, K. T., Westerman, M., Bui, D., Bell, K., Ashe, K. H., and Sweatt, J. D.
(2001) Beta-amyloid activates the mitogen-activated protein kinase cascade via
hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms
related to Alzheimer's disease, The Journal of neuroscience : the official journal of the
Society for Neuroscience 21, 4125-4133.
98. Heeschen, C., Jang, J. J., Weis, M., Pathak, A., Kaji, S., Hu, R. S., Tsao, P. S.,
Johnson, F. L., and Cooke, J. P. (2001) Nicotine stimulates angiogenesis and promotes
tumor growth and atherosclerosis, Nature medicine 7, 833-839.
99. D'Hoedt, D., and Bertrand, D. (2009) Nicotinic acetylcholine receptors: an overview
on drug discovery, Expert opinion on therapeutic targets 13, 395-411.
100. Davis, L., Pollock, L. J., and Stone, T. T. (1932) Visceral pain, Surg Gynecol Obstet
55, 418-427.
101. Daly, J. W. (2005) Nicotinic agonists, antagonists, and modulators from natural
sources, Cellular and molecular neurobiology 25, 513-552.
102. Decker, M. W., Rueter, L. E., and Bitner, R. S. (2004) Nicotinic acetylcholine receptor
agonists: a potential new class of analgesics, Current topics in medicinal chemistry 4,
369-384.
103. Decker, M. W., Curzon, P., Holladay, M. W., Nikkel, A. L., Bitner, R. S., Bannon, A.
W., Donnelly-Roberts, D. L., Puttfarcken, P. S., Kuntzweiler, T. A., Briggs, C. A.,
Williams, M., and Arneric, S. P. (1998) The role of neuronal nicotinic acetylcholine
receptors in antinociception: effects of ABT-594, Journal of physiology, Paris 92,
221-224.
54
104. Holladay, M. W., Wasicak, J. T., Lin, N. H., He, Y., Ryther, K. B., Bannon, A. W.,
Buckley, M. J., Kim, D. J., Decker, M. W., Anderson, D. J., Campbell, J. E.,
Kuntzweiler, T. A., Donnelly-Roberts, D. L., Piattoni-Kaplan, M., Briggs, C. A.,
Williams, M., and Arneric, S. P. (1998) Identification and initial structure-activity
relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent,
orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine
receptors, Journal of medicinal chemistry 41, 407-412.
105. Cordero-Erausquin, M., Marubio, L. M., Klink, R., and Changeux, J. P. (2000)
Nicotinic receptor function: new perspectives from knockout mice, Trends in
pharmacological sciences 21, 211-217.
106. Gao, B., Hierl, M., Clarkin, K., Juan, T., Nguyen, H., Valk, M., Deng, H., Guo, W.,
Lehto, S. G., Matson, D., McDermott, J. S., Knop, J., Gaida, K., Cao, L., Waldon, D.,
Albrecht, B. K., Boezio, A. A., Copeland, K. W., Harmange, J. C., Springer, S. K.,
Malmberg, A. B., and McDonough, S. I. (2010) Pharmacological effects of
nonselective and subtype-selective nicotinic acetylcholine receptor agonists in animal
models of persistent pain, Pain 149, 33-49.
107. Damaj, M. I., Meyer, E. M., and Martin, B. R. (2000) The antinociceptive effects of
alpha7 nicotinic agonists in an acute pain model, Neuropharmacology 39, 2785-2791.
108. de Jonge, W. J., van der Zanden, E. P., The, F. O., Bijlsma, M. F., van Westerloo, D.
J., Bennink, R. J., Berthoud, H. R., Uematsu, S., Akira, S., van den Wijngaard, R. M.,
and Boeckxstaens, G. E. (2005) Stimulation of the vagus nerve attenuates macrophage
activation by activating the Jak2-STAT3 signaling pathway, Nature immunology 6,
844-851.
109. Rowley, T. J., McKinstry, A., Greenidge, E., Smith, W., and Flood, P. (2010)
Antinociceptive and anti-inflammatory effects of choline in a mouse model of
postoperative pain, British journal of anaesthesia 105, 201-207.
55
110. Ramirez-Latorre, J., Yu, C. R., Qu, X., Perin, F., Karlin, A., and Role, L. (1996)
Functional contributions of alpha5 subunit to neuronal acetylcholine receptor
channels, Nature 380, 347-351.
111. Sandall, D. W., Satkunanathan, N., Keays, D. A., Polidano, M. A., Liping, X., Pham,
V., Down, J. G., Khalil, Z., Livett, B. G., and Gayler, K. R. (2003) A novel alpha-
conotoxin identified by gene sequencing is active in suppressing the vascular response
to selective stimulation of sensory nerves in vivo, Biochemistry 42, 6904-6911.
112. Satkunanathan, N., Livett, B., Gayler, K., Sandall, D., Down, J., and Khalil, Z. (2005)
Alpha-conotoxin Vc1.1 alleviates neuropathic pain and accelerates functional recovery
of injured neurones, Brain research 1059, 149-158.
113. American Cancer Society. Cancer facts & figures, p v., The Society, Atlanta, GA.
114. Burns, D. M. (2003) Tobacco-related diseases, Seminars in oncology nursing 19, 244-
249.
115. Proctor, R. N. (2001) Tobacco and the global lung cancer epidemic, Nature reviews.
Cancer 1, 82-86.
116. Hecht, S. S. (1999) Tobacco smoke carcinogens and lung cancer, Journal of the
National Cancer Institute 91, 1194-1210.
117. Hecht, S. S., and Hoffmann, D. (1988) Tobacco-specific nitrosamines, an important
group of carcinogens in tobacco and tobacco smoke, Carcinogenesis 9, 875-884.
118. Schuller, H. M., and Orloff, M. (1998) Tobacco-specific carcinogenic nitrosamines.
Ligands for nicotinic acetylcholine receptors in human lung cancer cells, Biochemical
pharmacology 55, 1377-1384.
119. Schuller, H. M. (1989) Cell type specific, receptor-mediated modulation of growth
kinetics in human lung cancer cell lines by nicotine and tobacco-related nitrosamines,
Biochemical pharmacology 38, 3439-3442.
56
120. Maneckjee, R., and Minna, J. D. (1990) Opioid and nicotine receptors affect growth
regulation of human lung cancer cell lines, Proceedings of the National Academy of
Sciences of the United States of America 87, 3294-3298.
121. Bierut, L. J. (2009) Nicotine dependence and genetic variation in the nicotinic
receptors, Drug and alcohol dependence 104 Suppl 1, S64-69.
122. West, K. A., Brognard, J., Clark, A. S., Linnoila, I. R., Yang, X., Swain, S. M., Harris,
C., Belinsky, S., and Dennis, P. A. (2003) Rapid Akt activation by nicotine and a
tobacco carcinogen modulates the phenotype of normal human airway epithelial cells,
The Journal of clinical investigation 111, 81-90.
123. Lawlor, M. A., and Alessi, D. R. (2001) PKB/Akt: a key mediator of cell proliferation,
survival and insulin responses?, Journal of cell science 114, 2903-2910.
124. Brognard, J., Clark, A. S., Ni, Y., and Dennis, P. A. (2001) Akt/protein kinase B is
constitutively active in non-small cell lung cancer cells and promotes cellular survival
and resistance to chemotherapy and radiation, Cancer research 61, 3986-3997.
125. Tsurutani, J., Castillo, S. S., Brognard, J., Granville, C. A., Zhang, C., Gills, J. J.,
Sayyah, J., and Dennis, P. A. (2005) Tobacco components stimulate Akt-dependent
proliferation and NFkappaB-dependent survival in lung cancer cells, Carcinogenesis
26, 1182-1195.
126. Tonder, J. E., and Olesen, P. H. (2001) Agonists at the alpha4beta2 nicotinic
acetylcholine receptors: structure-activity relationships and molecular modelling,
Current medicinal chemistry 8, 651-674.
127. Arredondo, J., Chernyavsky, A. I., and Grando, S. A. (2006) The nicotinic receptor
antagonists abolish pathobiologic effects of tobacco-derived nitrosamines on BEP2D
cells, Journal of cancer research and clinical oncology 132, 653-663.
128. Plummer, H. K., 3rd, Dhar, M., and Schuller, H. M. (2005) Expression of the alpha7
nicotinic acetylcholine receptor in human lung cells, Respiratory research 6, 29.
57
129. Codignola, A., Tarroni, P., Cattaneo, M. G., Vicentini, L. M., Clementi, F., and Sher,
E. (1994) Serotonin release and cell proliferation are under the control of alpha-
bungarotoxin-sensitive nicotinic receptors in small-cell lung carcinoma cell lines,
FEBS letters 342, 286-290.
130. Plummer, H. K., 3rd, Sheppard, B. J., and Schuller, H. M. (2000) Interaction of
tobacco-specific toxicants with nicotinic cholinergic regulation of fetal pulmonary
neuroendocrine cells: implications for pediatric lung disease, Experimental lung
research 26, 121-135.
131. Cattaneo, M. G., Codignola, A., Vicentini, L. M., Clementi, F., and Sher, E. (1993)
Nicotine stimulates a serotonergic autocrine loop in human small-cell lung carcinoma,
Cancer research 53, 5566-5568.
132. Jull, B. A., Plummer, H. K., 3rd, and Schuller, H. M. (2001) Nicotinic receptor-
mediated activation by the tobacco-specific nitrosamine NNK of a Raf-1/MAP kinase
pathway, resulting in phosphorylation of c-myc in human small cell lung carcinoma
cells and pulmonary neuroendocrine cells, Journal of cancer research and clinical
oncology 127, 707-717.
133. Xu, L., and Deng, X. (2004) Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanone induces phosphorylation of mu- and m-calpain in association
with increased secretion, cell migration, and invasion, The Journal of biological
chemistry 279, 53683-53690.
134. Jin, Z., Gao, F., Flagg, T., and Deng, X. (2004) Tobacco-specific nitrosamine 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone promotes functional cooperation of
Bcl2 and c-Myc through phosphorylation in regulating cell survival and proliferation,
The Journal of biological chemistry 279, 40209-40219.
135. Dasgupta, P., Rastogi, S., Pillai, S., Ordonez-Ercan, D., Morris, M., Haura, E., and
Chellappan, S. (2006) Nicotine induces cell proliferation by beta-arrestin-mediated
58
activation of Src and Rb-Raf-1 pathways, The Journal of clinical investigation 116,
2208-2217.
136. Dasgupta, P., Kinkade, R., Joshi, B., Decook, C., Haura, E., and Chellappan, S. (2006)
Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP
and survivin, Proceedings of the National Academy of Sciences of the United States of
America 103, 6332-6337.
137. Hung, R. J., McKay, J. D., Gaborieau, V., Boffetta, P., Hashibe, M., Zaridze, D.,
Mukeria, A., Szeszenia-Dabrowska, N., Lissowska, J., Rudnai, P., Fabianova, E.,
Mates, D., Bencko, V., Foretova, L., Janout, V., Chen, C., Goodman, G., Field, J. K.,
Liloglou, T., Xinarianos, G., Cassidy, A., McLaughlin, J., Liu, G., Narod, S., Krokan,
H. E., Skorpen, F., Elvestad, M. B., Hveem, K., Vatten, L., Linseisen, J., Clavel-
Chapelon, F., Vineis, P., Bueno-de-Mesquita, H. B., Lund, E., Martinez, C., Bingham,
S., Rasmuson, T., Hainaut, P., Riboli, E., Ahrens, W., Benhamou, S., Lagiou, P.,
Trichopoulos, D., Holcatova, I., Merletti, F., Kjaerheim, K., Agudo, A., Macfarlane,
G., Talamini, R., Simonato, L., Lowry, R., Conway, D. I., Znaor, A., Healy, C.,
Zelenika, D., Boland, A., Delepine, M., Foglio, M., Lechner, D., Matsuda, F.,
Blanche, H., Gut, I., Heath, S., Lathrop, M., and Brennan, P. (2008) A susceptibility
locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25,
Nature 452, 633-637.
138. Lam, D. C., Girard, L., Ramirez, R., Chau, W. S., Suen, W. S., Sheridan, S., Tin, V.
P., Chung, L. P., Wong, M. P., Shay, J. W., Gazdar, A. F., Lam, W. K., and Minna, J.
D. (2007) Expression of nicotinic acetylcholine receptor subunit genes in non-small-
cell lung cancer reveals differences between smokers and nonsmokers, Cancer
research 67, 4638-4647.
59
139. Improgo, M. R., Schlichting, N. A., Cortes, R. Y., Zhao-Shea, R., Tapper, A. R., and
Gardner, P. D. (2010) ASCL1 regulates the expression of the CHRNA5/A3/B4 lung
cancer susceptibility locus, Molecular cancer research : MCR 8, 194-203.
140. Linnoila, R. I., Zhao, B., DeMayo, J. L., Nelkin, B. D., Baylin, S. B., DeMayo, F. J.,
and Ball, D. W. (2000) Constitutive achaete-scute homologue-1 promotes airway
dysplasia and lung neuroendocrine tumors in transgenic mice, Cancer research 60,
4005-4009.
141. Jiang, T., Collins, B. J., Jin, N., Watkins, D. N., Brock, M. V., Matsui, W., Nelkin, B.
D., and Ball, D. W. (2009) Achaete-scute complex homologue 1 regulates tumor-
initiating capacity in human small cell lung cancer, Cancer research 69, 845-854.
142. Terlau, H., and Olivera, B. M. (2004) Conus venoms: a rich source of novel ion
channel-targeted peptides, Physiological reviews 84, 41-68.
143. Haddad, V., Jr., Coltro, M., and Simone, L. R. (2009) Report of a human accident
caused by Conus regius (Gastropoda, Conidae), Revista da Sociedade Brasileira de
Medicina Tropical 42, 446-448.
144. Olivera, B. M., Quik, M., Vincler, M., and McIntosh, J. M. (2008) Subtype-selective
conopeptides targeted to nicotinic receptors: Concerted discovery and biomedical
applications, Channels 2, 143-152.
145. Hinegardner, R. T. (1958) The venom apparatus of the cone shell, Hawaii medical
journal 17, 533-536.
146. Marshall, J., Kelley, W. P., Rubakhin, S. S., Bingham, J. P., Sweedler, J. V., and
Gilly, W. F. (2002) Anatomical correlates of venom production in Conus californicus,
The Biological bulletin 203, 27-41.
147. Olivera, B. M. (2006) Conus peptides: biodiversity-based discovery and exogenomics,
The Journal of biological chemistry 281, 31173-31177.
60
148. Woodward, S. R., Cruz, L. J., Olivera, B. M., and Hillyard, D. R. (1990) Constant and
hypervariable regions in conotoxin propeptides, The EMBO journal 9, 1015-1020.
149. Safavi-Hemami, H., Siero, W. A., Gorasia, D. G., Young, N. D., Macmillan, D.,
Williamson, N. A., and Purcell, A. W. (2011) Specialisation of the venom gland
proteome in predatory cone snails reveals functional diversification of the conotoxin
biosynthetic pathway, Journal of proteome research 10, 3904-3919.
150. Buczek, O., Yoshikami, D., Watkins, M., Bulaj, G., Jimenez, E. C., and Olivera, B. M.
(2005) Characterization of D-amino-acid-containing excitatory conotoxins and
redefinition of the I-conotoxin superfamily, The FEBS journal 272, 4178-4188.
151. Craig, A. G., Bandyopadhyay, P., and Olivera, B. M. (1999) Post-translationally
modified neuropeptides from Conus venoms, European journal of biochemistry /
FEBS 264, 271-275.
152. Gray, W. R., Olivera, B. M., and Cruz, L. J. (1988) Peptide toxins from venomous
Conus snails, Annual review of biochemistry 57, 665-700.
153. Kaas, Q., Westermann, J. C., Halai, R., Wang, C. K., and Craik, D. J. (2008)
ConoServer, a database for conopeptide sequences and structures, Bioinformatics 24,
445-446.
154. Kaas, Q., Westermann, J. C., and Craik, D. J. (2010) Conopeptide characterization and
classifications: an analysis using ConoServer, Toxicon : official journal of the
International Society on Toxinology 55, 1491-1509.
155. Daly, N. L., and Craik, D. J. (2009) Structural studies of conotoxins, IUBMB life 61,
144-150.
156. Millard, E. L., Daly, N. L., and Craik, D. J. (2004) Structure-activity relationships of
alpha-conotoxins targeting neuronal nicotinic acetylcholine receptors, European
journal of biochemistry / FEBS 271, 2320-2326.
61
157. Marx, U. C., Daly, N. L., and Craik, D. J. (2006) NMR of conotoxins: structural
features and an analysis of chemical shifts of post-translationally modified amino
acids, Magnetic resonance in chemistry : MRC 44 Spec No, S41-50.
158. Sharpe, I. A., Gehrmann, J., Loughnan, M. L., Thomas, L., Adams, D. A., Atkins, A.,
Palant, E., Craik, D. J., Adams, D. J., Alewood, P. F., and Lewis, R. J. (2001) Two
new classes of conopeptides inhibit the alpha1-adrenoceptor and noradrenaline
transporter, Nature neuroscience 4, 902-907.
159. Nielsen, K. J., Adams, D., Thomas, L., Bond, T., Alewood, P. F., Craik, D. J., and
Lewis, R. J. (1999) Structure-activity relationships of omega-conotoxins MVIIA,
MVIIC and 14 loop splice hybrids at N and P/Q-type calcium channels, Journal of
molecular biology 289, 1405-1421.
160. Loughnan, M., Nicke, A., Jones, A., Schroeder, C. I., Nevin, S. T., Adams, D. J.,
Alewood, P. F., and Lewis, R. J. (2006) Identification of a novel class of nicotinic
receptor antagonists: dimeric conotoxins VxXIIA, VxXIIB, and VxXIIC from Conus
vexillum, The Journal of biological chemistry 281, 24745-24755.
161. Clark, R. J., Fischer, H., Nevin, S. T., Adams, D. J., and Craik, D. J. (2006) The
synthesis, structural characterization, and receptor specificity of the alpha-conotoxin
Vc1.1, The Journal of biological chemistry 281, 23254-23263.
162. Nilsson, K. P., Lovelace, E. S., Caesar, C. E., Tynngard, N., Alewood, P. F.,
Johansson, H. M., Sharpe, I. A., Lewis, R. J., Daly, N. L., and Craik, D. J. (2005)
Solution structure of chi-conopeptide MrIA, a modulator of the human norepinephrine
transporter, Biopolymers 80, 815-823.
163. Nielsen, K. J., Thomas, L., Lewis, R. J., Alewood, P. F., and Craik, D. J. (1996) A
consensus structure for omega-conotoxins with different selectivities for voltage-
sensitive calcium channel subtypes: comparison of MVIIA, SVIB and SNX-202,
Journal of molecular biology 263, 297-310.
62
164. Nicke, A., Loughnan, M. L., Millard, E. L., Alewood, P. F., Adams, D. J., Daly, N. L.,
Craik, D. J., and Lewis, R. J. (2003) Isolation, structure, and activity of GID, a novel
alpha 4/7-conotoxin with an extended N-terminal sequence, The Journal of biological
chemistry 278, 3137-3144.
165. Hu, S. H., Loughnan, M., Miller, R., Weeks, C. M., Blessing, R. H., Alewood, P. F.,
Lewis, R. J., and Martin, J. L. (1998) The 1.1 A resolution crystal structure of
[Tyr15]EpI, a novel alpha-conotoxin from Conus episcopatus, solved by direct
methods, Biochemistry 37, 11425-11433.
166. Azam, L., and McIntosh, J. M. (2009) Alpha-conotoxins as pharmacological probes of
nicotinic acetylcholine receptors, Acta pharmacologica Sinica 30, 771-783.
167. Inserra, M. C., Kompella, S. N., Vetter, I., Brust, A., Daly, N. L., Cuny, H., Craik, D.
J., Alewood, P. F., Adams, D. J., and Lewis, R. J. (2013) Isolation and characterization
of alpha-conotoxin LsIA with potent activity at nicotinic acetylcholine receptors,
Biochemical pharmacology 86, 791-799.
168. Whiteaker, P., Christensen, S., Yoshikami, D., Dowell, C., Watkins, M., Gulyas, J.,
Rivier, J., Olivera, B. M., and McIntosh, J. M. (2007) Discovery, synthesis, and
structure activity of a highly selective alpha7 nicotinic acetylcholine receptor
antagonist, Biochemistry 46, 6628-6638.
169. Franco, A., Kompella, S. N., Akondi, K. B., Melaun, C., Daly, N. L., Luetje, C. W.,
Alewood, P. F., Craik, D. J., Adams, D. J., and Mari, F. (2012) RegIIA: an alpha4/7-
conotoxin from the venom of Conus regius that potently blocks alpha3beta4 nAChRs,
Biochemical pharmacology 83, 419-426.
170. Talley, T. T., Olivera, B. M., Han, K. H., Christensen, S. B., Dowell, C., Tsigelny, I.,
Ho, K. Y., Taylor, P., and McIntosh, J. M. (2006) Alpha-conotoxin OmIA is a potent
ligand for the acetylcholine-binding protein as well as alpha3beta2 and alpha7
63
nicotinic acetylcholine receptors, The Journal of biological chemistry 281, 24678-
24686.
171. McIntosh, J. M., Dowell, C., Watkins, M., Garrett, J. E., Yoshikami, D., and Olivera,
B. M. (2002) Alpha-conotoxin GIC from Conus geographus, a novel peptide
antagonist of nicotinic acetylcholine receptors, The Journal of biological chemistry
277, 33610-33615.
172. Luo, S., Kulak, J. M., Cartier, G. E., Jacobsen, R. B., Yoshikami, D., Olivera, B. M.,
and McIntosh, J. M. (1998) alpha-conotoxin AuIB selectively blocks alpha3 beta4
nicotinic acetylcholine receptors and nicotine-evoked norepinephrine release, The
Journal of neuroscience : the official journal of the Society for Neuroscience 18,
8571-8579.
173. Ellison, M., Haberlandt, C., Gomez-Casati, M. E., Watkins, M., Elgoyhen, A. B.,
McIntosh, J. M., and Olivera, B. M. (2006) Alpha-RgIA: a novel conotoxin that
specifically and potently blocks the alpha9alpha10 nAChR, Biochemistry 45, 1511-
1517.
174. Ulens, C., Hogg, R. C., Celie, P. H., Bertrand, D., Tsetlin, V., Smit, A. B., and Sixma,
T. K. (2006) Structural determinants of selective alpha-conotoxin binding to a
nicotinic acetylcholine receptor homolog AChBP, Proceedings of the National
Academy of Sciences of the United States of America 103, 3615-3620.
175. Dutertre, S., Ulens, C., Buttner, R., Fish, A., van Elk, R., Kendel, Y., Hopping, G.,
Alewood, P. F., Schroeder, C., Nicke, A., Smit, A. B., Sixma, T. K., and Lewis, R. J.
(2007) AChBP-targeted alpha-conotoxin correlates distinct binding orientations with
nAChR subtype selectivity, The EMBO journal 26, 3858-3867.
176. Celie, P. H., Kasheverov, I. E., Mordvintsev, D. Y., Hogg, R. C., van Nierop, P., van
Elk, R., van Rossum-Fikkert, S. E., Zhmak, M. N., Bertrand, D., Tsetlin, V., Sixma, T.
K., and Smit, A. B. (2005) Crystal structure of nicotinic acetylcholine receptor
64
homolog AChBP in complex with an alpha-conotoxin PnIA variant, Nature structural
& molecular biology 12, 582-588.
177. Halai, R., Clark, R. J., Nevin, S. T., Jensen, J. E., Adams, D. J., and Craik, D. J. (2009)
Scanning mutagenesis of alpha-conotoxin Vc1.1 reveals residues crucial for activity at
the alpha9alpha10 nicotinic acetylcholine receptor, The Journal of biological
chemistry 284, 20275-20284.
178. Ellison, M., Feng, Z. P., Park, A. J., Zhang, X., Olivera, B. M., McIntosh, J. M., and
Norton, R. S. (2008) Alpha-RgIA, a novel conotoxin that blocks the alpha9alpha10
nAChR: structure and identification of key receptor-binding residues, Journal of
molecular biology 377, 1216-1227.
179. Johnson, D. S., Martinez, J., Elgoyhen, A. B., Heinemann, S. F., and McIntosh, J. M.
(1995) alpha-Conotoxin ImI exhibits subtype-specific nicotinic acetylcholine receptor
blockade: preferential inhibition of homomeric alpha 7 and alpha 9 receptors,
Molecular pharmacology 48, 194-199.
180. McIntosh, J. M., Azam, L., Staheli, S., Dowell, C., Lindstrom, J. M., Kuryatov, A.,
Garrett, J. E., Marks, M. J., and Whiteaker, P. (2004) Analogs of alpha-conotoxin MII
are selective for alpha6-containing nicotinic acetylcholine receptors, Molecular
pharmacology 65, 944-952.
181. Carstens, B. B., Clark, R. J., Daly, N. L., Harvey, P. J., Kaas, Q., and Craik, D. J.
(2011) Engineering of conotoxins for the treatment of pain, Current pharmaceutical
design 17, 4242-4253.
182. Halai, R., Callaghan, B., Daly, N. L., Clark, R. J., Adams, D. J., and Craik, D. J.
(2011) Effects of cyclization on stability, structure, and activity of alpha-conotoxin
RgIA at the alpha9alpha10 nicotinic acetylcholine receptor and GABA(B) receptor,
Journal of medicinal chemistry 54, 6984-6992.
65
183. Robinson, A. J., Elaridi, J., Van Lierop, B. J., Mujcinovic, S., and Jackson, W. R.
(2007) Microwave-assisted RCM for the synthesis of carbocyclic peptides, Journal of
peptide science : an official publication of the European Peptide Society 13, 280-285.
184. Whelan, A. N., Elaridi, J., Harte, M., Smith, S. V., Jackson, W. R., and Robinson, A.
J. (2004) A tandem metathesis-hydrogenation route to dicarba analogues of cystine-
containing cyclic peptides, Tetrahedron Lett 45, 9545-9547.
185. MacRaild, C. A., Illesinghe, J., van Lierop, B. J., Townsend, A. L., Chebib, M., Livett,
B. G., Robinson, A. J., and Norton, R. S. (2009) Structure and activity of (2,8)-
dicarba-(3,12)-cystino alpha-ImI, an alpha-conotoxin containing a nonreducible
cystine analogue, Journal of medicinal chemistry 52, 755-762.
186. van Lierop, B. J., Robinson, S. D., Kompella, S. N., Belgi, A., McArthur, J. R., Hung,
A., Macraild, C. A., Adams, D. J., Norton, R. S., and Robinson, A. J. (2013) Dicarba
alpha-Conotoxin Vc1.1 Analogues with Differential Selectivity for Nicotinic
Acetylcholine and GABAB Receptors, ACS chemical biology 8, 1815-1821.
187. Livett, B. G., Sandall, D. W., Keays, D., Down, J., Gayler, K. R., Satkunanathan, N.,
and Khalil, Z. (2006) Therapeutic applications of conotoxins that target the neuronal
nicotinic acetylcholine receptor, Toxicon : official journal of the International Society
on Toxinology 48, 810-829.
188. Heading, C. E. (2001) Ziconotide (Elan Pharmaceuticals), IDrugs : the investigational
drugs journal 4, 339-350.
189. Sharpe, I. A., Palant, E., Schroeder, C. I., Kaye, D. M., Adams, D. J., Alewood, P. F.,
and Lewis, R. J. (2003) Inhibition of the norepinephrine transporter by the venom
peptide chi-MrIA. Site of action, Na+ dependence, and structure-activity relationship,
The Journal of biological chemistry 278, 40317-40323.
66
190. Malmberg, A. B., Gilbert, H., McCabe, R. T., and Basbaum, A. I. (2003) Powerful
antinociceptive effects of the cone snail venom-derived subtype-selective NMDA
receptor antagonists conantokins G and T, Pain 101, 109-116.
191. Lippiello, P., Bencherif, M., Hauser, T., Jordan, K., Letchworth, S., and Mazurov, A.
(2007) Nicotinic receptors as targets for therapeutic discovery, Expert opinion on drug
discovery 2, 1185-1203.
67
CHAPTER 2
MATERIALS AND METHODS
68
This chapter describes the protocols followed for the synthesis, and structural and functional
characterisation of conotoxins.
2.1 Materials
Rink amide methylbenzhydrylamine (MBHA) resin (Novabiochem), O-benzotriazole-
N,N,N',N'-tetramethyl-uronium-hexafluoro-phosphate (HBTU), N-(9-fluorenyl)
methoxycarbonyl (Fmoc), dimethylformamide (DMF), N,N′-diisopropylethylamine (DIPEA),
trifluoroacetic acid (TFA), triisopropylsilane (TIPS), ether, HPLC grade acetonitrile (ACN),
potassium cyanide (KCN), ninhydrin, tricaine methanesulphonate (MS-222), acetylcholine
(ACh), hydrogen fluoride (HF).
2.2 Peptide synthesis
2.2.1 Solid-phase peptide synthesis (SPPS)
Chemical synthesis using SPPS involves building a peptide chain that is covalently attached
to a solid resin support. This concept was introduced by Merrifield in 1963 [1]. Stepwise
assembly of the amino acids on the resin uses one of two types of chemistry, depending on the
N-terminal protecting group of amino acids - 9-fluorenylmethoxycarbonyl (Fmoc) and tert-
butyloxycarbonyl (t-Boc). Along with one of these orthogonal protecting groups, side chain
protecting groups are also present on amino acids which prevent any intermediate reactions
during peptide elongation.
Peptide elongation involves two basic steps: N-terminal deprotection and a coupling reaction.
These steps are where the major differences between Fmoc and Boc peptide synthesis are
seen. In Boc chemistry, the deprotection step uses an acid, such as TFA, whereas Fmoc
chemistry uses a base, such as piperidine. The two also require different reactions to cleave
the peptide from the solid resin. Boc needs HF, while Fmoc uses TFA [1, 2]. Because Fmoc
69
uses low-hazard reagents, it is safer than Boc, which is why many scientists prefer it.
However, both methods have specific advantages, and the type of SPPS method used depends
on the final peptide needed.
2.2.2 Fmoc SPPS
All peptide analogues discussed in Chapter 3 were synthesised using Fmoc chemistry. The
various steps involved in this method are detailed below. Fmoc peptide synthesis was carried
out in collaboration with Dr Richard Clark (The University of Queensland, Brisbane).
Our collaborators provided the peptides described in other chapters.
2.2.2.1 Peptide assembly
The basic apparatus for SPPS includes a reaction vessel with a sintered glass filter and tap at
the bottom, which is connected to a vacuum line via a solvent trap [Figure 2.1]. The filter
supports the resin upon which the peptides are assembled. The tap allows solvents to be
removed from the vessel.
Figure 2.1: The basic apparatus set up needed for solid-phase peptide synthesis.
70
All peptide analogues were assembled on rink amide MBHA resin (Novabiochem;
0.7 mmol·g−1) using HBTU-mediated manual SPSS with an in situ neutralisation procedure
for Fmoc chemistry [3]. The amount of resin needed for each reaction was calculated based
on the scale of peptide synthesised in mmoles and the resin’s substitution value (provided
with resin).
Mass of resin = scale in mmoles/substitution value
All peptide analogues were synthesised at 0.25 mmoles scale, where 460 mg of rink amide
MBHA resin (substitution value of 0.54) was used, calculated using the above formula. The
resin was allowed to swell overnight, soaked in DMF, and then transferred into the reaction
vessel.
Each amino acid assembly cycle consisted of Fmoc deprotection with 20% piperidine
in DMF, followed by Fmoc amino acid coupling using HBTU and DIPEA in DMF. A two-
fold excess of Fmoc amino acids was used in the coupling reactions. Each coupling reaction
used 2 mmoles of each amino acid. The amino acids are activated by dissolving them in 2 mL
of 0.5 M of HBTU/DMF solution followed by the addition of 174 µL of DIPEA. When
DIPEA was added, the amino acid mixture was immediately added to the resin and left for
10–15 min to allow for efficient coupling.
A Kaiser Ninhydrin test was carried out to determine the coupling percentage [4]. The Kaiser
Ninhydrin test detects the amount of free amine present on the resin, indicated by the solution
turning purple. In this test, 3–5 mg of the resin was removed, washed with 50%
DCM/methanol and then air dried. To this dried resin, 2 drops of 76% w/w phenol in ethanol,
4 drops of 0.2 mM KCN in pyridine and 2 drops of 0.28 M ninhydrin in ethanol was added.
71
The sample was incubated at 100 oC for 5 min, and then 2.8 mL of 60% ethanol in water was
added to it before it was briefly centrifuged to settle the resin at the bottom. The solution’s
absorbance at 570 nm, was then calculated against the reagent blank using ultraviolet-visible
spectrophotometry. The coupling % was calculated using the following equation:
% coupling = 100 x (1-(A570 x 200/SV x mass of resin))
where, A570 is the absorbance value obtained at 570 nm and SV is the substitution value of the
resin.
Values > 99% indicated a successful coupling reaction, and peptide assembly continued with
the addition of the next amino acid [4]. However, the ninhydrin test cannot be used to
determine the coupling efficiency of an amino acid after proline. This is due to lack of
primary amines at the N-termini of proline. Under these conditions, the coupling reaction is
generally either repeated or an Isatin test can be performed to check for coupling.
In the Isatin test, 5 drops of Isatin were dissolved in 3% n-butanol and 2 drops of 10% acetic
acid were added to the dry resin, before the solution was incubated for 5 min at 100 oC.
Yellow or colourless resin indicated efficient coupling, whereas a blue or grey-green colour
represented poor coupling [5].
2.2.2.2 Peptide cleavage
When the last amino acid was coupled, the N-terminal Fmoc group was removed using the
usual deprotection procedure and washed with DMF. Peptide cleavage from the dried resin
(0.4 g) was achieved by treating it with 100 mL of a chemical cocktail composed of TFA,
TIPS and water (95:2.5:2.5 TFA:TIPS:water v/v/v). TIPS and water within the cocktail are
scavengers that prevent the modification of unprotected side-chains. The reaction proceeded
at room temperature (20–23 °C) for 2.5 h. The TFA was then evaporated (not completely
72
dried) and the peptide was precipitated with 30 mL of ice-cold ether. The peptide was then
extracted using 50% buffer A/B (Buffer A: H2O/0.05% TFA; Buffer B: 90%
CH3CN/10%H2O/0.045% TFA) using a separating funnel. Any residual ether was removed
and the peptide was lyophilised [6].
2.2.2.3 Directed disulphide formation
All peptides were synthesised in globular conformation (I–III; II–IV disulphide connectivity)
through Fmoc – Cys(Acm) – OH coupling at positions 2 and 8 of the amino acid sequence (I–
III disulphide bond). The scavengers in the chemical cocktail used for cleaving the peptide do
not deprotect the Acm group on I–III Cys residues.
Crude peptides were purified by reversed-phase high-performance liquid chromatography
(RP-HPLC) on a Phenomenex C18 column using a gradient of 0–80% B in 80 min, with the
eluent monitored at 215/280 nm. These conditions were used in subsequent purification steps
unless stated otherwise. Electrospray mass spectroscopy (ES-MS) confirmed the molecular
mass of the fractions collected. Those fractions displaying the correct molecular mass of
linear peptide were pooled and lyophilised for oxidation.
Linear peptides were oxidised in two steps [Figure 2.2]. First, they were dissolved in
0.1 m NH4HCO3 (pH 8.2) at a concentration of 0.3 mg/mL, and stirred overnight at room
temperature. This created the II–IV disulphide bond. The Acm protecting groups were stable
under these conditions. The [II–IV]-disulphide peptides were purified using RP-HPLC,
confirmed with ES-MS and then lyophilised.
Second, the second disulphide bond (I–III) was formed using the oxidation by iodine method.
The peptides were dissolved (1 mg/mL) in buffer A (H2O/0.05% TFA) before iodine in
73
acetonitrile was added until the solution turned orange/yellow. The reaction was incubated for
5 min at 37 oC. Excess iodine was destroyed by adding sodium ascorbate. The oxidised
peptides were then purified by RP-HPLC using a gradient of 0–80% buffer B over 160 min.
Analytical RP-HPLC and ES-MS confirmed the synthesised peptides’ purity and molecular
mass [7].
Figure 2.2: Directed disulphide formation of α-conotoxins using orthogonal cysteine
protecting groups.
74
2.2.3 NMR spectroscopy
Dr Richard Clark (School of Biomedical Sciences, The University of Queensland) carried out
all NMR spectroscopy experiments.
1H NMR was done to determine the successful folding of all peptide analogues outlined in
Chapter 3. NMR data for all peptides were recorded on Bruker Avance 500- and 600-MHz
spectrometers, with samples of > 95% purity dissolved in 90% H2O and 10% D2O
(Cambridge Isotope laboratories, Massachusetts, USA).
Two-dimensional NMR experiments included total correlation spectroscopy (TOCSY) and
nuclear overhauser effect spectroscopy (NOESY) recorded at 280 K. Spectra were analysed
using Topspin 1.3 (Bruker) and Sparky software. Most spectra were recorded at pH 3.5.
Sequence-specific resonance assignment was carried out for each peptide’s spectra in
collaboration with Dr Norelle Daly (Institute for Molecular Biosciences, The University of
Queensland) [8].
2.3 Electrophysiological recordings in Xenopus oocytes
Xenopus laevis frogs were anesthetised using MS-222 (1.3 g/L) solution before oocytes were
surgically extracted. The oocytes were then incubated with collagenase (3 mg/mL) dissolved
in OR2 buffer (82.5 mM NaCl, 2 mM KCl, 1 mM MgCl2 and 5 mM HEPES, pH 7.4) for 1–2
h (until the vitelline membrane surrounding the oocytes was digested). The collagenase was
then removed by washing the oocytes with OR2 buffer.
Oocytes at stages V–VI (larger in size) with distinct animal (dark) and vegetal pole (white)
were selected for mRNA injection [Figure 2.3]. cDNAs encoding the rat α3, α4, α9, α10, β2
and β4 nAChR subunits and human α7 nAChR subunit, subcloned into the oocyte expression
75
vector pT7TS, were used for the mRNA preparation using the mMESSAGE mMACHINE Kit
(Ambion Inc, USA). All oocytes were injected with 25 ng of cRNA for α9 and α10, and 5 ng
of cRNA for all other subunits. They were then kept at 18 °C in ND96 buffer (96 mM NaCl, 2
mM KCl, 1 mM CaCl2, 1 mM MgCl2 and 5 mM HEPES, pH 7.4) supplemented with 50
mg/L gentamicin and 100 µg/units/mL penicillin streptomycin for 2–5 days before recording
[Figure 2.3].
Membrane currents from Xenopus oocytes were recorded using two-electrode voltage clamp
(virtual ground circuit) with either a GeneClamp 500B amplifier (Molecular Devices) or an
automated workstation with eight channels in parallel, including drug delivery and online
analysis (OpusXpressTM 6000A workstation, Axon Instruments Inc.) [Figure 2.3]. Voltage-
recording and current-injecting electrodes were pulled from borosilicate glass (GC150T-7.5,
Harvard Apparatus Ltd) and had resistances of 0.3–1.5 MΩ when filled with 3 M KCl [9].
Figure 2.3: Schematic representation of the various steps involved in two-electrode
voltage-clamp studies using Xenopus laevis oocytes.
76
All recordings were made at room temperature using a bath solution of ND96, as described
above. During recordings, oocytes were perfused continuously at a rate of 2 mL/min, and
peptides were incubated for 300 s before the ACh was added. ACh (200 µM for α7 and 50
µM for all other nAChR subtypes) was applied for 2 s at 2 mL/min, with 180–240 s washout
periods between applications. Cells were voltage-clamped at a holding potential of −80 mV.
Data were filtered at 10 Hz and sampled at 500 Hz [10].
Desensitisation experiments were carried out using 50 µM ACh applied for 30 s, followed by
a 300 s washout. The onset (kon) and recovery (koff) from block by the peptide was measured
by bath applying the peptide at 2 mL/min for 5 min, followed by washout. On-rate kinetics
were carried out with ACh + peptide pulse applied at the indicated time intervals. ACh pulses
during recovery from block contained no peptide. The percentage response or percentage
inhibition was obtained by averaging the peak amplitude of three control responses directly
before exposure to the peptide.
2.4 Data analysis
Concentration–response curves for antagonists were fitted by unweighted nonlinear regression
to the logistic equation:
Ex = Emax XnH/(XnH + IC50
nH)
where Ex is the response, X is the antagonist concentration, Emax is the maximal response, nH
is the slope factor and IC50 is the antagonist concentration that gives 50% inhibition of the
maximal response.
All electrophysiological data were pooled (n = 4–8 for each data point) and represent
arithmetic means ± standard error of the fit.
77
The rates of onset and recovery from block during peptide washout were obtained from
exponential fits to the data using GraphPad Prism 5. The ki for the peptide was then
calculated using the equation:
ki = koff / kon.
Computation was done using GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA,
USA).
2.5 References
1. Merrifield, R. B. (1963) Solid Phase Peptide Synthesis .1. Synthesis of a Tetrapeptide,
J Am Chem Soc 85, 2149-&.
2. Meienhofer, J., Waki, M., Heimer, E. P., Lambros, T. J., Makofske, R. C., and Chang,
C. D. (1979) Solid phase synthesis without repetitive acidolysis. Preparation of leucyl-
alanyl-glycyl-valine using 9-fluorenylmethyloxycarbonylamino acids, International
journal of peptide and protein research 13, 35-42.
3. Alewood, P., Alewood, D., Miranda, L., Love, S., Meutermans, W., and Wilson, D.
(1997) Rapid in situ neutralization protocols for Boc and Fmoc solid-phase
chemistries, Methods in enzymology 289, 14-29.
4. Sarin, V. K., Kent, S. B., Tam, J. P., and Merrifield, R. B. (1981) Quantitative
monitoring of solid-phase peptide synthesis by the ninhydrin reaction, Analytical
biochemistry 117, 147-157.
5. Kaiser, E., Colescott, R. L., Bossinger, C. D., and Cook, P. I. (1970) Color test for
detection of free terminal amino groups in the solid-phase synthesis of peptides,
Analytical biochemistry 34, 595-598.
6. Lloyd-Williams, P., Albericio, F., and Giralt, E. (1997) Chemical approaches to the
synthesis of peptides and proteins, CRC Press, Boca Raton.
78
7. Banerjee, J., Gyanda, R., Chang, Y. P., and Armishaw, C. J. (2013) The chemical
synthesis of alpha-conotoxins and structurally modified analogs with enhanced
biological stability, Methods in molecular biology 1081, 13-34.
8. Wuthrich, K. (2003) NMR studies of structure and function of biological
macromolecules (Nobel lecture), Angewandte Chemie 42, 3340-3363.
9. Hogg, R. C., Hopping, G., Alewood, P. F., Adams, D. J., and Bertrand, D. (2003)
Alpha-conotoxins PnIA and [A10L]PnIA stabilize different states of the alpha7-
L247T nicotinic acetylcholine receptor, The Journal of biological chemistry 278,
26908-26914.
10. Nevin, S. T., Clark, R. J., Klimis, H., Christie, M. J., Craik, D. J., and Adams, D. J.
(2007) Are {alpha}9{alpha}10 nicotinic acetylcholine receptors a pain target for
{alpha}-conotoxins?, Mol Pharmacol.
79
CHAPTER 3
α-Conotoxin RegIIA targeting α3β4 nAChR:
unlocking novel therapeutics towards lung cancer
Conus regius
80
3.1 INTRODUCTION
3.1.1 Nicotinic acetylcholine receptors
Nicotinic acetylcholine receptors (nAChR) are ligand-gated ion channels expressed in the
central nervous system (CNS) and peripheral nervous system (PNS) [1, 2]. They are
pentameric receptors composed of a combination of alpha subunits (α2–10) and beta subunits
(β2–4). nAChRs exhibit a diverse structural and functional heterogeneity through formation
of various heteromeric (e.g. α3β2 and α4β2) and homomeric isoforms (formed by only α7 and
α9 subunits) [3]. Their physiological role is well understood and they are known to modulate
pre- and post-synaptic transmission in the CNS, and visceral and somatic sensory
transmission in the PNS [4-6].
nAChRs have been implicated in various pathophysiological conditions, including
Alzheimer’s disease, schizophrenia, tobacco addiction and lung cancer [2]. Despite
considerable progress in understanding these pathological conditions, knowledge of the
distribution and neurophysiological role of individual receptor subtypes is limited by the lack
of adequate isoform-specific probes [7].
3.1.2 The pathophysiological role of the α3β4 nAChR subtype
Following the first report by Schuller’s group in 1989, which suggested that nAChRs may
have a role in regulating cancer cell growth [8], many studies were initiated to investigate the
role of nAChRs in cancer development and progression [9]. Two reports identified nicotine
and its derivatives as potent nAChR agonists and their regulatory role in cancer cell apoptosis
[10, 11]. Genome-wide association studies (GWAS) led to the identification of various single
81
nucleotide polymorphisms (SNP) within a gene cluster encoding α3, α5 and β4 nAChR
subunits, and these SNPs are associated with lung cancer [9, 12]. In addition, the α3β4
subtype has been shown to be involved in nicotine addiction and drug-abuse [13]. However,
knowledge of the distribution and physiological role of the α3β4 subtype is still limited. The
development of a α3β4 subtype-selective inhibitor, which could help develop drugs to treat
cancer and nicotine addiction, is very desirable.
3.1.3 α-Conotoxins targeting neuronal nAChRs
Conotoxins are bioactive peptides isolated from the venom of cone snails belonging to the
genus Conus [14, 15]. α-Conotoxins, a class of short disulphide-rich peptides from this venom
[16], specifically target various nAChR subtypes and are excellent molecular probes for
identifying the physiological role of nAChR subtypes in normal and disease states [17]. To
date, many α-conotoxins have been characterised, and their structural and functional
properties are well documented in various reviews and online databases
(http://www.conoserver.org) [14, 18-22]. While it is evident that α-conotoxins, such as ImII
and MII, exhibit selective inhibitory activity at α7 [23] and α3β2 [24] nAChR subtypes
respectively, most known peptides target multiple subtypes [25]. Mutagenesis experiments
have therefore become an important tool to improve the selectivity and potency of these
peptides [26]. Furthermore, α-conotoxin AuIB is the only peptide known to selectively target
the α3β4 nAChR subtype with an IC50 of 2.5 µM [27].
Here, I describe the discovery, and biochemical, biophysical and functional characterisation,
of RegIIA. This α4/7-conotoxin was isolated from the venom of Conus regius, a worm-
hunting cone snail species that inhabits the Western Atlantic Ocean. It is one of the most
82
potent α3β4 nAChR antagonists, but does not inhibit the α4β2 subtype. This selectivity profile
makes RegIIA a prospective probe for studying nicotine addiction processes.
RegIIA has a classical α-conotoxin globular structure (ω-shaped fold) indicating that it has an
exquisite balance of shape, charges, and polarity exposed on its surface to enable it to potently
block the α3β4 nAChR. The pathophysiological association of α3β4 nAChRs in various
diseases such as lung cancer and nicotine addiction, along with RegIIA being one of the most
potent known α3β4 nAChR antagonists, led us to investigate and improve RegIIA’s
selectivity profile at the α3β4 nAChR subtype. Using alanine scanning mutagenesis and
modelling studies, we identified critical residues of α-conotoxin RegIIA that interact with the
ACh-binding site of α3β2, α3β4 and α7 nAChRs.
83
3.2 AIMS
3.2.1 Characterisation of α-conotoxin RegIIA isolated from Conus regius.
To determine the pharmacological profile of RegIIA using two-electrode
voltage-clamp technique in Xenopus oocytes expressing recombinant
nAChR subtypes.
3.2.2 Alanine scan mutagenesis.
To understand the molecular mechanism and critical residues that
determine RegIIA’s specific nAChR subtype selectivity.
3.2.3 Significance
In conjunction with modelling simulation being done by our collaborators,
this study could provide a detailed understanding of RegIIA’s molecular
pharmacology at the α3β4 and α3β2 nAChR subtypes.
This study could also provide valuable information to aid the future design
and development of α3β4-selective drugs to treat lung cancer and nicotine
addiction.
84
3.3 RESULTS
3.3.1 Selective α-conotoxin RegIIA inhibition of recombinant nAChR subtypes
RegIIA selectivity was examined by inhibiting ACh-evoked currents mediated by various
nAChRs subtypes expressed in Xenopus oocytes. ACh was applied at 5 min intervals and the
corresponding membrane currents were assessed. The peptide was bath incubated for 5 mins
before co-application of ACh and the peptide. Synthetic RegIIA (1 µM) completely inhibited
ACh-evoked current amplitude produced by α3β4, α3β2 and α7 nAChRs [Figure 3.1].
However, RegIIA did not inhibit muscle (αβγδ) or α4β2 nAChRs (n = 4–5). RegIIA (1 µM)
inhibited only 20 ± 5% of ACh-evoked current amplitude of α9α10 nAChR. Concentration–
response curves of RegIIA display the order of selectivity and their corresponding IC50 values
for α3β2 (11 nM) > α3β4 (47 nM) > α7 (61 nM) [Figure 3.2 and Table 3.1].
Figure 3.1: Concentration-dependent RegIIA inhibition of ACh-evoked current
amplitude mediated by (A) α3β2, (B) α3β4 and (C) α7 nAChRs expressed in oocytes.
85
Figure 3.2: Selectivity of α-conotoxin RegIIA inhibition of nAChR subtypes. RegIIA (1
µM) completely inhibited α3β2, α3β4 and α7 receptors, and inhibited the α9α10 receptor by
~20%. Concentration–response curves for RegIIA inhibition gave IC50 of 16 nM for α3β2
(●), 48 nM for α3β4 (▲) and 51 nM for α7 (□). All data represents mean ± SEM; n = 4–7.
Table 3.1: α-Conotoxin RegIIA inhibition of recombinant nAChR subunits expressed in Xenopus oocytes.
nAChR subtype IC50 (95% CI) nH α3β2 10.7 nM (8.8–12.9) –1.1 ± 0.1 α3β4 47.3 nM (39.5–56.6) –1.5 ± 0.2
α7 61.2 nM (47.8–78.4) –1.2 ± 0.2 α9α10 >1 µM α4β2 >1 µM αβδγ >1 µM
RegIIA (1 µM) had no effect on α4β2 or αβγδ, and inhibited α9α10 by only 20%. All data represents n = 4–7.
86
3.3.2 Directed peptide synthesis of α-conotoxin RegIIA analogues and NMR
α-Conotoxins have a conserved Cys-framework. Their three-dimensional structure is
dominated by a helical structure. In native α-conotoxins, I–III and II–IV disulfide connectivity
is dominant and folds the peptide into globular conformation [28, 29]. However, α-conotoxin
disulfide connectivity can change upon oxidation and reduction to form ribbon (I–IV and II–
III disulfide bonds) or beads (I–II and III–IV disulfide bonds). These conformations play
significant roles in potency and specificity of α-conotoxins at nAChRs [24, 30].
Under normal conditions of solid-phase peptide synthesis, the percentage of a peptide in a
single conformation varies, which can be undesirable. This problem was solved by using
amino acids with stable protective groups (Acm) under normal oxidative conditions
(0.1 M NH4HCO3, pH 8.2). The use of Cys-Acm amino acids at positions 1 and 3 and a two-
step oxidation procedure, yielded the alanine mutants in a globular conformation (I–III and
II–IV disulfide bonds), shown by HPLC. This was confirmed by 2D NMR (COSY and
NOESY), which showed the negative 1H shift values between the amino acids 3 and 7
positions and indicated the presence of α-helix secondary structure [Figure 3.3].
87
Figure 3.3: RegIIA and alanine analogues secondary αH shifts.
3.3.3 Inhibition of nAChR subtypes by α-conotoxin RegIIA analogues:
To understand the RegIIA structure–activity relationship at nAChRs, RegIIA analogues were
tested on α3β2, α3β4 and α7 nAChR subtypes at a concentration of 300 nM [Figure 3.4].
[H14A]RegIIA showed complete loss in activity at all of the above-mentioned nAChR
subtypes. At α7 nAChR subtype, no noticeable change was seen for [P13A]RegIIA inhibition,
whereas inhibition by all other analogues was significantly reduced or completely lost
[Figure 3.4(B)]. In contrast, no change in inhibition of the α3β4 nAChR subtype by RegIIA
analogues was observed except for [N9A]RegIIA which completely lost its activity at α3β4.
Furthermore, [N11A]RegIIA and [N12A]RegIIA selectivity for α3β4 nAChR subtypes
improved. Their inhibition of the α3β2 nAChR subtype was significantly reduced (by
approximately 50%), whereas no change was observed at α3β4 nAChR subtype [Figure
3.4(B)]. This was apparent in the concentration–response curves for [N11A]RegIIA and
88
[N12A]RegIIA, which showed the inhibition curve for the α3β2 (red line) nAChR subtype
shifted toward the right [Figure 3.5]. The IC50 values for [N11A]RegIIA and [N12A]RegIIA
at the α3β2 nAChR subtype was 115.9 nM (95% Cl 62.7 – 214.1; nH = –0.9 ± 0.22) and 278
nM (95% Cl 153.4 – 503.8; nH = –1.1 ± 0.25) respectively, and at the α3β4 nAChR subtype is
51.6 nM (95% Cl 44.2 – 60.1; nH = –2.0 ± 0.21) and 112 nM (95% Cl 92.1 – 136.2; nH = –1.7
± 0.32), respectively [Table 3.2].
Figure 3.4. RegIIA and alanine analogue (300 nM) inhibition of various nAChR
subtypes expressed in Xenopus oocytes. (A) Bar graph of inhibition of nAChR subtypes by
RegIIA and its analogues. Data represents mean ± SEM, n = 4–6. (B) Two-way ANOVA
scatter plot illustrating the loss of activity of the RegIIA analogues (300 nM) relative to wild-
type RegIIA at various nAChR subtypes. [H14A]RegIIA completely lost its activity at α3β2,
α3β4 and α7 nAChRs. [N9A]RegIIA was more selective for the α3β2 subtype than RegIIA
was. [N11A]RegIIA and [N12A]RegIIA selectivity for the α3β4 nAChR subtype significantly
improved. All analogues, except [P13A]RegIIA, significantly lost activity at the α7 nAChR
subtype. *** p < 0.001, * p < 0.05; n = 4–6.
89
Figure 3.5: [N11A]RegIIA and [N12A]RegIIA exhibiting improved selectivity at α3β4
nAChR subtypes (A) Superimposed traces showing ACh-evoked current inhibition of the
α3β2 nAChR subtype by 100 nM (i) RegIIA, (ii) [N11A]RegIIA and (iii) [N11A]RegIIA . (B)
Concentration–response curves for (ii) [N11A]RegIIA and (iii) [N12A]RegIIA inhibition of
the α3β4 nAChR (black line, open symbols) and α3β2 nAChR subtypes (red line, closed
symbols). [N11A]RegIIA and [N12A]RegIIA shifted the curve to the right for the α3β2 (red
line) nAChR subtype, giving an IC50 value of 116 nM and 278 nM, respectively. All data
represents mean ± SEM; n = 4–6.
90
Table 3.2: RegIIA and analogues inhibition of nAChR subtypes.
α3β4 α3β2 α7
IC50 (95% Cl) nH IC50 (95% Cl) nH IC50 (95% Cl) nH
RegIIA 47.3 nM (39.5–56.6) –1.5 ± 0.2
10.7 nM (8.8–12.9) –1.1 ± 0.1
61.2 nM (47.8–78.4) –1.2 ± 0.2
[N11A]RegIIA 51.6 nM (44.2–60.1) –2.0 ± 0.2
115.9 nM (62.7–214.1) –0.9 ± 0.2
ND –
[N12A]RegIIA 112 nM (92.1–136.2) –1.7 ± 0.3
278 nM (153.4–503.8) –1.1 ± 0.2
ND –
[N11A,N12A]RegIIA 370 nM (3.09–442.3) –1.7 ± 0.2
9.87 µM (7.9–12.4) –1.5 ± 0.3
21.5 µM (17.1–27.0) –3.1 ± 0.8
IC50 values with 95% Cl. and Hill slope (nH) obtained from concentration–response curves for RegIIA and analogues at α3β2, α3β4 and α7 nAChR subtypes. All data represent mean of n = 4–6 experiments. ND – not determined.
91
3.3.4 Double mutant [N11A,N12A]RegIIA selectively inhibits α3β4 nAChR subtype
Double mutant [N11A,N12A]RegIIA was synthesised to better understand the cumulative
effect of the two residues on nAChR activity. When tested, [N11A,N12A]RegIIA inhibited
the α3β4 nAChR subtype with an IC50 of 370 nM (95% Cl 3.09 – 442.3; nH = –1.7 ± 0.2) and
a 7-fold decrease in potency compared with RegIIA [Figure 3.6]. However, at the α3β2 and
α7 nAChR subtypes, potency decreased by approximately 1,000-fold (IC50 = 9.9 µM) and
360-fold (IC50 = 21.5 µM), respectively [Table 3.2]. This indicates an approximate 27-fold
change in selectivity at the α3β2 nAChR subtype, and an approximate 58-fold change at the
α7 nAChR subtype.
Figure 3.6: [N11A,N12A]RegIIA inhibition of α3β2 and α3β4 nAChR compared with
that of wild-type RegIIA. Concentration–response curve of [N11A,N12A]RegIIA gave an
IC50 of 370 nM at α3β4 (▲) and 9.9 µM at α3β2 (■), with an approximate 27-fold change
in selectivity. All data represents mean ± SEM; n = 4–6.
92
3.4 DISCUSSION
3.4.1 Conus regius: characterisation of novel α-conotoxin RegIIA
Since 1994, when the first α-conotoxin ImI was discovered in the worm-hunting Conus
imperialis and found to target neuronal nAChRs, numerous α-conotoxins have been
identified and functionally characterised [14, 31]. Most native α-conotoxins have a ω-shaped,
three-dimensional globular conformation, which results from the two disulfide bonds (I–III
and II–IV) in the peptide’s characteristic cysteine framework CCXnCXmC (classified as
cysteine framework I) [29]. The number of amino acids indicated by n and m designate the
subclass of the peptide. RegIIA belongs to the α4/7 subclass and exhibits the classical ω-
shaped globular structure, with balanced shape, charges and polarity.
Today, various peptides have been identified from the venom of C. regius, a Western Atlantic
worm-hunting cone snail species that belongs to various superfamilies, of which 8 belong to
the A-superfamily with the cysteine framework I [32]. The conotoxin composition of C.
regius venom gained special importance due to the identification of α-conotoxin RgIA, which
selectively targets the α9α10 nAChR subtype and high voltage-activated (HVA) calcium
channel currents via GABAB receptors [33]. α-Conotoxin RegIIA, also isolated from C.
regius, potently inhibits the α3β4 nAChR subtype [34]. HVA calcium channels modulated by
GABAB receptors are involved in pain pathways and the α3β4 nAChR subtype is implicated
in lung cancer pathophysiology. This makes the discovery of RgIA and RegIIA very
significant and puts them at the forefront of potential new therapeutics.
93
3.4.2 Alanine mutagenesis reveals the pharmacological role of the –NNP– motif in
RegIIA
RegIIA exhibits high homology to various known peptides [Table 3.8], with two main
features: an –SHPA– conserved sequence and –NNP– motif. While the –SHPA– conserved
sequence is observed in the peptides of different subclasses that target various nAChR
subtypes, the –NNP– motif has been specifically observed in peptides that inhibit α3β2 and
α7 nAChR subtypes, such as OmIA [35], EpI [36], PnIA [37], TxIA [38] and ArIB [39]. This
observation corroborates with the most important finding of this study – the alanine mutation
of the –NNP– motif significantly affected the peptide’s inhibitory activity at α3β2 and α7
nAChR subtypes. Additionally, the [N11A,N12A]RegIIA analogue is the most potent of the
α3β4 nAChR subtype-selective peptides.
Alanine mutations at other positions also provided vital information about the structure–
function relationship between α-conotoxins and neuronal nAChRs. Asparagine at the ninth
position is critical for RegIIA inhibition of the α7 and α3β4 nAChRs, because alanine
mutation of this residue completely abolished RegIIA inhibition of both nAChR subtypes.
3.4.3 Molecular modelling and molecular dynamics reveal structural topology of α3β2
and α3β4 nAChRs and residues that interact with RegIIA
To elucidate the molecular mechanism of RegIIA’s inhibition of the α3β4 nAChR subtype,
an alanine scan mutagenesis protocol was used. This technique is well established, and in
conjunction with atomistic molecular dynamics (MD) simulations, it has previously enabled
spectacular progress in the field of molecular pharmacology [26, 40]. X-ray and NMR studies
of AChBP–α-conotoxin complexes, and the support of synthetic analogues, promoted the
94
understanding of ligand–receptor interactions [41-44]. The extracellular N-terminal domain
(ECD) of β2 and β4 nAChR subunits, to which α-conotoxins bind, exhibited a high sequence
homology (70%). Recent MD simulation studies also reveal a well-preserved structural
topology of α3β2 and α3β4 nAChRs. However, the ACh-binding pocket interface between
the α and β subunits was larger in α3β2 than α3β4 nAChR subtypes [45]. This difference
could signify a distinct shift in [N11A] and [N12A]RegIIA selectivity for α3β2 and α3β4,
even though both of these residues primarily interact with the α3(+) interface.
To elucidate the structure–function relationship of the alanine scan mutagenesis results, our
collaborators carried out atomistic MD simulations of [N11A,N12A]RegIIA. The results
indicated that the double mutant induced a significant loss in contact Y92, S149, Y189, Y196
residues of the α3 subunit, and W57, and F119 residues of the β2 subunit induced by the
double mutant. A comprehensive receptor mutagenesis study of various α-conotoxins (MII,
GID and PnIA) that inhibit the α3β2 nAChR indicated that the β2 subunit pharmacophore,
comprised of T59, E61, V111, F119 and L121 residues, has a significant role in ligand
binding [46].
A more recent molecular docking study of α-conotoxin GIC and the ECD of human α3β2 and
α3β4 nAChR subtypes revealed that all three subunits have residues that interact with the
conotoxin (α3 subunit: Y92, Y150, Y189 and Y196; β2 subunit: W57, V111, F119 and L121;
β4 subunit: W57, I111, L119 (Q119 in rat β4) and L121). It is also interesting to note that the
α3Y196 and β2F119 residues of the α3β2-GIC model were more closely located than the
α3Y196 and β4L119 residues of the α3β4-GIC model [45]. These results are consistent with
the MD simulations displaying the loss of pairwise contacts between wt RegIIA and
[N11A,N12A]RegIIA at α3β2 compared to α3β4 nAChR subtypes. This study provides the
95
first experimental evidence into the molecular pharmacological difference between an α-
conotoxin and these two nAChR subtypes at structural and functional levels.
3.5 SUMMARY AND CONCLUSION
The CHRNA3, CHRNB4 and CHRNA5 gene clusters encoding the α3, β4 and α5 nAChR
subunits gained significant importance in recent years. This may be due to the recent genetic
and physiological studies implicating that the α3β4 nAChR has a direct functional role in the
pathophysiology of lung cancer and nicotine addiction [9, 12]. While the α3β4 nAChR was
initially identified in ganglia, recent studies show it is also distributed throughout the CNS
and other tissues, such as the interpeduncular nucleus and medial habenula [47, 48].
Identifying and successfully synthesising [N11A,N12A]RegIIA, a α3β4 nAChR subtype-
selective antagonist, could help to decipher the physiological role of this receptor. Our study
also extends the understanding of RegIIA interactions with various nAChR subtypes and
elucidated the key residues on the toxin and receptor binding sites. This information is
invaluable in the design and development of α3β4-selective drugs to treat lung cancer and
nicotine addiction.
96
Table 3.3: Sequence alignment of α-conotoxins targeting various nAChR subtypes.
α-Conotoxin Sequence nAChR selectivity IC50 for α3β4 nAChR inhibition Reference
RegIIA GCCSHPACNVNNPHIC* α3β2>α3β4> α7 50 nM [34]
OmIA GCCSHPACNVNNPHICG* α3β2>α7>α6β2 - [49]
GIC GCCSHPACAGNNQHIC* α3β2≈α6β2>α7 - [50]
PeIA GCCSHPACSVNHPELC* α9α10>α3β2>α6β2*>α3β4>α7 480 nM [51]
Mr1.1 GCCSHPACSVNNPDIC* α3β2>α3β4>α7 1400 nM [52]
Ls1a SGCCSNPACRVNNPNIC* α3β2>α7 - [53]
AuIB GCCSYPPCFATNPD-C* α3β4 2500 nM [54]
BuIA GCCSTPPCAVLY---C* β2*>β4* 28 nM [55]
PIA RDPCCSNPVCTVHNPQIC* α6β2*>α6β4≈α3β2>α3β4 520 nM [56]
ArIB DECCSNPACRVNNPHVCRRR* α7≈α6β2*>α3β2 - [57]
Amino acids homologous to RegIIA are labelled with grey background. Peptides inhibiting the α3β4 nAChR subtype (orange) and their
corresponding IC50 values are shown. The conserved cysteine framework is highlighted in yellow.
97
3.6 References
1. Albuquerque, E. X., Pereira, E. F., Castro, N. G., Alkondon, M., Reinhardt, S.,
Schroder, H., and Maelicke, A. (1995) Nicotinic receptor function in the mammalian
central nervous system, Annals of the New York Academy of Sciences 757, 48-72.
2. Dani, J. A., and Bertrand, D. (2007) Nicotinic acetylcholine receptors and nicotinic
cholinergic mechanisms of the central nervous system, Annual review of
pharmacology and toxicology 47, 699-729.
3. Gotti, C., and Clementi, F. (2004) Neuronal nicotinic receptors: from structure to
pathology, Progress in neurobiology 74, 363-396.
4. McGehee, D. S., Heath, M. J., Gelber, S., Devay, P., and Role, L. W. (1995) Nicotine
enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors,
Science 269, 1692-1696.
5. Yu, R., Kompella, S. N., Adams, D. J., Craik, D. J., and Kaas, Q. (2013)
Determination of the alpha-conotoxin Vc1.1 binding site on the alpha9alpha10
nicotinic acetylcholine receptor, Journal of medicinal chemistry 56, 3557-3567.
6. Steen, K. H., and Reeh, P. W. (1993) Actions of cholinergic agonists and antagonists
on sensory nerve endings in rat skin, in vitro, Journal of neurophysiology 70, 397-405.
7. Albuquerque, E. X., Pereira, E. F., Alkondon, M., and Rogers, S. W. (2009)
Mammalian nicotinic acetylcholine receptors: from structure to function,
Physiological reviews 89, 73-120.
8. Schuller, H. M. (1989) Cell type specific, receptor-mediated modulation of growth
kinetics in human lung cancer cell lines by nicotine and tobacco-related nitrosamines,
Biochemical pharmacology 38, 3439-3442.
98
9. Thunnissen, F. B. (2009) Acetylcholine receptor pathway and lung cancer, Journal of
thoracic oncology : official publication of the International Association for the Study
of Lung Cancer 4, 943-946.
10. Maneckjee, R., and Minna, J. D. (1990) Opioid and nicotine receptors affect growth
regulation of human lung cancer cell lines, Proceedings of the National Academy of
Sciences of the United States of America 87, 3294-3298.
11. Schuller, H. M., and Orloff, M. (1998) Tobacco-specific carcinogenic nitrosamines.
Ligands for nicotinic acetylcholine receptors in human lung cancer cells, Biochemical
pharmacology 55, 1377-1384.
12. Improgo, M. R., Scofield, M. D., Tapper, A. R., and Gardner, P. D. (2010) The
nicotinic acetylcholine receptor CHRNA5/A3/B4 gene cluster: dual role in nicotine
addiction and lung cancer, Progress in neurobiology 92, 212-226.
13. Spitz, M. R., Amos, C. I., Dong, Q., Lin, J., and Wu, X. (2008) The CHRNA5-A3
region on chromosome 15q24-25.1 is a risk factor both for nicotine dependence and
for lung cancer, Journal of the National Cancer Institute 100, 1552-1556.
14. Azam, L., and McIntosh, J. M. (2009) Alpha-conotoxins as pharmacological probes of
nicotinic acetylcholine receptors, Acta pharmacologica Sinica 30, 771-783.
15. Knapp, O., McArthur, J. R., and Adams, D. J. (2012) Conotoxins targeting neuronal
voltage-gated sodium channel subtypes: potential analgesics?, Toxins 4, 1236-1260.
16. McIntosh, J. M., Santos, A. D., and Olivera, B. M. (1999) Conus peptides targeted to
specific nicotinic acetylcholine receptor subtypes, Annual review of biochemistry 68,
59-88.
17. Dutton, J. L., and Craik, D. J. (2001) alpha-Conotoxins: nicotinic acetylcholine
receptor antagonists as pharmacological tools and potential drug leads, Current
medicinal chemistry 8, 327-344.
99
18. Changeux, J. P., Kasai, M., Huchet, M., and Meunier, J. C. (1970) [Extraction from
electric tissue of gymnotus of a protein presenting several typical properties
characteristic of the physiological receptor of acetylcholine], Comptes rendus
hebdomadaires des seances de l'Academie des sciences. Serie D: Sciences naturelles
270, 2864-2867.
19. Unwin, N. (2005) Refined structure of the nicotinic acetylcholine receptor at 4A
resolution, Journal of molecular biology 346, 967-989.
20. Hibbs, R. E., and Gouaux, E. (2011) Principles of activation and permeation in an
anion-selective Cys-loop receptor, Nature 474, 54-60.
21. Conti-Fine, B. M., Navaneetham, D., Lei, S., and Maus, A. D. (2000) Neuronal
nicotinic receptors in non-neuronal cells: new mediators of tobacco toxicity?,
European journal of pharmacology 393, 279-294.
22. van Nierop, P., Keramidas, A., Bertrand, S., van Minnen, J., Gouwenberg, Y.,
Bertrand, D., and Smit, A. B. (2005) Identification of molluscan nicotinic
acetylcholine receptor (nAChR) subunits involved in formation of cation- and anion-
selective nAChRs, The Journal of neuroscience : the official journal of the Society for
Neuroscience 25, 10617-10626.
23. Ellison, M., McIntosh, J. M., and Olivera, B. M. (2003) Alpha-conotoxins ImI and
ImII. Similar alpha 7 nicotinic receptor antagonists act at different sites, The Journal
of biological chemistry 278, 757-764.
24. Cartier, G. E., Yoshikami, D., Gray, W. R., Luo, S., Olivera, B. M., and McIntosh, J.
M. (1996) A new alpha-conotoxin which targets alpha3beta2 nicotinic acetylcholine
receptors, The Journal of biological chemistry 271, 7522-7528.
25. Inserra, M. C., Kompella, S. N., Vetter, I., Brust, A., Daly, N. L., Cuny, H., Craik, D.
J., Alewood, P. F., Adams, D. J., and Lewis, R. J. (2013) Isolation and
100
characterization of alpha-conotoxin LsIA with potent activity at nicotinic
acetylcholine receptors, Biochemical pharmacology.
26. Halai, R., Clark, R. J., Nevin, S. T., Jensen, J. E., Adams, D. J., and Craik, D. J. (2009)
Scanning mutagenesis of alpha-conotoxin Vc1.1 reveals residues crucial for activity at
the alpha9alpha10 nicotinic acetylcholine receptor, The Journal of biological
chemistry 284, 20275-20284.
27. Kawashima, K., and Fujii, T. (2003) The lymphocytic cholinergic system and its
contribution to the regulation of immune activity, Life sciences 74, 675-696.
28. Millard, E. L., Daly, N. L., and Craik, D. J. (2004) Structure-activity relationships of
alpha-conotoxins targeting neuronal nicotinic acetylcholine receptors, European
journal of biochemistry / FEBS 271, 2320-2326.
29. Daly, N. L., and Craik, D. J. (2009) Structural studies of conotoxins, IUBMB life 61,
144-150.
30. Dutton, J. L., Bansal, P. S., Hogg, R. C., Adams, D. J., Alewood, P. F., and Craik, D.
J. (2002) A new level of conotoxin diversity, a non-native disulfide bond connectivity
in alpha-conotoxin AuIB reduces structural definition but increases biological activity,
The Journal of biological chemistry 277, 48849-48857.
31. McIntosh, J. M., Yoshikami, D., Mahe, E., Nielsen, D. B., Rivier, J. E., Gray, W. R.,
and Olivera, B. M. (1994) A nicotinic acetylcholine receptor ligand of unique
specificity, alpha-conotoxin ImI, The Journal of biological chemistry 269, 16733-
16739.
32. Braga, M. C., Nery, A. A., Ulrich, H., Konno, K., Sciani, J. M., and Pimenta, D. C.
(2013) alpha -RgIB: A Novel Antagonist Peptide of Neuronal Acetylcholine Receptor
Isolated from Conus regius Venom, International journal of peptides 2013, 543028.
101
33. Witzemann, V., Barg, B., Nishikawa, Y., Sakmann, B., and Numa, S. (1987)
Differential regulation of muscle acetylcholine receptor gamma- and epsilon-subunit
mRNAs, FEBS letters 223, 104-112.
34. Franco, A., Kompella, S. N., Akondi, K. B., Melaun, C., Daly, N. L., Luetje, C. W.,
Alewood, P. F., Craik, D. J., Adams, D. J., and Mari, F. (2012) RegIIA: an alpha4/7-
conotoxin from the venom of Conus regius that potently blocks alpha3beta4 nAChRs,
Biochemical pharmacology 83, 419-426.
35. Criado, M., Valor, L. M., Mulet, J., Gerber, S., Sala, S., and Sala, F. (2012)
Expression and functional properties of alpha7 acetylcholine nicotinic receptors are
modified in the presence of other receptor subunits, Journal of neurochemistry 123,
504-514.
36. Castelan, F., Mulet, J., Aldea, M., Sala, S., Sala, F., and Criado, M. (2007)
Cytoplasmic regions adjacent to the M3 and M4 transmembrane segments influence
expression and function of alpha7 nicotinic acetylcholine receptors. A study with
single amino acid mutants, Journal of neurochemistry 100, 406-415.
37. Couturier, S., Bertrand, D., Matter, J. M., Hernandez, M. C., Bertrand, S., Millar, N.,
Valera, S., Barkas, T., and Ballivet, M. (1990) A neuronal nicotinic acetylcholine
receptor subunit (alpha 7) is developmentally regulated and forms a homo-oligomeric
channel blocked by alpha-BTX, Neuron 5, 847-856.
38. Corringer, P. J., Galzi, J. L., Eisele, J. L., Bertrand, S., Changeux, J. P., and Bertrand,
D. (1995) Identification of a new component of the agonist binding site of the
nicotinic alpha 7 homooligomeric receptor, The Journal of biological chemistry 270,
11749-11752.
39. Bertrand, D., and Changeux, J. P. (1995) Nicotinic Receptor - an Allosteric Protein
Specialized for Intercellular Communication, Semin Neurosci 7, 75-90.
102
40. Hogg, R. C., Miranda, L. P., Craik, D. J., Lewis, R. J., Alewood, P. F., and Adams, D.
J. (1999) Single amino acid substitutions in alpha-conotoxin PnIA shift selectivity for
subtypes of the mammalian neuronal nicotinic acetylcholine receptor, The Journal of
biological chemistry 274, 36559-36564.
41. Weill, C. L., McNamee, M. G., and Karlin, A. (1974) Affinity-labeling of purified
acetylcholine receptor from Torpedo californica, Biochemical and biophysical
research communications 61, 997-1003.
42. Galzi, J. L., Revah, F., Black, D., Goeldner, M., Hirth, C., and Changeux, J. P. (1990)
Identification of a novel amino acid alpha-tyrosine 93 within the cholinergic ligands-
binding sites of the acetylcholine receptor by photoaffinity labeling. Additional
evidence for a three-loop model of the cholinergic ligands-binding sites, The Journal
of biological chemistry 265, 10430-10437.
43. Dellisanti, C. D., Yao, Y., Stroud, J. C., Wang, Z. Z., and Chen, L. (2007) Crystal
structure of the extracellular domain of nAChR alpha1 bound to alpha-bungarotoxin at
1.94 A resolution, Nature neuroscience 10, 953-962.
44. Ulens, C., Hogg, R. C., Celie, P. H., Bertrand, D., Tsetlin, V., Smit, A. B., and Sixma,
T. K. (2006) Structural determinants of selective alpha-conotoxin binding to a
nicotinic acetylcholine receptor homolog AChBP, Proceedings of the National
Academy of Sciences of the United States of America 103, 3615-3620.
45. Lee, C., Lee, S. H., Kim, D. H., and Han, K. H. (2012) Molecular docking study on
the alpha3beta2 neuronal nicotinic acetylcholine receptor complexed with alpha-
conotoxin GIC, BMB reports 45, 275-280.
46. Changeux, J. P., Galzi, J. L., Devillers-Thiery, A., and Bertrand, D. (1992) The
functional architecture of the acetylcholine nicotinic receptor explored by affinity
labelling and site-directed mutagenesis, Quarterly reviews of biophysics 25, 395-432.
103
47. Perry, D. C., Xiao, Y., Nguyen, H. N., Musachio, J. L., Davila-Garcia, M. I., and
Kellar, K. J. (2002) Measuring nicotinic receptors with characteristics of alpha4beta2,
alpha3beta2 and alpha3beta4 subtypes in rat tissues by autoradiography, Journal of
neurochemistry 82, 468-481.
48. McCallum, S. E., Cowe, M. A., Lewis, S. W., and Glick, S. D. (2012) alpha3beta4
nicotinic acetylcholine receptors in the medial habenula modulate the mesolimbic
dopaminergic response to acute nicotine in vivo, Neuropharmacology 63, 434-440.
49. Talley, T. T., Olivera, B. M., Han, K. H., Christensen, S. B., Dowell, C., Tsigelny, I.,
Ho, K. Y., Taylor, P., and McIntosh, J. M. (2006) Alpha-conotoxin OmIA is a potent
ligand for the acetylcholine-binding protein as well as alpha3beta2 and alpha7
nicotinic acetylcholine receptors, The Journal of biological chemistry 281, 24678-
24686.
50. McIntosh, J. M., Dowell, C., Watkins, M., Garrett, J. E., Yoshikami, D., and Olivera,
B. M. (2002) Alpha-conotoxin GIC from Conus geographus, a novel peptide
antagonist of nicotinic acetylcholine receptors, The Journal of biological chemistry
277, 33610-33615.
51. McIntosh, J. M., Plazas, P. V., Watkins, M., Gomez-Casati, M. E., Olivera, B. M., and
Elgoyhen, A. B. (2005) A novel alpha-conotoxin, PeIA, cloned from Conus
pergrandis, discriminates between rat alpha9alpha10 and alpha7 nicotinic cholinergic
receptors, The Journal of biological chemistry 280, 30107-30112.
52. Peng, C., Chen, W., Sanders, T., Chew, G., Liu, J., Hawrot, E., and Chi, C. (2010)
Chemical synthesis and characterization of two alpha4/7-conotoxins, Acta biochimica
et biophysica Sinica 42, 745-753.
53. Inserra, M. C., Kompella, S. N., Vetter, I., Brust, A., Daly, N. L., Cuny, H., Craik, D.
J., Alewood, P. F., Adams, D. J., and Lewis, R. J. (2013) Isolation and
104
characterization of alpha-conotoxin LsIA with potent activity at nicotinic
acetylcholine receptors, Biochemical pharmacology 86, 791-799.
54. Luo, S., Kulak, J. M., Cartier, G. E., Jacobsen, R. B., Yoshikami, D., Olivera, B. M.,
and McIntosh, J. M. (1998) alpha-conotoxin AuIB selectively blocks alpha3 beta4
nicotinic acetylcholine receptors and nicotine-evoked norepinephrine release, The
Journal of neuroscience : the official journal of the Society for Neuroscience 18,
8571-8579.
55. Azam, L., Dowell, C., Watkins, M., Stitzel, J. A., Olivera, B. M., and McIntosh, J. M.
(2005) Alpha-conotoxin BuIA, a novel peptide from Conus bullatus, distinguishes
among neuronal nicotinic acetylcholine receptors, The Journal of biological chemistry
280, 80-87.
56. Dowell, C., Olivera, B. M., Garrett, J. E., Staheli, S. T., Watkins, M., Kuryatov, A.,
Yoshikami, D., Lindstrom, J. M., and McIntosh, J. M. (2003) Alpha-conotoxin PIA is
selective for alpha6 subunit-containing nicotinic acetylcholine receptors, The Journal
of neuroscience : the official journal of the Society for Neuroscience 23, 8445-8452.
57. Whiteaker, P., Christensen, S., Yoshikami, D., Dowell, C., Watkins, M., Gulyas, J.,
Rivier, J., Olivera, B. M., and McIntosh, J. M. (2007) Discovery, synthesis, and
structure activity of a highly selective alpha7 nicotinic acetylcholine receptor
antagonist, Biochemistry 46, 6628-6638.
105
CHAPTER 4
Characterisation of LsIA:
First α-conotoxin isolated from Conus limpusi
Conus limpusi
106
4.1 INTRODUCTION
α-Conotoxins are a class of bioactive peptides isolated from the venom of cone snails
belonging to the genus Conus. They inhibit various nAChR subtypes with a high degree of
specificity and potency. This unique pharmacological profile has led to the development of α-
conotoxins as novel molecular probes for the physiological study of nAChR subtypes and
drugs to treat various pathological conditions involving cholinergic mechanisms of action [1].
The pharmacological profile of an α-conotoxin is determined by the peptide’s structure and
sequence. α-Conotoxins of the α4/7 and α4/3 subclass, defined by their characteristic cysteine
framework, inhibit neuronal nAChR subtypes almost exclusively [2].
nAChRs are pentameric transmembrane ion channels. They are constituted by various nAChR
subunits, which classifies them into homomeric receptors, such as α7 or α9, or heteromeric
receptors, such as α4β2 or α3β2 [3]. nAChRs primarily mediate fast synaptic transmissions in
the CNS and PNS. They also modulate cholinergic transmission in non-neuronal cells,
mediating subtype-specific physiological functions [4].
α3β2 and α7 nAChR subtypes play vital roles in various functions, such as neuronal plasticity,
angiogenesis and gene regulation [5]. They also are involved in various pathophysiological
conditions, such as schizophrenia, Alzheimer’s disease and myasthenia gravis [6].
Here I describe the pharmacological properties of the novel α-conotoxin LsIA, the first
peptide isolated from Conus limpusi, a species of worm-hunting cone snail commonly found
on the south east coast of Queensland, Australia. LsIA is an α4/7-conotoxin with the
characteristic I–III and II–IV disulfide connectivity. LsIA exhibited selective and potent α7
and α3β2 nAChR subtype antagonism. In this report, I also examined the structure–function
relationship of the presence of a unique N-terminal serine at position 2 and C-terminal
107
carboxylation. Furthermore, I also investigated the pharmacological implications, involving
incorporation of the α5 subunit towards the inhibition of LsIA at α3β2 nAChR subtypes.
4.2 AIMS
4.2.1 Characterisation of LsIA.
To functionally characterise LsIA – the first α-conotoxin isolated from
Conus limpusi.
To identify the role the N-terminal sequence and C-terminal carboxylation
play towards the pharmacological profile of LsIA.
4.2.2 Significance
To identify and understand the pharmacological profile of novel α-
conotoxins at nAChR.
To understand the structure–functional relationship of unique α-conotoxin
features.
To understand the functional implication of α5 subunit in conotoxin
pharmacology.
108
4.3 RESULTS
4.3.1 LsIA inhibition of recombinant nAChR subtypes
I determined LsIA potency and selectivity at neuronal nAChRs by examining its effect on
ACh-evoked currents mediated by different nAChR subunit combinations expressed in
Xenopus oocytes. ACh was applied every 5 min and ACh-evoked membrane currents were
assessed. LsIA (1 µM) completely inhibited ACh-evoked current amplitude mediated by α7,
α3β2 and α3α5β2 nAChR subtypes. However, LsIA (3 µM) inhibited α3β4 nAChR-mediated
currents by only 40 ± 5% (n = 6) and had no effect on α9α10 and α4-containing nAChR
subtypes (n = 4–8) [Figure 4.1].
500 nA
500 ms
α7ACh
α3β2ACh
300 nA
2 s
100 nA
1 s
AChα3α5β2
30 nM
10 nM
Control
30 nM
10 nM
Control
3 nM
100 nM
30 nM
Control
10 nM
A
-10 -9 -8 -7 -6 -5
0.0
0.2
0.4
0.6
0.8
1.0
1.2α3β2
α7
α3β4α4β2α4β4
α9α10
α3α5β2
[LsIA] (M)
Rela
tive
Cur
rent
Am
plitu
de
B
Figure 4.1: α-Conotoxin LsIA selectivity for various nAChR subunit combinations
expressed in Xenopus oocytes. (A) Superimposed traces of ACh-evoked currents in the
absence (control) and presence of various LsIA concentrations at α7, α3β2 and α3α5β2
nAChR subtypes. (B) Concentration–response curves for LsIA inhibition of different nAChR
subtypes gave IC50 values of 10.3 nM (95% CI, 8.8–12.1 nM; nH = –1.3 ± 0.1) at α3β2; 31.2
nM (95% CI, 26.1–37.3 nM; nH = –1.1 ± 0.1) at α3α5β2; and 10.1 nM (95% CI, 8.7–11.6 nM;
nH = –2.1 ± 0.4) at α7 subtypes. LsIA (1 µM) completely inhibited ACh-evoked currents
mediated by α3β2, α3α5β2 and α7 nAChRs. Data represents mean ± SEM, n = 3–6.
109
LsIA reversibly inhibited α3α5β2 about three times less potently (IC50 = 31.2 nM) than it did
the α3β2 subtype (IC50 = 10.3 nM). α5 subunit expression was confirmed by desensitisation
experiments described in the Material and methods section. As shown in a previous study [7],
the time course response of the α3α5β2 nAChR subtype showed notably faster desensitisation
of ACh-evoked currents compared with those of the α3β2 nAChR subtype [Figure 4.2 Inset].
Concentration–response curves for LsIA inhibition of ACh-evoked currents at different
nAChR subtypes and their corresponding IC50 value exhibit the following selectivity
sequence: α7 (10.1 nM) ≅ α3β2 (10.3 nM) > α3α5β2 (31.2 nM) [Figure 4.1].
The on- and off-rates (kon and koff) for nAChR inhibition by the peptide were obtained from
the time course of responses in the presence and upon washout of the peptide [Figure 4.2 and
4.3 and Table 4.1]. LsIA (10 nM) recovered more slowly from block at the α7 nAChR
subtype than at the α3β2 and α3α5β2 nAChR subtypes, giving a ki of 1.47 x 10-9 M [Figure
4.3 and Table 4.1]. This ki value is 6.8-fold lower than IC50. A similar trend was observed at
the α3α5β2 subtype, which had a ki value 3.3-fold lower than IC50 [Table 4.1].
110
Time (min)
Rela
tive
Inhi
bitio
n
0 1 2 3 4 5 6 7 8 9 10 11 12 13
0.0
0.2
0.4
0.6
0.8
1.0LsIA Washout
A
200 nA
30 s
ACh
α3β2
Time (min)
Rel
ativ
e In
hibi
tion
0 1 2 3 4 5 6 7 8 9 10
0.0
0.2
0.4
0.6
0.8
1.0LsIA washout
B
200 nA
30 s
ACh
α3α5β2
Figure 4.2: Kinetics of LsIA inhibition of peak ACh-evoked current amplitude as a
function of time. Onset (filled bar) of LsIA (30 nM) block and recovery (open bar) upon
washout at α3β2 (A) and α3α5β2 (B) nAChR subtypes. Inset: Representative ACh (50 µM)-
evoked currents in oocytes expressing (A) α3β2 and (B) α3α5β2 nAChR subtypes.
111
Time (min)
Rela
tive I
nhib
ition
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 180.0
0.2
0.4
0.6
0.8
1.0LsIA Washout
B α7
Figure 4.3: Kinetics of α-conotoxin LsIA block and recovery at the α7 nAChR subtype.
(A) Representative ACh-evoked currents in the absence and presence of LsIA in oocytes
expressing α7 nAChR. LsIA (10 nM) was bath applied for 5 min before washout. Responses
to a 1-s pulse of ACh (200 µM) and toxin for on-rate, and ACh alone for off-rate, kinetics was
measured at various time intervals. C is the ACh control response before the toxin was
applied. (B) LsIA inhibition of peak ACh-evoked current amplitude as a function of time.
Onset (filled bar) of block by LsIA (10 nM) and recovery (open bar) upon washout at the α7
nAChR subtype.
112
Table 4.1: α-Conotoxin LsIA’s kinetic constants for blocking nAChR subtypesa.
kon (min–1 M–1) koff (min–1) ki (M) IC50 (M)
α3β2 6.93 (4.99–8.87) x 107 1.052 (0.910–1.194) 15.2 x 10–9 10.3 x 10–9
α3α5β2 1.26 (0.28–2.24) x 108 1.205 (0.766–1.644) 9.6 x 10–9 31.2 x 10–9
α7 1.35 (1.17–1.53) x 108 0.199 (0.182–0.215) 1.47 x 10–9 10.1 x 10–9
a Numbers in parentheses are 95% CI. Mean of data from n = 6–8 experiments.
113
4.3.2 Influence of C-terminal carboxylation and N-terminal truncation of LsIA
Conotoxins typically have a high degree of post-translational modification [8, 9], with
C-terminal amidation shown to influence structure and enhance target specificity [9].
Native α-conotoxin LsIA also undergoes C-terminal amidation. Our collaborators
synthesised a C-terminally carboxylated analogue of LsIA (LsIA#) to examine its
activity at different nAChR subtypes. Interestingly, LsIA# was ~ three-times less
potent at the α7 subtype and ~ three-fold more potent at the α3β2 subtype [Figure
4.4].
α7 nAChR
-9 -8 -7 -6
0.0
0.2
0.4
0.6
0.8
1.0
1.2 LsIA#LsIA[∆1]LsIA[∆1-2]LsIA
[Peptide] (M)
Rela
tive
Cur
rent
Am
plitu
de
α3β2 nAChR
-10 -9 -8 -7 -6 -5
0.0
0.2
0.4
0.6
0.8
1.0
1.2
LsIALsIA#
[∆1]LsIA[∆1-2]LsIA
[Peptide] (M)
Rela
tive
Cur
rent
Am
plitu
deA B
Figure 4.4: Influence of N-terminus truncation and C-terminus carboxylation of
LsIA on ACh-evoked current inhibition at the α7 (A) and α3β2 (B) nAChR
subtypes. Concentration–response curves for LsIA#, [∆1]LsIA and [∆1–2]LsIA
inhibition gave IC50 values of 30.7 nM (95% CI, 21.7–43.4 nM; nH = –1.5 ± 0.4), 23
nM (95% CI, 19.3–27.5 nM; nH = –2.0 ± 0.3) and 44.1 nM (95% CI, 37.1–52.4 nM;
nH = –2.5 ± 0.4) at α7, respectively; and 3.3 nM (95% CI, 2.2–5.1 nM; nH
= –1.0 ±
0.2), 56.2 nM (95% CI, 40.4–78.2 nM; nH = –1.0 ± 0.2) and 92.4 nM (95% CI, 69.3–
123.3 nM; nH = –0.9 ± 0.1) at α3β2, respectively. The broken line represents the
carboxylated LsIA (LsIA#) concentration–response curve. Data represents means ±
SEM, n = 4–7.
114
α-Conotoxin LsIA contains a unique N-terminal serine residue. Truncation of the four
residue N-terminal tail of α-GID has been shown to influence activity at neuronal
nAChRs [10]. Our collaborators synthesised two truncated analogues, [∆1]LsIA
(lacking the serine at position 1) and [∆1-2]LsIA (lacking the serine at position 1 and
glycine at position 2). [∆1]LsIA- and [∆1-2]LsIA-amidated peptides were two-fold
and four-fold less potent at the α7 subtype than LsIA, respectively [Figure 4.4 and
Table 4.2]. They were also five-fold and nine-fold less potent at the α3β2 subtype
than LsIA, respectively [Figure 4.4 and Table 4.2]. These results indicate that the N-
terminal sequence plays a major role in LsIA potency.
Table 4.2: Half-maximal inhibitory concentrations (IC50) and Hill slope (nH)
values from concentration–response curves for LsIA and its analogues at the
α3β2 and α7 nAChR subtypesa.
α3β2 α7 Peptide IC50 (nM) nH IC50 (nM) nH
LsIA 10.3 (8.8–12.1) –1.3 ± 0.1
10.1 (8.7–11.6) –2.1 ± 0.4
[∆1] LsIA 56.2 (40.4–78.2) –1.0 ± 0.2
23 (19.3–27.5) –2.0 ± 0.4
[∆1–2] LsIA 92.4 (69.3–123.3) –0.9 ± 0.1
44.1 (37.1–52.4) –2.5 ± 0.3
LsIA# 3.3 (2.2–5.1) –1.0 ± 0.2 30.7 (21.7–43.4) –1.5 ± 0.4 a Numbers in parentheses are 95% CI. Mean of data from n = 5–8 experiments.
115
4.4 DISCUSSION
α-Conotoxins evolved as selective probes that target nicotinic receptors, parallel with the
phylogenetic evolution of marine cone snails belonging to the genus Conus. This corresponds
with the structural similarities between various conotoxins, including conserved cysteine
framework and residues. The cysteine framework of α-conotoxins (CC-C-C) divides the
peptide sequence into two loops, from which they are classified into various subclasses. A
high-sequence homology or conserved residues are observed across various α-conotoxins
[Table 4.3].
Table 4.3: Sequence alignment of LsIA and α-conotoxins.
α-Conotoxin Sequence nAChR selectivity Reference
Ls1a SGCCSNPACRVNNPNIC* α3β2≈α7>α3α5β2 This study GID IRDγCCSNPACRVNNOHVC# α7≈α3β2>α4β2 [10] ArIA IRDECCSNPACRVNNOHVCRRR# α7>α3β2 [11] ArIB DECCSNPACRVNNPHVCRRR# α7≈α6β2*>α3β2 [11] MII GCCSNPVCHLEHSNLC* α3β2≈α6β2*>α6β4 [12] RegIIA GCCSHPACNVNNPHIC* α3β2>α3β4> α7 [13] OmIA GCCSHPACNVNNPHICG* α3β2>α7>α6β2* [14] GIC GCCSHPACAGNNQHIC* α3β2≈α6β2*>α7 [15] Mr1.1 GCCSHPACSVNNPDIC* α3β2>α3β4>α7 [16] PnIA GCCSLPPCAANNPDYC* α3β2>α7 [17] AuIB GCCSYPPCFATNPD-C* α3β4 [18] BuIA GCCSTPPCAVLY---C* β2*>β4* [19] RgIA GCCSDPRCRYR----CR# α9α10>>α7 [20]
* denotes an amidated C-terminus; #, free carboxyl C-terminus; γ, γ-carboxyglutamate. Cysteine residues are highlighted yellow. Residues homologous to LsIA are highlighted grey.
Previous studies that aimed to understand the molecular interactions involved in α-conotoxin
subtype-selective antagonism of nAChRs used X-ray studies of co-crystal AChBP and ImI
structures, [A10L,D14K]PnIA and [A10L]TxIA. They revealed significant interaction
between loop 1 (residues between Cys II and III) and the principal face of the receptor [21,
22]. The loop 2 residues of the peptide were shown to majorly interact with the
complementary side of the receptor. These studies identified the general role of loop1 in
116
peptide affinity, while loop2 contributes to the subtype selectivity of the α-conotoxin. Also,
structurally, loop1 plays a vital role in the secondary structure of the peptide (presence of α-
helix). NMR studies revealed significant disruption of the peptide’s classic ω-globular
structure upon mutagenesis [23]. This was also indicated through the presence of conserved
residues within loop1 of various subclasses of α-conotoxins [Table 4.3]. AChBP co-crystal
studies also showed significant hydrogen bonding and van der Waals interactions between the
Ser-, Pro- and Gly-conserved residues of loop1 in almost all α-conotoxins and the receptor
binding pocket [21].
α-Conotoxin LsIA is a new peptide isolated from C. limpusi that potently inhibits nAChRs. It
is an α4/7 conotoxin and exhibits equipotent inhibition at α3β2 and α7 subtypes. Pairwise
sequence alignment shows strong homology between LsIA and previously characterised α-
conotoxins that target the α3β2 and α7 nAChR subtypes.
LsIA exhibits two sequence motifs, namely –SXPA– and –NNP–. These motifs are also found
among OmIA, RegIIA, Mr1.1 and ArIB conotoxins, which have a similar pharmacological
profile to LsIA [Table 4.3]. The structural and functional significance of the –SXPA– motif
within loop1 of conotoxins was discussed earlier.
Mutation of Ser and Pro residues to Ala in α-conotoxin GID led to significant activity loss at
α7 and α7/α3β2 nAChR subtypes, respectively [24]. A similar interaction between LsIA and
α7 and α3β2 nAChR subtypes is expected.
Along with conserved motifs, LsIA exhibits a unique N-terminal Ser residue. In this study, I
examined the functional implication of the N-terminal sequence, including the most common
post-transcriptional modification found in the α-conotoxins: C-terminal amidation. The
117
influence of the N-terminal sequence was previously examined in α-conotoxin GID. Initial
studies with [∆1-4]GID showed significant activity loss at the α4β2 nAChR subtype, but no
change in IC50 was observed at α7 and α3β2 nAChR subtypes [10]. Interestingly, a noticeable
loss in activity at α7 and α3β2 subtypes was observed when the first three residues were
deleted ([∆1-3]GID). However, [∆1] and [∆1-2]GID truncation only affected α3β2 inhibition
[24].
A similar trend was observed in LsIA, where truncation of first and second residues lead to
considerable loss in activity at the α7 and α3β2 nAChR subtypes [Figure 4.4 and Table 4.2].
This activity loss was more prominent at the α3β2 subtype, with ~5-fold reduction, than at the
α7 subtype, which only showed ~2-fold less activity, with [∆1]LsIA. This effect was further
amplified for [∆1-2]LsIA, which triggered ~9-fold and ~4-fold activity loss at α3β2 and α7
nAChR subtypes, respectively. Surprisingly, the most striking effect on peptide function was
observed when the C-terminus was carboxylated (LsIA#). This modification led to a ~3-fold
increase in potency at the α3β2 nAChR subtype, but caused an opposite effect at the α7
nAChR subtype, with a ~3-fold activity loss.
In α-conotoxin GID, C-terminus carboxylation only influenced peptide activity at the α3β2
nAChR subtype [24]. One explanation for this is the formation of intra-molecular salt bridges
or hydrogen bonds when the free C-terminus carboxyl group is incorporated into LsIA.
In this study, I report a difference in pharmacological activity of LsIA at α5-containing
nAChRs, with LsIA being 3-fold less potent at the α3α5β2 subtype than at the α3β2 subtype.
Unlike the α3 subunit, the α5 subunit is an auxiliary subunit that does not form functional
receptors when expressed with β2 or β4 [25]. However, its role as the fifth subunit in nAChR
pharmacology and physiology has recently gained prominence, because it influences
118
conductance [26], agonist sensitivity [27] and ion permeability [7]. Previous studies of α-
conotoxin Vc1.1 at α5-containing nAChRs showed no significant IC50 change [28].
Interestingly, kinetic analysis of LsIA inhibition revealed faster onset of block (kon) at the
α3α5β2 subtype than at the α3β2 subtype, which contributes to the 3-fold lower ki value at
α3α5β2. No significant difference in koff was observed between the α3α5β2 and α3β2 nAChR
subtypes. LsIA off-rate kinetics was slower at the α7 subtype than at the α3β2 and α3α5β2
subtypes. Also, a significant ~ 7-fold difference was observed in the ki and IC50 values at the
α7 subtype. This difference could be due to a higher Hill slope (nH) of –2.1 at the α7 subtype
than at the other subtypes, indicating positive peptide binding cooperativity.
4.5 SUMMARY AND CONCLUSION
LsIA is the first peptide isolated from the venom of C. limpusi. Structure–activity data
collected in this study indicates N-terminal and C-terminal sequences have unique and
specific roles in the pharmacology of this peptide. The N-terminal sequence (Ser1 and Gly2
residues) contributes to nAChR binding affinity, while C-terminus modification imparts
subtype selectivity. While a number of α-conotoxins that potently inhibit α3β2 and α7
nAChR subtypes exist [Table 4.3], I report differences between α-conotoxin LsIA’s
pharmacology and kinetics of inhibition in the presence and absence of the auxiliary α5
subunit. In conclusion, this study provides vital information to improve our understanding of
nAChR inhibition and aid development of novel analogues with improved subtype selectivity.
119
4.6 References
1. Olivera, B. M., Quik, M., Vincler, M., and McIntosh, J. M. (2008) Subtype-selective
conopeptides targeted to nicotinic receptors: Concerted discovery and biomedical
applications, Channels 2, 143-152.
2. Daly, N. L., and Craik, D. J. (2009) Structural studies of conotoxins, IUBMB life 61,
144-150.
3. Albuquerque, E. X., Pereira, E. F., Alkondon, M., and Rogers, S. W. (2009)
Mammalian nicotinic acetylcholine receptors: from structure to function,
Physiological reviews 89, 73-120.
4. Albuquerque, E. X., Pereira, E. F., Castro, N. G., Alkondon, M., Reinhardt, S.,
Schroder, H., and Maelicke, A. (1995) Nicotinic receptor function in the mammalian
central nervous system, Annals of the New York Academy of Sciences 757, 48-72.
5. Dajas-Bailador, F., and Wonnacott, S. (2004) Nicotinic acetylcholine receptors and
the regulation of neuronal signalling, Trends in pharmacological sciences 25, 317-
324.
6. D'Hoedt, D., and Bertrand, D. (2009) Nicotinic acetylcholine receptors: an overview
on drug discovery, Expert opinion on therapeutic targets 13, 395-411.
7. Gerzanich, V., Wang, F., Kuryatov, A., and Lindstrom, J. (1998) alpha 5 Subunit
alters desensitization, pharmacology, Ca++ permeability and Ca++ modulation of
human neuronal alpha 3 nicotinic receptors, The Journal of pharmacology and
experimental therapeutics 286, 311-320.
8. Craig, A. G., Bandyopadhyay, P., and Olivera, B. M. (1999) Post-translationally
modified neuropeptides from Conus venoms, European journal of biochemistry /
FEBS 264, 271-275.
120
9. Kang, T. S., Vivekanandan, S., Jois, S. D., and Kini, R. M. (2005) Effect of C-
terminal amidation on folding and disulfide-pairing of alpha-conotoxin ImI,
Angewandte Chemie 44, 6333-6337.
10. Nicke, A., Loughnan, M. L., Millard, E. L., Alewood, P. F., Adams, D. J., Daly, N. L.,
Craik, D. J., and Lewis, R. J. (2003) Isolation, structure, and activity of GID, a novel
alpha 4/7-conotoxin with an extended N-terminal sequence, The Journal of biological
chemistry 278, 3137-3144.
11. Whiteaker, P., Christensen, S., Yoshikami, D., Dowell, C., Watkins, M., Gulyas, J.,
Rivier, J., Olivera, B. M., and McIntosh, J. M. (2007) Discovery, synthesis, and
structure activity of a highly selective alpha7 nicotinic acetylcholine receptor
antagonist, Biochemistry 46, 6628-6638.
12. Everhart, D., Cartier, G. E., Malhotra, A., Gomes, A. V., McIntosh, J. M., and Luetje,
C. W. (2004) Determinants of potency on alpha-conotoxin MII, a peptide antagonist
of neuronal nicotinic receptors, Biochemistry 43, 2732-2737.
13. Franco, A., Kompella, S. N., Akondi, K. B., Melaun, C., Daly, N. L., Luetje, C. W.,
Alewood, P. F., Craik, D. J., Adams, D. J., and Mari, F. (2012) RegIIA: an alpha4/7-
conotoxin from the venom of Conus regius that potently blocks alpha3beta4 nAChRs,
Biochemical pharmacology 83, 419-426.
14. Talley, T. T., Olivera, B. M., Han, K. H., Christensen, S. B., Dowell, C., Tsigelny, I.,
Ho, K. Y., Taylor, P., and McIntosh, J. M. (2006) Alpha-conotoxin OmIA is a potent
ligand for the acetylcholine-binding protein as well as alpha3beta2 and alpha7
nicotinic acetylcholine receptors, The Journal of biological chemistry 281, 24678-
24686.
15. McIntosh, J. M., Dowell, C., Watkins, M., Garrett, J. E., Yoshikami, D., and Olivera,
B. M. (2002) Alpha-conotoxin GIC from Conus geographus, a novel peptide
121
antagonist of nicotinic acetylcholine receptors, The Journal of biological chemistry
277, 33610-33615.
16. Peng, C., Chen, W., Sanders, T., Chew, G., Liu, J., Hawrot, E., and Chi, C. (2010)
Chemical synthesis and characterization of two alpha4/7-conotoxins, Acta biochimica
et biophysica Sinica 42, 745-753.
17. Luo, S., Nguyen, T. A., Cartier, G. E., Olivera, B. M., Yoshikami, D., and McIntosh,
J. M. (1999) Single-residue alteration in alpha-conotoxin PnIA switches its nAChR
subtype selectivity, Biochemistry 38, 14542-14548.
18. Luo, S., Kulak, J. M., Cartier, G. E., Jacobsen, R. B., Yoshikami, D., Olivera, B. M.,
and McIntosh, J. M. (1998) alpha-conotoxin AuIB selectively blocks alpha3 beta4
nicotinic acetylcholine receptors and nicotine-evoked norepinephrine release, The
Journal of neuroscience : the official journal of the Society for Neuroscience 18,
8571-8579.
19. Azam, L., Dowell, C., Watkins, M., Stitzel, J. A., Olivera, B. M., and McIntosh, J. M.
(2005) Alpha-conotoxin BuIA, a novel peptide from Conus bullatus, distinguishes
among neuronal nicotinic acetylcholine receptors, The Journal of biological chemistry
280, 80-87.
20. Ellison, M., Haberlandt, C., Gomez-Casati, M. E., Watkins, M., Elgoyhen, A. B.,
McIntosh, J. M., and Olivera, B. M. (2006) Alpha-RgIA: a novel conotoxin that
specifically and potently blocks the alpha9alpha10 nAChR, Biochemistry 45, 1511-
1517.
21. Ulens, C., Hogg, R. C., Celie, P. H., Bertrand, D., Tsetlin, V., Smit, A. B., and Sixma,
T. K. (2006) Structural determinants of selective alpha-conotoxin binding to a
nicotinic acetylcholine receptor homolog AChBP, Proceedings of the National
Academy of Sciences of the United States of America 103, 3615-3620.
122
22. Dutertre, S., Ulens, C., Buttner, R., Fish, A., van Elk, R., Kendel, Y., Hopping, G.,
Alewood, P. F., Schroeder, C., Nicke, A., Smit, A. B., Sixma, T. K., and Lewis, R. J.
(2007) AChBP-targeted alpha-conotoxin correlates distinct binding orientations with
nAChR subtype selectivity, The EMBO journal 26, 3858-3867.
23. Millard, E. L., Daly, N. L., and Craik, D. J. (2004) Structure-activity relationships of
alpha-conotoxins targeting neuronal nicotinic acetylcholine receptors, European
journal of biochemistry / FEBS 271, 2320-2326.
24. Millard, E. L., Nevin, S. T., Loughnan, M. L., Nicke, A., Clark, R. J., Alewood, P. F.,
Lewis, R. J., Adams, D. J., Craik, D. J., and Daly, N. L. (2009) Inhibition of neuronal
nicotinic acetylcholine receptor subtypes by alpha-Conotoxin GID and analogues, The
Journal of biological chemistry 284, 4944-4951.
25. Boulter, J., Connolly, J., Deneris, E., Goldman, D., Heinemann, S., and Patrick, J.
(1987) Functional expression of two neuronal nicotinic acetylcholine receptors from
cDNA clones identifies a gene family, Proceedings of the National Academy of
Sciences of the United States of America 84, 7763-7767.
26. Lukas, R. J., Changeux, J. P., Le Novere, N., Albuquerque, E. X., Balfour, D. J., Berg,
D. K., Bertrand, D., Chiappinelli, V. A., Clarke, P. B., Collins, A. C., Dani, J. A.,
Grady, S. R., Kellar, K. J., Lindstrom, J. M., Marks, M. J., Quik, M., Taylor, P. W.,
and Wonnacott, S. (1999) International Union of Pharmacology. XX. Current status of
the nomenclature for nicotinic acetylcholine receptors and their subunits,
Pharmacological reviews 51, 397-401.
27. Wang, F., Gerzanich, V., Wells, G. B., Anand, R., Peng, X., Keyser, K., and
Lindstrom, J. (1996) Assembly of human neuronal nicotinic receptor alpha5 subunits
with alpha3, beta2, and beta4 subunits, The Journal of biological chemistry 271,
17656-17665.
123
28. Clark, R. J., Fischer, H., Nevin, S. T., Adams, D. J., and Craik, D. J. (2006) The
synthesis, structural characterization, and receptor specificity of the alpha-conotoxin
Vc1.1, The Journal of biological chemistry 281, 23254-23263.
124
CHAPTER 5
Novel αD-conotoxin GeXXA from Conus generalis
reveals unique nAChR binding mechanism
Conus generalis
125
5.1 INTRODUCTION
As mentioned earlier (Chapter 1, Section 2), various bioactive peptides have been identified
from the venom of cone snails belonging to the genus Conus, labelled conotoxins. The
disulphide-rich peptides targeting nAChRs are grouped into various superfamilies, based on
their structural and functional properties: the A- (α- and αA-conotoxins), M- (ψ-conotoxins),
S- (αS-conotoxins) and C-conotoxins (αC-conotoxins) [1].
Conotoxins from the D-superfamily were only recently discovered and functionally
characterised [2, 3]. First isolated from the venom C. vexillum, three novel αD-conotoxins,
αD-VxXIIA, αD-VxXIIB and αD-VxXIIC, were functionally characterised as potent
inhibitors of α7- and β2-containing neuronal nAChRs [2]. Kauferstein et al. (2009) identified
and analysed two new αD-conopeptides from the vermivorous snails Conus mustilinus (αD–
M) and Conus capitaneus (αD–Cp). These peptides have a pharmacological profile similar to
that of αD-VxXIIA with a 72% sequence homology [Table 5.1] [4].
In the present study, we identified novel αD-conotoxin GeXXA from the venom of Conus
generalis. Functional characterisation revealed αD-GeXXA non-selectively inhibits nAChRs,
an action not previously identified in αD-conotoxins, which usually exhibit characteristic
subtype selectivity. We also report the first synthesis of a functionally active monomeric αD-
GeXXA isoform.
126
Table 5.1: Sequence alignment of αD-conotoxin GeXXA with other, previously discovered αD-conotoxins.
αD-Conotoxin Sequence nAChR selectivity Reference GeXXA DVH-RPCQSVRPGRVWGKCCLTRLCSTMCCARADCTCVYHTWRGHGCSCV- α7>α3*>αβδγ This study Ms20.3 DVR--ECQVNTPGSSWGKCCMTRMCGTMCCARSGCTCVYHWRRGHGCSCPG α7>β2* [4, 5] Cp20.3 EVQ--ECQVDTPGSSWGKCCMTRMCGTMCCSRSVCTCVYHWRRGHGCSCPG α7>β2* [4, 5] VxXXA D--VQDCQVSTPGSKWGRCCLNRVCGPMCCPASHCYCVYHRGRGHGCSC-- α7>α3β2 [2] VxXXB DDE-SECIINTRDSPWGRCCRTRMCGSMCCPRNGCTCVYHWRRGHGCSCPG α7>β2*>αβδγ [2] VxXXC DLR--QCTRNAPGSTWGRCCLNPMCGNFCCPRSGCTCAYNWRRGIYCSC-- α7>β2* [2]
127
5.2 AIMS
5.2.1 Characterisation of αD-conotoxin GeXXA isolated from Conus generalis
To determine the pharmacological potency and selectivity of dimeric and
monomeric GeXXA at recombinant nAChR subtypes expressed in
Xenopus oocytes using the two-electrode voltage clamp technique.
5.2.2 Receptor hybrid studies
To identify the site where dimeric and monomeric αD-conotoxin GeXXAs
bind with nAChRs, and the molecular mechanism behind their inhibition
of nAChRs.
5.2.3 Significance
This study, in conjunction with modelling simulations our collaborators
are doing, could shed light on the molecular mechanism behind the αD-
conotoxins interaction with nAChR subtypes.
αD-conotoxins represent a novel class of nAChR-inhibiting peptides as
potential neurophysiological tools and drug therapeutics. This study could
also provide valuable information that could aid novel peptide design and
the development of future drugs.
128
5.3 RESULTS
5.3.1 Concentration-dependent inhibition of α3-containing nAChRs by αD-conotoxin
GeXXA
To examine the pharmacological activity of αD-conotoxin GeXXA at nAChRs, it was tested on
ACh-evoked currents mediated by different nAChR subtypes expressed in Xenopus oocytes.
GeXXA (1 µM) had no or little effect on α4β2 and α4β4 subtypes, but inhibited α3β4 and
muscle (α1β1εγ) by 70–80%, and inhibited α9α10, α7 and α3β2 subtypes completely [Figure
5.1(A)].
Concentration–response curves showed GeXXA was more selective for α3-containing than
α4-containing nAChR subtypes [Figure 5.1(B)]. It was most potent at the α7 nAChR subtype,
with an IC50 of 210 nM (95% CI, 174–253) and Hill slope (nH) of –1.6 ± 0.2. The IC50 (95%
CI) and Hill slope values from concentration–response curves for the inhibition of various
nAChR subtypes are summarised in Table 5.2.
Table 5.2: Pharmacological profile of dimeric αD-conotoxin GeXXA inhibition of
various nAChRs.
nAChR subtype IC50 (95% CI) nH
α7 210 nM (174–253) –1.6 ± 0.2 α3β2 498 nM (407–609) >> –1.0 α3β4 614 nM (491–768) –2.1 ± 0.4 α4β2 > 3 µM – α4β4 > 3 µM –0.9 ± 0.2 αβδγ 743 nM (606–911) –1.6 ± 0.2
All data points indicate mean ± SEM; n = 4–7.
129
Figure 5.1: Dimeric αD-conotoxin GeXXA inhibition of various nAChR subtypes. (A)
Superimposed current traces obtained in the absence (control) and presence of 300 nM of
dimeric αD-conotoxin GeXXA inhibition at the (i) α7 nAChR subtype and (ii) α3β2 nAChR
subtype. (B) Concentration–response curves obtained for dimeric αD-conotoxin GeXXA
inhibition of nAChR subtypes. Dimeric GeXXA (3 µM) non-selectively inhibited all nAChR
subtypes, except α4β2. The highest potency of inhibition was observed at the α7 nAChR
subtype. The IC50 (95% CI) and Hill slope (nH) values from concentration–response curves
are summarised in Table 5.2. All data points represent the mean ± SEM; n = 4–7.
130
5.3.2 Monomeric αD-conotoxin GeXXA selectively inhibits the α9α10 nAChR subtype
We describe for the first time monomeric αD-conotoxin GeXXA inhibition of nAChRs. When
tested on various nAChR subtypes, 1 µM of monomeric GeXXA completely inhibited the
α9α10 nAChR subtype, but had little or no activity at other nAChR subtypes. This
antagonism of α9α10 was also reversible [Figure 5.2(A)], unlike dimeric αD-conotoxin
GeXXA which irreversibly inhibited α9α10 subtype [data not shown]. The concentration–
response curve obtained for the monomeric GeXXA at α9α10 nAChR gave an IC50 of 198
nM (95% CI, 164–238; nH = –1.7 ± 0.3) [Figure 5.2(B)].
Figure 5.2: α9α10 hybrid nAChR inhibition by monomeric αD-conotoxin GeXXA. (A)
Superimposed ACh-evoked currents obtained in the absence (control) and presence of 1 µM
of monomeric αD-contoxin GeXXA at human and rat α9α10 nAChR subtype. (B) Monomeric
αD-conotoxin GeXXA was 10-fold less potent at the human α9α10 nAChR subtype than at
the rat α9α10 nAChR subtype, whereas no change was observed at the hybrid hα9rα10
receptor. All data points indicate mean ± SEM; n = 4–7.
131
5.3.3 α9α10 hybrid nAChR studies reveal the site of monomeric αD-conotoxin GeXXA
binding
The difference between dimeric and monomeric αD-conotoxin GeXXA inhibition of the
α9α10 nAChR subtype was further investigated on hybrid receptors using human and rat α9
and α10 nAChR subunits. When initially tested on human α9α10, monomeric α-D GeXXA
was 10-fold less potent compared with rat α9α10. However, similar potency was observed on
the hybrid hα9rα10 receptor to that of rat α9α10 subtype [Figure 5.2(B)].
Concentration–response curves for monomeric αD-conotoxin GeXXA inhibition of rat, hybrid
and human α9α10 nAChR subtypes gave IC50 values of 198 nM (95% CI, 164–238; nH = –1.7
± 0.3), 224 nM (95% CI, 194–258; nH = –1.4 ± 0.1) and 2.02 µM (95% CI, 1.82–2.25; nH = –
1.7 ± 0.1), respectively. All data points represent the mean ± SEM; n = 4–7.
132
5.4 DISCUSSION AND CONCLUSION
Conotoxins are invaluable pharmacological tools, each with unique structural and functional
features. αA-Conotoxins consist of up to 30 amino acid residues and generally characterised
by their competitive antagonism of muscle nAChRs, while ψ-Conotoxins are known to be
non-competitive muscle nAChR antagonists [6].
While there have been significant advances in developing our understanding of nAChRs,
much of their physiological role and pharmacology of these unique peptides on nAChRs is
still unknown.
D-superfamily conotoxins consist of 45–50 amino acid residues and have characteristic 10
cysteine residue framework [Table 5.1] [5]. They have various structural and functional
features. First, several post-translational modifications, such as carboxylation and
hydroxylation, are seen in native peptides. Second, native peptides occur as homodimers
connected by disulphide bonds [4]. αD-conotoxin GeXXA is a disulphide-linked homodimer
of two identical peptides and consists of 50 amino acid residues with 10 cysteines [Figure
5.3].
Figure 5.3: The sequence and disulphide linkage of αD-conotoxin GeXXA. For clarity,
only the N-terminal sequence of the second subunit is shown.
133
Previous pharmacologically characterised αD-conotoxins were shown to be non-competitive
muscle and neuronal nAChR antagonists, with selectivity for α7- and β2-containing receptors
[2]. However, even though each GeXXA peptide chain shared high homology with other
known αD-conotoxins [Table 5.1], αD-GeXXA exhibited concentration-dependent inhibition
of various nAChR subtypes, with selectivity for α7 and α3-containing nAChRs. αD-GeXXA
inhibits α7 (IC50 210 nM), α3β2 (IC50 498 nM), α3β4 (IC50 614 nM) and muscle (α1β1δγ)
(IC50 743 nM) nAChR subtypes, and weakly inhibits α4β2 and α4β4 nAChR subtypes (IC50 >
3 µM). However, its inhibition of both rat and human α9α10 nAChR subtypes was
irreversible, indicating that it binds tightly to these receptors.
The crystal structure of native αD-GeXXA [contributed to this study by collaborators]
provided further insight into its unique pharmacological activity and mechanisms of action.
Structures at 1.5 Ǻ resolution revealed an N-terminal domain (NTD, residues 1–20) and a C-
terminal domain (CTD, residues 21–50) in each peptide chain, arranged in an approximately
2-fold symmetric architecture. An interchain disulphide bond between Cys6 of one chain and
Cys18 of another chain within the NTD facilitates αD-GeXXA dimerisation [Figure 5.4].
Figure 5.4: The crystal structure of αD-conotoxin GeXXA. The NTDs of two GeXXA
subunits are shown in green and light green. The CTDs are represented in orange and light
orange. The disulphide bonds are colored yellow. [Provided to this study by collaborators].
134
We report the first synthesis of αD-GeXXA’s C-terminal domain (CTD) and its activity. The
isolated CTD adopts a canonical inhibitory cysteine knot (ICK) disulphide linkage. When
tested on various nAChR subtypes, αD-GeXXA-CTD selectively and reversibly antagonises
the rat α9α10 nAChR subtype, with an IC50 of 198 nM, but is 10-fold less potent at the human
α9α10 nAChR subtype (IC50 2.02 µM). Hybrid receptor studies indicate that the α10 nAChR
subunit contributes to the difference between αD-GeXXA’s potency for human and rat α9α10
nAChR subtype.
These results indicate that the α10 nAChR subunit is a major binding site for αD-conotoxin
GeXXA. Peptide sequence alignment revealed residue differences between the extracellular
domains of mature human and rat α10 subunits [Figure 5.5]. Molecular dynamics simulations
[contributed to this study by collaborators] indicate a two-site binding interaction between
αD-GeXXA and the His7 of the α10 subunit. Recently, similar hybrid-receptor studies of the
α9α10 nAChR subtype found that α-conotoxin Vc1.1 and RgIA preferentially bound to the
α10α9 pocket [3, 7]. These findings are also supported by electrophysiological data that show
Hill slope values > 1 for αD-GeXXA interaction with various nAChRs, which indicates a
positive cooperative binding mode. The Hill equation has been extensively used to aid
understanding of the complex pharmacokinetic and pharmacodynamic models of drug–
receptor interaction [8-10].
This study is the first to report monomeric αD-conotoxin activity, and gives insight into αD-
conotoxin GeXXA’s novel binding mechanism at nAChRs.
135
Figure 5.5: Pairwise sequence alignment of the ACh-binding site of the mature α10 subunit peptide. This alignment reveals the difference
between human and rat residues (background white). The mature α10 subunit peptide lacks the signal sequence (first 25 residues). Peptide sequences
were obtained from the NCBI Protein online database.
136
5.5 References
1. Arias, H. R., and Blanton, M. P. (2000) Alpha-conotoxins, International Journal of
Biochemistry & Cell Biology 32, 1017-1028.
2. Loughnan, M., Nicke, A., Jones, A., Schroeder, C. I., Nevin, S. T., Adams, D. J.,
Alewood, P. F., and Lewis, R. J. (2006) Identification of a novel class of nicotinic
receptor antagonists: dimeric conotoxins VxXIIA, VxXIIB, and VxXIIC from Conus
vexillum, Journal of Biological Chemistry 281, 24745-24755.
3. Azam, L., and McIntosh, J. M. (2012) Molecular basis for the differential sensitivity
of rat and human alpha9alpha10 nAChRs to α-conotoxin RgIA, Journal of
Neurochemistry 122, 1137-1144.
4. Kauferstein, S., Kendel, Y., Nicke, A., Coronas, F. I., Possani, L. D., Favreau, P.,
Krizaj, I., Wunder, C., Kauert, G., and Mebs, D. (2009) New conopeptides of the D-
superfamily selectively inhibiting neuronal nicotinic acetylcholine receptors, Toxicon
54, 295-301.
5. Loughnan, M. L., Nicke, A., Lawrence, N., and Lewis, R. J. (2009) Novel α D-
conopeptides and their precursors identified by cDNA cloning define the D-conotoxin
superfamily, Biochemistry 48, 3717-3729.
6. Jacobsen, R., Yoshikami, D., Ellison, M., Martinez, J., Gray, W. R., Cartier, G. E.,
Shon, K. J., Groebe, D. R., Abramson, S. N., Olivera, B. M., and McIntosh, J. M.
(1997) Differential targeting of nicotinic acetylcholine receptors by novel αA-
conotoxins, Journal of Biological Chemistry 272, 22531-22537.
7. Yu, R., Kompella, S. N., Adams, D. J., Craik, D. J., and Kaas, Q. (2013)
Determination of the α-conotoxin Vc1.1 binding site on the α9α10 nicotinic
acetylcholine receptor, Journal of Medicinal Chemistry 56, 3557-3567.
137
8. Goutelle, S., Maurin, M., Rougier, F., Barbaut, X., Bourguignon, L., Ducher, M., and
Maire, P. (2008) The Hill equation: a review of its capabilities in pharmacological
modelling, Fundamental & clinical pharmacology 22, 633-648.
9. Prinz, H. (2010) Hill coefficients, dose-response curves and allosteric mechanisms,
Journal of Chemical Biology 3, 37-44.
10. Weiss, J. N. (1997) The Hill equation revisited: uses and misuses, FASEB Journal 11,
835-841.
138
CHAPTER 6
Dicarba modification of α-conotoxins exhibits differential selectivity
for nAChRs and GABAB receptors
Conus victoriae
139
6.1 INTRODUCTION
6.1.1 Conotoxins - Conus victoriae and Conus regius
α-Conotoxins in the venom of the marine cone snails, are short disulphide-bonded peptides
ranging from 12–30 amino acids. These peptides specifically target nAChR subtypes and have
potential therapeutic applications. Conus victoriae and Conus regius venoms gained a special
interest, due to identification of two novel peptides, α-conotoxins Vc1.1 and RgIA,
respectively. These peptides have exhibited analgesic properties in rat neuropathic pain
models [1, 2].
α-Conotoxins Vc1.1 and RgIA belong to the cysteine framework I family (CCXnCXmC) and
exist in a globular conformation with I–III and II–IV disulphide connectivity in native form
[3]. Both of these peptides were first identified using a cDNA approach [4, 5]. Vc1.1 is 16
amino acids in length and belongs to the α4/7 subclass of conotoxins. Like most conotoxins,
Vc1.1 exhibited various post-translational modifications, including C-terminus amidation,
hydroxylation of Pro6 and γ-carboxylation of Glu14 residues. This modified peptide, called
vc1a, was identified in the venom of Conus victoriae and is the native form of Vc1.1 [6]. On
the other hand, RgIA is an α4/3 conotoxin, consisting of 12 amino acids, and lacks post-
translational modification.
6.1.2 The molecular mechanism of analgesia
The involvement of nAChRs in pain pathways is now well established [7]. However, the role
of nAChR subtypes in pain pathways and the molecular mechanism of these pathways are yet
to be elucidated. Various small molecule compounds acting as α4β2 and α7 nAChR
antagonists are the primary leads for pain therapeutics [8]. However, the identification of α-
conotoxins as nAChR subtype-selective probes has led to the development of novel drugs to
140
treat neuropathic pain [9]. A major breakthrough came with the discovery of α-conotoxins
Vc1.1 and RgIA, which have acute and cumulative anti-nociceptive effects in chronic
constriction nerve injury (CCI) and partial sciatic nerve ligation (PSNL) rat models of
neuropathic pain [1, 2]. Subcutaneous or intramuscular administration of these peptides
alleviated mechanical hyperalgesia and allodynia. This effect lasted up to 24 h post-
administration without the rats developing a tolerance to the drug. In addition, Vc1.1’s
analgesic effects lasted up to one week after treatment was ceased [10].
The pharmacological profiles of Vc1.1 and RgIA were only established three years after their
analgesic properties were identified. Initial electrophysiological studies using synthetic Vc1.1
confirmed the α3β4 nAChR subtype is its pharmacological target, with an IC50 of 3 µM [11].
However, concurrent studies revealed Vc1.1 and RgIA also potently inhibit the α9α10 nAChR
subtype, with an IC50 of 64 nM and 5 nM, respectively [4, 12]. These studies suggested the
α9α10 nAChR subtype as a novel therapeutic target for neuropathic pain.
Recent studies have also uncovered a new biological target for both of these peptides. Vc1.1
and RgIA inhibit high voltage-activated (HVA) calcium channel currents via GABAB
receptor activation, which suggests these α-conotoxins may mediate a novel pain pathway
[13-15].
6.1.3 The α9α10 nAChR subtype: expression and function
Of the various nAChR subunits, only the α7 and α9 subunits form homopentamers, and the
α10 subunit assembles only with the α9 subunit to form functional receptors [16]. Co-
assembly with the α10 subunit also significantly increases the expression of α9α10 nAChRs
[17]. α9 and α10 subunits are expressed in various tissues, such as skin, dorsal root ganglia
(DRG), pars tuberalis of the pituitary gland, and cochlear hair cells [10]. In the auditory
141
system, which is composed of cochlear hair cells, α9-containing receptors mediate the
synaptic transmission, and therefore modulate auditory stimuli [18]. In skin, α9 and α10
subunits regulate the cell-adhesion properties of keratinocytes and modulate wound-healing
(re-epithelialisation) [19, 20]. While α9 and α10 subunits are implicated in cholinergic
signalling in the above-mentioned tissues, their precise subunit stoichiometry is yet to be
determined. Although α9 can form a functional homomeric receptor, the expression of α10
subunit was found to be necessary for synaptic transmission in cochlear cells [21].
Furthermore, Plazas et al. (2005) showed that α9α10 when recombinantly expressed in
oocytes, stoichiometry of (α9)2(α10)3 was observed [22].
6.1.4 α-Conotoxin drug development: limitations and strategies
The nature of the compound is an important aspect of drug development, because it
determines the drug’s side effects. While the peptidic nature of α-conotoxins is a unique
advantage for drug development, it is also their Achilles’ heel. α-Conotoxins are susceptible
to natural peptidic degradation, which drastically affects their bioavailability and half-life.
The functional impediment of α-conotoxins via peptidic-degradation can result from a
proteolytic attack on the N- and/or the C-terminus of the peptide, or from disruption
(scrambling) of the disulphide linkage within the α-conotoxin.
Various strategies to improve α-conotoxin stability have been implemented, such as
cyclisation and selenocysteine modification. Peptide cyclisation has been shown to counter
the proteolytic degradation problem in Vc1.1, RgIA and other peptides [23, 24]. The α-
conotoxin three-dimensional structure is dominated by a helical structure shaped by a
conserved disulphide framework. The most predominant I–III and II–IV disulphide
connectivity is found in native α-conotoxins and folds the peptide into globular conformation.
However, the disulphide connectivity of α-conotoxins can interchange under oxidative and
142
reduced conditions to form ribbon (I–IV and II–III disulphide bonds) or bead (I–II and III–IV
disulphide bonds) conformations.
Peptide exploitation in research and clinical settings has also been hampered by the lability of
the disulphide bridges that are essential for conotoxin structure and activity [25]. Alteration of
disulphide linkage by methods such as selenocysteine modification broke new ground in drug
development [26]. Replacing the cysteine bridges with non-reducible dicarba links has also
been identified as a novel solution to the lability problem. It was shown to significantly
improve α-conotoxin ImI stability, while its functional activity remained comparable with that
of the native peptide.
Here, I explore the functional implications of this approach on novel analgesic α-conotoxin
Vc1.1 and RgIA, which inhibit HVA calcium channel currents via GABAB receptor
activation and α9α10 and α3β4 nAChR subtypes.
143
6.2 AIMS
6.2.1 Characterisation of dicarba modified α-conotoxins Vc1.1 and RgIA.
To functionally characterise regioselective dicarba analogues of α-
conotoxins Vc1.1 and RgIA using two-electrode voltage-clamp technique
in Xenopus oocytes expressing recombinant nAChR subtypes.
6.2.2 Significance
This study, in conjunction with structural studies by our collaborators,
could provide a detailed understanding of the functional implications of
dicarba modification on the Vc1.1 and RgIA activity at nAChRs.
It could also provide valuable information about the development of
dicarba peptides as novel drugs to treat neuropathic pain.
144
6.3 RESULTS
6.3.2 Regioselective dicarba Vc1.1 analogues exhibit differential activity at α9α10
nAChR subtypes
The functional effects of dicarba modification on Vc1.1 was tested on recombinant α9α10 and
α3β4 nAChR subtypes heterogeneously expressed in Xenopus oocytes using the two-electrode
voltage-clamp technique. When tested, cis- and trans-[3,16]-dicarba Vc1.1 analogues (3 µM)
inhibited the α9α10 nAChR subtype by 24% and 54%, respectively, but the [2,8]-dicarba
Vc1.1 analogue showed no inhibitory effects [Figure 6.1(A)]. A similar trend was observed
for these peptides at the α3β4 nAChR subtype [Figure 6.1(B)].
Figure 6.1: Percentage inhibition of ACh-evoked currents by dicarba Vc1.1 analogues (3
µM) at α9α10 (A) and α3β4 (B) nAChR subtypes. All data represent the mean ± SEM; n ≥
3.
A concentration–response analysis gave an IC50 of 2.8 µM (95% CI, 2.0–4.1 µM) and a Hill
slope of –1.3 ± 0.3 (n = 4) for trans-[3,16]-dicarba Vc1.1. The cis isomer was ~ five-fold less
active, with an IC50 of 12.5 µM (95% CI, 5.6–27.9 µM) and a Hill slope of –0.8 ± 0.2 (n = 4)
[Figure 6.2(C)].
145
Figure 6.2: Dicarba Vc1.1 analogues concentration-dependent inhibition of ACh-evoked
currents at the α9α10 nAChR subtype. Superimposed ACh (50 µM)-evoked current traces
mediated by (A) α9α10 and (B) α3β4 nAChR subtypes in the absence (control) and presence
of 3 µM of [3,16]-trans-dicarba Vc1.1 and [3,16]-cis-dicarba Vc1.1. (C) Concentration–
response curves for Vc1.1 and dicarba Vc1.1 analogue inhibition of the α9α10 nAChR
subtype. All data represents mean ± SEM; n ≥ 4.
6.3.2 Dicarba modification of RgIA confers similar pharmacological effects to those of
Vc1.1
In this study, each of the peptides was compared with native RgIA on α9α10 and α7 nAChRs
expressed in Xenopus oocytes. Native RgIA reversibly inhibited ACh-evoked currents
mediated by α9α10 and α7 nAChRs in a concentration-dependent manner, with an IC50 of 5.5
nM (nH = −1.3) and 3.3 µM (nH = −0.9), respectively [4].
146
At the α9α10 nAChR subtype, cis- and trans-[3,12]-dicarba RgIA analogues (3 µM each)
inhibited ACh-evoked currents by 35.4 ± 1.5% and 31.5 ± 2.1% (n = 3), respectively [Figure
6.3(A)(i)]. The cis isomer exhibited an IC50 of 1.15 µM (95% CI, 0.84–1.55 µM) and a Hill
slope of −1.9 ± 0.4 (n = 3). The trans isomer was 1.3-fold less active, with an IC50 of 1.47 µM
(95% CI, 1.01–2.15 µM) and a Hill slope of −1.2 ± 0.2 (n = 3) [Figure 6.3(B)].
In contrast, at the α7 nAChR subtype, cis-[3,12]-dicarba RgIA inhibition of ACh-evoked
currents was similar to that of native RgIA, with an IC50 of 3.73 µM (95% CI, 1.42–9.82 µM)
and a Hill slope of −1.6 ± 0.6 [Figure 6.3(B)]. The trans-isomer was inactive at α7 when
tested at a concentration of 3 µM [Figure 6.3(A)(ii)]. Replacing the [2,8]-cystine bridge
significantly abolished nAChR activity, with both the cis- and trans-[2,8]-dicarba RgIA
inactive when tested at 10 µM at the α9α10 nAChR subtype [data not shown].
147
Figure 6.3: [3,12]-Dicarba RgIA analogue inhibition of ACh-evoked currents at rat
α9α10 and human α7 nAChRs expressed in Xenopus oocytes. (A) (i) Superimposed ACh
(50 µM)-evoked currents mediated by α9α10 nAChRs in the absence (control) and presence
of 3 µM each of cis-[3,16]-dicarba RgIA and trans-[3,16]-dicarba RgIA. (ii) Superimposed
ACh (200 µM)-evoked currents at α7 nAChRs in the absence (control) and presence of 3 µM
each of cis-[3,16]-dicarba RgIA and trans-[3,16]-dicarba RgIA. (B) Concentration–response
curves for cis-[3,12]-dicarba RgIA gave an IC50 of 1.15 µM (95% CI, 0.84–1.55 µM) and a
Hill slope of −1.9 ± 0.4 at the α9α10 nAChR. trans-[3,12]-dicarba RgIA gave an IC50 of 1.47
µM (95% CI, 1.01–2.15 µM) and a Hill slope of −1.2 ± 0.2 at the α9α10 nAChR. At the α7
nAChR subtype, cis-[3,12]-dicarba RgIA had an IC50 of 3.73 µM (95% CI, 1.42–9.82 µM)
and a Hill slope of −1.6 ± 0.6, but trans-[3,12]-Dicarba RgIA was inactive. All data represent
mean ± SEM; n ≥ 3.
148
6.4 DISCUSSION
6.4.1 Dicarba modification imparts differential pharmacological selectivity to α-
conotoxins Vc1.1 and RgIA
Dicarba modification of the disulphide bridge imparted differential and significant changes to
the pharmacological profile of α-conotoxins Vc1.1 and RgIA. Dicarba modification of the
Cys2–Cys8 disulphide bond in Vc1.1 and RgIA, led to complete loss of activity at nicotinic
receptors. Both peptides also lost appreciable activity at the α9α10 nAChR subtype when the
Cys3–Cys16 disulphide bond in Vc1.1 and Cys3–Cys12 disulphide bond in RgIA were
replaced with dicarba linkage. The [3, 12]-dicarba RgIA analogues are more potent than the
corresponding dicarba Vc1.1 analogues, and their IC50 change was more prominent than the
native peptide. NMR structural analysis [experiments carried out by our collaborators;
data not shown] of these peptides shows a clear perturbation of the three dimensional
structure of [2,8]-trans-dicarba Vc1.1 and RgIA analogues, which contributes to its loss of
activity at nAChR subtypes.
While previous point mutation studies of Vc1.1 and RgIA revealed the key residues
interacting with the α9α10 nAChR subtype, this study and molecular dynamics simulations
[experiments conducted by our collaborators; data not shown] propose significant
interaction between the peptides’ disulphide bonds and ACh-binding pocket. Our
collaborators’ molecular docking studies revealed disulphide stacking interaction between the
Cys2–Cys8 bond and disulphide of the C-loop of the principal subunit. This interaction was
shown to be important for α4/7 conotoxin PnIA[A4L,D14K] bound to the AChBP [27]. This
model is corroborated by the complete loss of activity of the [2,8]-dicarba-modified Vc1.1
and RgIA peptides. It also explains the significant variance in peptide function, whereas NMR
studies [conducted by our collaborators] show no significant perturbation except for trans-
149
[2,8]-dicarba Vc1.1. Furthermore, when tested, these peptide analogues exhibited opposite
effects on their corresponding biological targets. [2,8]-Dicarba Vc1.1 analogues inhibited
HVA calcium channel currents via GABAB receptor activation in rat DRG neurons, but
[3,16]-dicarba Vc1.1 peptides were inactive [results published] [28]. Similar results were
also observed with RgIA dicarba analogues [experiments conducted by our collaborators;
data not shown]. These results suggest that the CysII–CysIV disulphide bond may interact
with GABAB receptors in a similar way to that in which the CysI–CysIII bond interact with
nAChRs.
6.4.2 Molecular determinants of Vc1.1 and RgIA pharmacological selectivity
Unlike other nAChR subtypes, α9α10 has very unique pharmacological properties, which are
yet to be fully understood. Various compounds, such as nicotine, cytisine and epibatine,
which are agonists of α7 and other heteromeric receptors, antagonise the α9α10 nAChR
subtype [10]. Furthermore, inhibition of α9α10 nAChR by non-cholinergic antagonists, such
as strychnine (glycine receptor antagonist), represents a distinctive and mixed
pharmacological property for this receptor subtype [17].
Vc1.1 emerged as novel drug to treat neuropathic pain after various studies showed it’s
cumulative and long-lasting alleviation of hyperalgesia and allodynia. However, drug
development of Vc1.1 was stopped at phase 2A of the human clinical trials, because potencies
at rat and human α9α10 nAChR subtype inhibition differed significantly [29]. Various studies
that aimed to explain the molecular determinants of Vc1.1 and RgIA identification of their
pharmacological target, the α9α10 nAChR subtype, were later conducted [3]. Point mutational
analyses of RgIA revealed that region 5–7 interacts with the α9α10 binding pocket [30].
Similar studies using Vc1.1 showed that as well as region 5–7, a second region, 11–15, is
needed for Vc1.1 activity at the α9α10 subtype [31]. This study also showed significantly
150
increased potency at rat and human α9α10 subtypes when Asn9 was changed to hydrophobic
residues in Vc1.1 [31].
These studies had two significant effects on the development of Vc1.1 and RgIA as drug
leads. Firstly, they elucidated the molecular mechanism of inhibition at α9α10, providing vital
information about the structure–function relationship between these two α-conotoxin classes.
Secondly, peptide analogues developed in these studies with increased activity at α9α10
subtype provided new lead compounds to aid in drug development.
6.5 SUMMARY AND CONCLUSION
α-Conotoxins are subtype-selective nAChR antagonists and established leads for drugs to
treat various pain conditions [23]. Here, I have outlined various studies that contributed to our
understanding of the molecular pharmacology of Vc1.1 and RgIA at α9α10 and GABAB
receptors. These studies have significantly progressed development of these novel α-
conotoxins as pain therapeutics. I have also successfully identified the potential use of dicarba
modification of these peptides to improve their bioavailability and half-life, and maintain their
biological activity. My results provide vital information about the molecular mechanism of
peptide inhibition of the α9α10 nAChR subtype. Together with previous mutational studies,
synthesis and functionally characterisation of new dicarba analogues that aim to improve
peptide potency are being carried out.
151
6.6 References
1. Satkunanathan, N., Livett, B., Gayler, K., Sandall, D., Down, J., and Khalil, Z. (2005)
Alpha-conotoxin Vc1.1 alleviates neuropathic pain and accelerates functional recovery
of injured neurones, Brain research 1059, 149-158.
2. Vincler, M., Wittenauer, S., Parker, R., Ellison, M., Olivera, B. M., and McIntosh, J.
M. (2006) Molecular mechanism for analgesia involving specific antagonism of
alpha9alpha10 nicotinic acetylcholine receptors, Proceedings of the National Academy
of Sciences of the United States of America 103, 17880-17884.
3. Azam, L., and McIntosh, J. M. (2009) Alpha-conotoxins as pharmacological probes of
nicotinic acetylcholine receptors, Acta pharmacologica Sinica 30, 771-783.
4. Ellison, M., Haberlandt, C., Gomez-Casati, M. E., Watkins, M., Elgoyhen, A. B.,
McIntosh, J. M., and Olivera, B. M. (2006) Alpha-RgIA: a novel conotoxin that
specifically and potently blocks the alpha9alpha10 nAChR, Biochemistry 45, 1511-
1517.
5. Sandall, D. W., Satkunanathan, N., Keays, D. A., Polidano, M. A., Liping, X., Pham,
V., Down, J. G., Khalil, Z., Livett, B. G., and Gayler, K. R. (2003) A novel alpha-
conotoxin identified by gene sequencing is active in suppressing the vascular response
to selective stimulation of sensory nerves in vivo, Biochemistry 42, 6904-6911.
6. Jakubowski, J. A., Keays, D. A., Kelley, W. P., Sandall, D. W., Bingham, J. P., Livett,
B. G., Gayler, K. R., and Sweedler, J. V. (2004) Determining sequences and post-
translational modifications of novel conotoxins in Conus victoriae using cDNA
sequencing and mass spectrometry, Journal of mass spectrometry : JMS 39, 548-557.
7. Lippiello, P., Bencherif, M., Hauser, T., Jordan, K., Letchworth, S., and Mazurov, A.
(2007) Nicotinic receptors as targets for therapeutic discovery, Expert opinion on drug
discovery 2, 1185-1203.
152
8. D'Hoedt, D., and Bertrand, D. (2009) Nicotinic acetylcholine receptors: an overview
on drug discovery, Expert opinion on therapeutic targets 13, 395-411.
9. Livett, B. G., Sandall, D. W., Keays, D., Down, J., Gayler, K. R., Satkunanathan, N.,
and Khalil, Z. (2006) Therapeutic applications of conotoxins that target the neuronal
nicotinic acetylcholine receptor, Toxicon : official journal of the International Society
on Toxinology 48, 810-829.
10. McIntosh, J. M., Absalom, N., Chebib, M., Elgoyhen, A. B., and Vincler, M. (2009)
Alpha9 nicotinic acetylcholine receptors and the treatment of pain, Biochemical
pharmacology 78, 693-702.
11. Clark, R. J., Fischer, H., Nevin, S. T., Adams, D. J., and Craik, D. J. (2006) The
synthesis, structural characterization, and receptor specificity of the alpha-conotoxin
Vc1.1, The Journal of biological chemistry 281, 23254-23263.
12. Nevin, S. T., Clark, R. J., Klimis, H., Christie, M. J., Craik, D. J., and Adams, D. J.
(2007) Are alpha9alpha10 nicotinic acetylcholine receptors a pain target for alpha-
conotoxins?, Molecular pharmacology 72, 1406-1410.
13. Cuny, H., de Faoite, A., Huynh, T. G., Yasuda, T., Berecki, G., and Adams, D. J.
(2012) gamma-Aminobutyric acid type B (GABAB) receptor expression is needed for
inhibition of N-type (Cav2.2) calcium channels by analgesic alpha-conotoxins, The
Journal of biological chemistry 287, 23948-23957.
14. Adams, D. J., Callaghan, B., and Berecki, G. (2012) Analgesic conotoxins: block and
G protein-coupled receptor modulation of N-type (Ca(V) 2.2) calcium channels,
British journal of pharmacology 166, 486-500.
15. Klimis, H., Adams, D. J., Callaghan, B., Nevin, S., Alewood, P. F., Vaughan, C. W.,
Mozar, C. A., and Christie, M. J. (2011) A novel mechanism of inhibition of high-
voltage activated calcium channels by alpha-conotoxins contributes to relief of nerve
injury-induced neuropathic pain, Pain 152, 259-266.
153
16. Millar, N. S., and Gotti, C. (2009) Diversity of vertebrate nicotinic acetylcholine
receptors, Neuropharmacology 56, 237-246.
17. Elgoyhen, A. B., Vetter, D. E., Katz, E., Rothlin, C. V., Heinemann, S. F., and
Boulter, J. (2001) alpha10: a determinant of nicotinic cholinergic receptor function in
mammalian vestibular and cochlear mechanosensory hair cells, Proceedings of the
National Academy of Sciences of the United States of America 98, 3501-3506.
18. Elgoyhen, A. B., Johnson, D. S., Boulter, J., Vetter, D. E., and Heinemann, S. (1994)
Alpha 9: an acetylcholine receptor with novel pharmacological properties expressed in
rat cochlear hair cells, Cell 79, 705-715.
19. Grando, S. A. (2006) Cholinergic control of epidermal cohesion, Experimental
dermatology 15, 265-282.
20. Chernyavsky, A. I., Arredondo, J., Vetter, D. E., and Grando, S. A. (2007) Central role
of alpha9 acetylcholine receptor in coordinating keratinocyte adhesion and motility at
the initiation of epithelialization, Experimental cell research 313, 3542-3555.
21. Katz, E., Elgoyhen, A. B., Gomez-Casati, M. E., Knipper, M., Vetter, D. E., Fuchs, P.
A., and Glowatzki, E. (2004) Developmental regulation of nicotinic synapses on
cochlear inner hair cells, The Journal of neuroscience : the official journal of the
Society for Neuroscience 24, 7814-7820.
22. Plazas, P. V., Katz, E., Gomez-Casati, M. E., Bouzat, C., and Elgoyhen, A. B. (2005)
Stoichiometry of the alpha9alpha10 nicotinic cholinergic receptor, The Journal of
neuroscience : the official journal of the Society for Neuroscience 25, 10905-10912.
23. Carstens, B. B., Clark, R. J., Daly, N. L., Harvey, P. J., Kaas, Q., and Craik, D. J.
(2011) Engineering of conotoxins for the treatment of pain, Current pharmaceutical
design 17, 4242-4253.
24. Halai, R., Callaghan, B., Daly, N. L., Clark, R. J., Adams, D. J., and Craik, D. J.
(2011) Effects of cyclization on stability, structure, and activity of alpha-conotoxin
154
RgIA at the alpha9alpha10 nicotinic acetylcholine receptor and GABA(B) receptor,
Journal of medicinal chemistry 54, 6984-6992.
25. Grishin, A. A., Wang, C. I., Muttenthaler, M., Alewood, P. F., Lewis, R. J., and
Adams, D. J. (2010) Alpha-conotoxin AuIB isomers exhibit distinct inhibitory
mechanisms and differential sensitivity to stoichiometry of alpha3beta4 nicotinic
acetylcholine receptors, The Journal of biological chemistry 285, 22254-22263.
26. Raffa, R. B. (2010) Diselenium, instead of disulfide, bonded analogs of conotoxins:
novel synthesis and pharmacotherapeutic potential, Life sciences 87, 451-456.
27. Celie, P. H., Kasheverov, I. E., Mordvintsev, D. Y., Hogg, R. C., van Nierop, P., van
Elk, R., van Rossum-Fikkert, S. E., Zhmak, M. N., Bertrand, D., Tsetlin, V., Sixma, T.
K., and Smit, A. B. (2005) Crystal structure of nicotinic acetylcholine receptor
homolog AChBP in complex with an alpha-conotoxin PnIA variant, Nature structural
& molecular biology 12, 582-588.
28. van Lierop, B. J., Robinson, S. D., Kompella, S. N., Belgi, A., McArthur, J. R., Hung,
A., Macraild, C. A., Adams, D. J., Norton, R. S., and Robinson, A. J. (2013) Dicarba
alpha-Conotoxin Vc1.1 Analogues with Differential Selectivity for Nicotinic
Acetylcholine and GABAB Receptors, ACS chemical biology 8, 1815-1821.
29. Metabolic. (2007) Metabolic discontinues clincal trial programme for neuropathic pain
drug, ACV1.
30. Ellison, M., Feng, Z. P., Park, A. J., Zhang, X., Olivera, B. M., McIntosh, J. M., and
Norton, R. S. (2008) Alpha-RgIA, a novel conotoxin that blocks the alpha9alpha10
nAChR: structure and identification of key receptor-binding residues, Journal of
molecular biology 377, 1216-1227.
31. Halai, R., Clark, R. J., Nevin, S. T., Jensen, J. E., Adams, D. J., and Craik, D. J. (2009)
Scanning mutagenesis of alpha-conotoxin Vc1.1 reveals residues crucial for activity at
155
the alpha9alpha10 nicotinic acetylcholine receptor, The Journal of biological
chemistry 284, 20275-20284.
156
CHAPTER 7
Conclusion & future directions
157
Nicotinic research has significantly grown over the past 30 years. [1-3]. However, there are
still numerous challenges and questions to be answered that are related to these ligand-gated
channels [4]. There has also been a prominent shift in the direction of research into nAChRs.
While previous studies focused on nAChR structure and function, present research aims to
understand the physiological roles played by various nAChR subtypes [5, 6]. Today, nAChR
subtypes are implicated in numerous neuronal and non-neuronal diseases, which further
indicate their vital physiological role [1, 7].
α-Conotoxins, a diverse group of peptides that act as subtype-specific nAChR antagonists, are
the ideal tool to identify the role played by nAChRs in various physio- and pathophysiological
processes. Developments in molecular techniques and peptide chemistry have exponentially
increased the number of α-conotoxins being discovered [8]. However, out of the 700 cone
snail species, each with 100s of α-conotoxins, only 0.1% have been functionally characterised
to date [9, 10]. There are also various challenges in the clinical exploitation of these peptides.
In this thesis, the collaborative studies identify and tackle some of the pressing issues related
to the therapeutic development of conotoxins, such as nAChR subtype-specific ligand potency
and selectivity, and α-conotoxin stability under physiological conditions.
α-Conotoxin AuIB is the only peptide known to selectively target the α3β4 nAChR subtype
with an IC50 of 2.5 µM [11]. In this thesis, I successfully characterised a novel α4/7 conotoxin
RegIIA, isolated from the venom of Conus regius. This peptide, although active at α3β2 and
α7 nAChRs, potently inhibited the α3β4 nAChR subtype, making it a significant discovery.
RegIIA is only the fifth α-conotoxin known to target the α3β4 nAChR subtype. Other
characterised α-conotoxins known to inhibit the α3β4 nAChR subtype are BuIA, AuIB, PIA
and PeIA [12]. Unlike α-conotoxin AuIB, which belongs to a unique α4/6 subclass and
exhibits distinct sequence, RegIIA and other α-conotoxins exhibit high-sequence homology.
158
This made RegIIA an ideal candidate to help us identify and understand the molecular
determinants governing its α3β4 nAChR subtype antagonism. Using alanine scanning
mutagenesis, I not only identified the critical residues that interact with each of the nAChR
subtypes, but also successfully synthesised an analogue that potently and selectively targets
the α3β4 nAChR subtype. This will be invaluable in deciphering the physiological role played
by the α3β4 nAChR subtype, and for the design and development of α3β4-selective drugs to
treat lung cancer and nicotine addiction.
In this thesis, I characterised another α-conotoxin, LsIA, isolated from Conus limpusi. This
peptide was of special interest, since it contained a unique N-terminal serine amino acid in
addition to a glycine, which is found in almost all conotoxins. To date, very few α-conotoxins
have been found to exhibit this N-terminal sequence [12]. Therefore, I examined the
significance of this sequence, including C-terminus carboxylation, on LsIA’s functional
activity. While the truncated analogues caused LsIA’s loss in activity at both of its
pharmacological targets, which was similar to previous studies with α-conotoxin GID [13], C-
terminal carboxylation changed selectivity between the α3β2 and α7 nAChR subtypes. I also
extended this study to identify the role the α5 nAChR subunit plays in α-conotoxin
pharmacology. Interestingly, while α5 subunit incorporation into the α3β2 nAChR subtype
decreased LsIA’s IC50 three-fold, a faster onset of block (kon) was observed at the α3α5β2
nAChR subtype. Together, these results present a novel strategy for the development of novel
analogues with improved subtype selectivity and suggest a pharmacological role played by
the auxiliary α5 subunit in the inhibition of nAChRs by α-conotoxins.
I also functionally characterised a novel conotoxin, GeXXA, which belongs to the D-
superfamily. αD-conotoxins are unique homo-dimeric peptides that non-competitively target
nAChRs. However, very few peptides from this family have been characterised. αD-GeXXA
159
selectively inhibits α7 and α3-containing nAChRs and irreversibly inhibits α9α10 nAChR
subtype. This is the first report of monomeric αD-conotoxin activity, selectively inhibiting the
α9α10 nAChR subtype. These results present a novel binding mechanism for an αD-
conotoxin and provide future insights for the development of new nAChR antagonists.
Finally, in a collaborative study, I examined the functional implications of dicarba
modification of the disulphide bonds in α-conotoxins Vc1.1 and RgIA. Both of these peptides
exhibit analgesic properties and inhibit α9α10 nAChR and N-type calcium channel currents
via GABAB receptor activation [14]. However, the lability of the disulphide bond has
hampered clinical exploitation of these and other α-conotoxins.
Dicarba modification of the disulphide bonds has been shown to improve peptide stability
[15, 16]. I identified a significant reduction in activity for Vc1.1 and RgIA at the α9α10
nAChR subtype. However, interestingly, regioselective I–III and II–IV dicarba analogues
exhibited differential selectively towards their biological targets. These results suggest that
the CysI–CysIII disulphide bond of Vc1.1 and RgIA interacts with α9α10 nAChR subtype
receptors. This may help us establish a novel strategy for developing subtype-selective
nAChR antagonists and new leads for stable drugs to treat various pain conditions.
Overall, the studies outlined in this thesis have provided crucial information to improve our
understanding of the molecular pharmacology and potential therapeutic use of α-conotoxins.
160
References:
1. Albuquerque, E. X., Pereira, E. F., Alkondon, M., and Rogers, S. W. (2009)
Mammalian nicotinic acetylcholine receptors: from structure to function,
Physiological reviews 89, 73-120.
2. Dani, J. A., and Bertrand, D. (2007) Nicotinic acetylcholine receptors and nicotinic
cholinergic mechanisms of the central nervous system, Annual review of
pharmacology and toxicology 47, 699-729.
3. Hurst, R., Rollema, H., and Bertrand, D. (2013) Nicotinic acetylcholine receptors:
from basic science to therapeutics, Pharmacology & therapeutics 137, 22-54.
4. Cassels, B. K., Bermudez, I., Dajas, F., Abin-Carriquiry, J. A., and Wonnacott, S.
(2005) From ligand design to therapeutic efficacy: the challenge for nicotinic receptor
research, Drug discovery today 10, 1657-1665.
5. Gotti, C., and Clementi, F. (2004) Neuronal nicotinic receptors: from structure to
pathology, Progress in neurobiology 74, 363-396.
6. Bencherif, M., Hauser, T. A., Jordan, K. G., and Gatto, G. J. (2006) Therapeutic
potential of novel selective drugs targeting nicotinic acetylcholine receptors, Journal
of molecular neuroscience : MN 30, 17-18.
7. D'Hoedt, D., and Bertrand, D. (2009) Nicotinic acetylcholine receptors: an overview
on drug discovery, Expert opinion on therapeutic targets 13, 395-411.
8. Olivera, B. M., Quik, M., Vincler, M., and McIntosh, J. M. (2008) Subtype-selective
conopeptides targeted to nicotinic receptors: Concerted discovery and biomedical
applications, Channels 2, 143-152.
9. Livett, B. G., Gayler, K. R., and Khalil, Z. (2004) Drugs from the sea: Conopeptides
as potential therapeutics, Current medicinal chemistry 11, 1715-1723.
161
10. Kaas, Q., Westermann, J. C., Halai, R., Wang, C. K., and Craik, D. J. (2008)
ConoServer, a database for conopeptide sequences and structures, Bioinformatics 24,
445-446.
11. Grishin, A. A., Wang, C. I., Muttenthaler, M., Alewood, P. F., Lewis, R. J., and
Adams, D. J. (2010) Alpha-conotoxin AuIB isomers exhibit distinct inhibitory
mechanisms and differential sensitivity to stoichiometry of alpha3beta4 nicotinic
acetylcholine receptors, The Journal of biological chemistry 285, 22254-22263.
12. Azam, L., and McIntosh, J. M. (2009) Alpha-conotoxins as pharmacological probes of
nicotinic acetylcholine receptors, Acta pharmacologica Sinica 30, 771-783.
13. Millard, E. L., Nevin, S. T., Loughnan, M. L., Nicke, A., Clark, R. J., Alewood, P. F.,
Lewis, R. J., Adams, D. J., Craik, D. J., and Daly, N. L. (2009) Inhibition of neuronal
nicotinic acetylcholine receptor subtypes by alpha-Conotoxin GID and analogues, The
Journal of biological chemistry 284, 4944-4951.
14. Callaghan, B., Haythornthwaite, A., Berecki, G., Clark, R. J., Craik, D. J., and Adams,
D. J. (2008) Analgesic alpha-conotoxins Vc1.1 and Rg1A inhibit N-type calcium
channels in rat sensory neurons via GABAB receptor activation, The Journal of
neuroscience : the official journal of the Society for Neuroscience 28, 10943-10951.
15. MacRaild, C. A., Illesinghe, J., van Lierop, B. J., Townsend, A. L., Chebib, M., Livett,
B. G., Robinson, A. J., and Norton, R. S. (2009) Structure and activity of (2,8)-
dicarba-(3,12)-cystino alpha-ImI, an alpha-conotoxin containing a nonreducible
cystine analogue, Journal of medicinal chemistry 52, 755-762.
16. Stymiest, J. L., Mitchell, B. F., Wong, S., and Vederas, J. C. (2005) Synthesis of
oxytocin analogues with replacement of sulfur by carbon gives potent antagonists with
increased stability, The Journal of organic chemistry 70, 7799-7809.